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Abstract

THE EXPRESSION AND FUNCTION OF PHOSPHACAN/RPTPβ IN ADAPTIVE
SYNAPTOGENESIS AFTER TRAUMATIC BRAIN INJURY
By Janna L. Harris
A Dissertation submitted in partial fulfillment of the requirements for the degree of
Doctor of Philosophy at Virginia Commonwealth University.
Virginia Commonwealth University, 2008
Major Director: Linda L. Phillips
Professor, Anatomy & Neurobiology

Traumatic brain injury (TBI) affects 1.5 million Americans annually and is a
major health concern. Increasing evidence suggests that the brain extracellular
environment regulates plasticity and synaptic recovery following TBI. Here we
have focused on phosphacan/RPTPβ, an alternatively spliced group of
chondroitin sulfate proteoglycans which are prominent within the mature brain
extracellular matrix (ECM). Previous studies show that phosphacan/RPTPβ
influences neuronal migration, adhesion, neurite outgrowth, and morphogenesis.
However, our understanding of how these important ECM components are
involved in recovery from brain trauma remains unclear. In the present study, we
xiii

used unilateral entorhinal cortex lesion (UEC), a model which induces robust
hippocampal reactive plasticity, to investigate the role(s) of phosphacan/RPTPβ
isoforms in adaptive synaptogenesis after TBI. Using detailed protein and mRNA
quantification, immunohistochemistry, and qualitative ultrastructural analyses, we
show elevated phosphacan expression in the deafferented hippocampus at the
early degenerative phase and during the subsequent period of active sprouting.
By contrast, the receptor variant sRPTPβ is persistently elevated in hippocampus
over the first two weeks following UEC. We have further characterized a process
for validating appropriate reference genes for quantitative real-time RT-PCR
studies of plasticity and recovery after TBI. From these studies we conclude that
injury model, brain region, survival period and correlative protein expression are
critical factors which must be considered for reference gene selection. Finally,
we investigated functional implications of sRPTPβ increase during reactive
synaptogenesis, showing that the sRPTPβ substrate β-catenin, an important
cytoskeletal regulator, is altered in hippocampus during injury-induced plasticity.
Together, these results support a role for phosphacan/RPTPβ in both
degenerative and regenerative phases of reactive synaptogenesis. Phosphacan
may promote adaptive plasticity at earlier post-injury phases through interactions
with adhesion molecules or growth factors in the extracellular space. The
prolonged increase in sRPTPβ after UEC, along with its localization at
postsynaptic profiles, suggests that this isoform may work with intracellular
substrates to influence spine morphogenesis and/or stabilization of new
xiv

synapses. Gaining a better understanding of the roles of ECM components in
recovery from TBI will be an essential part of defining the difference between
injuries where recovery is successful, and those where recovery fails.

xv

CHAPTER 1
INTRODUCTION

General Introduction: Traumatic Brain Injury
Traumatic brain injury (TBI) is an enormous health concern in the United
States and around the world. Every year at least 1.5 million people in this
country sustain a TBI (Langlois et al., 2006; Rutland-Brown et al., 2006; Centers
for Disease Control and Prevention, 2006), and since this statistic excludes mild
TBI and unreported cases it is likely to be a significant underestimate of the true
incidence of brain trauma. The U.S. Centers for Disease Control and Prevention
reported that in the year 2003 alone, TBI claimed 51,000 lives, and resulted in
300,000 hospitalizations and more than 1.2 million emergency department visits
(Rutland-Brown et al., 2006). Persons under the age of 24 and over the age of
75 are at the highest risk of acquiring brain trauma, and males are affected
nearly twice as often as females (Thurman & Guerrero, 1999; Langlois et al.,
2006; Centers for Disease Control and Prevention, 2006). In recent years TBI
has come to be known as the “signature injury” among U.S. military personnel
serving in Iraq and Afghanistan; in 2005 it was estimated that more than 20% of
1

all service personnel who were injured in Iraq had sustained a TBI (Okie 2005).
Beyond the impact on U.S. citizens, TBI has been identified as a growing
problem around the world (Hyder et al., 2007). The World Health Organization
has estimated that by the year 2020, injury will surpass many diseases to
account for 20% of the global burden of death and disability (Murray & Lopez,
1997).
For survivors of brain trauma and for the families that support them, TBIrelated deficits in motor, sensory, and cognitive functioning present considerable
challenges which may last for years. Finkelstein and colleagues (2006) recently
reported that 1 in 5 hospitalized survivors of brain trauma were unable to return
to work one year after TBI due to injury-related disabilities, and this analysis
concluded that the total productivity loss from TBI is higher than from any other
type of injury. Considering both direct costs for medical treatment and indirect
costs such as lost productivity, the annual financial burden of TBI approaches
$60 billion dollars (Finkelstein et al. 2006). Given the magnitude of the problem,
a better understanding of the pathobiological mechanisms underlying the
morbidity and mortality of TBI could help to identify therapies with the potential to
improve many lives.

Pathobiological Mechanisms of TBI
Clearly the high incidence of TBI has enormous personal, social, and
economic ramifications. Yet despite decades of research, there are still no
2

approved therapies to ameliorate outcomes for TBI patients. The reasons behind
this are complex, but undoubtedly one factor which has made it more difficult to
develop effective therapeutic approaches is the heterogeneity of TBI pathology.
A TBI may involve focal tissue damage such as contusion or hematoma, or
diffuse tissue damage such as diffuse axonal injury (DAI) or diffuse damage to
the microvasculature (Povlishock & Katz, 2005). While this delineation of focal
versus diffuse injury is of use conceptually, in actuality most TBI patients present
with elements of both focal and diffuse pathologies. Furthermore the effects of
overt tissue damage may be compounded by secondary effects of the traumatic
insult, including widespread changes in cell metabolism, edema and elevated
intracranial pressure, hypoxia, ischemia, and inflammatory responses (Yoshino
et al., 1991; Vespa et al., 2004; Marmarou 2003; Gennarelli 1993; MorgantiKossmann et al., 2001). For example, focal injuries may result in greatly reduced
regional cerebral blood flow, causing ischemic and hypoxic damage which
contribute to a broader zone of neuronal cell death surrounding the area of initial
injury (Gaetz et al., 2004; Muller et al., 2004). Edema is also an important factor
in secondary brain injury, causing increased intracranial pressure (ICP) and
decreased cerebral perfusion and oxygen delivery. Numerous mediators are
released from damaged brain tissue which can enhance both cytotoxic and
vasogenic edema, including glutamate, K+ ions, Ca++ ions, and oxygen free
radicals (Marmarou 2003; Unterberg et al., 2004). The resulting elevation in ICP
worsens TBI outcome, and in the most extreme cases can lead to brain
3

herniation and death. Thus it is clear that the pathophysiological components of
initial and delayed tissue damage following TBI can be varied and complex.
However at its simplest level, the pathology of each individual trauma case will
include two core components, namely, some amount of cellular death, and some
degree of axonal injury (Parikh et al., 2007; Gaetz et al., 2004).

TBI-induced Cell Death
Cell death occurs after brain injury both in the regions directly affected by
a focal insult (typically cortical), and in more widespread areas including
thalamus, hippocampus, and cerebellum (Reviewed in Farkas & Povlishock,
2007; Raghupathi 2004). In both cases, necrotic and apoptotic death pathways
appear to contribute to the total cellular loss. Necrotic pathways are likely
induced by disruption of ionic homeostasis, due at least in part to trauma-induced
mechanical disruption of the plasmolemma (Farkas et al. 2006). The resulting
rise in intracellular Ca++ can activate several enzymes which contribute to
cytotoxicity. One important example is the cysteine protease calpain, which
degrades intracellular proteins and plays a key role in the cascade which
ultimately leads to necrotic cell death (Kermer et al., 1999; Raghupathi 2004). By
contrast, apoptotic cell death after TBI primarily occurs as a result of injuryinduced excitotoxic neurotransmitter release. Abnormally high levels of
extracellular glutamate act on several types of receptors to produce an influx of
Ca++ and to initiate multiple intracellular signaling cascades. Shifts in
4

intracellular levels of Bcl-2 family members regulate the release of cytochrome c
from mitochondria, which helps to activate apoptosis-promoting caspases
(McIntosh et al., 1998; Raghupathi 2004; Yakovlev & Faden 2004). While injuryinduced neuronal loss has received the most attention in clinical and
experimental studies, astrocytes and oligodendrocytes also appear to undergo
apoptosis after TBI (Conti et al., 1998; Newcomb et al., 1999). Thus it may be
that a loss of adequate glial support further contributes to the functional deficits
associated with brain trauma.

Traumatic Axonal Injury in TBI
In addition to cell death, diffuse traumatic axonal injury (TAI) is a major
contributor to TBI-associated morbidity (Genarelli et al., 1982; Adams et al.,
1991; Smith et al., 2003; Buki & Povlishock, 2006). The definitive diagnosis of
TAI is based on histological observation of axonal swellings at autopsy, so it is
difficult to determine the true prevalence of TAI among survivors of mild-tomoderate brain injury. However findings in experimental models of TBI suggest
that TAI is likely to be a component of most brain injuries, from the mildest to the
most severe, and its prevalence is probably under-diagnosed in patients
(Povlishock & Katz, 2005; Povlishock et al., 1992). While previously it was
thought that TAI reflected the overt tearing of axons due to mechanical shear at
the moment of impact, this view has been expanded to include the occurrence of
both immediate “primary axotomy”, as well as “secondary axotomy” which
5

develops progressively over the course of hours to days after the initial injury
(Maxwell et al., 1993). It is now generally accepted that the majority of TAI falls
in the latter category, where transient local perturbations of the axolemma initiate
intracellular cascades including activation of calpain and caspase, leading to
collapse of the axonal cytoskeletal, impairment of axonal transport, and
eventually to complete disconnection of the proximal axon stump (Povlishock et
al., 1983; Povlishock & Becker, 1985; Christman et al., 1994). A devastating
component of TBI pathology, axonal injury is a major contributor to the morbidity
and mortality seen in head-injured patients without mass lesions (Meythaler et
al., 2001). However the mechanism posited to underlie TAI-associated functional
deficits—the deafferentation of target neurons and resulting transneuronal
effects—has been generally underappreciated (Povlishock & Katz, 2005).

Neuroplasticity and Recovery from Injury
The death of cells and the degeneration of axons which occur in TBI
produce a shared downstream effect, namely, the deafferentation of brain areas
targeted by those cells or axons (Povlishock et al., 1992; Buki & Povlishock,
2006). However in numerous experimental models and in human patients,
evidence indicates that deafferentation is capable of inducing some amount of
compensatory neuronal growth (Steward 1989; Nadler & Cotman, 1978; Grady et
al., 1989; Stein & Hoffman, 2003; Deller et al., 2006). This phenomenon of
6

injury-induced or ‘reactive’ neuroplasticity was initially demonstrated after focal
lesions which disrupted input to specific brain regions, e.g. the septal nuclei
(Raisman 1969), superior colliculus (Lund & Lund, 1971), and hippocampal
dentate gyrus (Steward et al., 1976). Later, it was also shown that a similar
reactive plasticity could be induced by the scattered axonal damage that arose
from diffuse brain injury (Erb & Povlishock 1991; Christman et al. 1997). In a
clinically relevant model of diffuse brain trauma Christman et al.(1997) observed,
in the same regions showing histological features of TAI, “evidence of a
sustained regenerative attempt,” including axons stained with the growthassociated protein GAP-43, and ultrastructural changes consistent with adaptive
sprouting and tissue reorganization.
Whether such injury-induced axonal growth and synaptogenesis can
support meaningful functional recovery has been the focus of many experimental
studies, and recent developments in functional neuroimaging have opened up
the possibility of examining this question in the clinical setting as well. In several
recent reviews on the topic (Ramirez 2001; Stein & Hoffman, 2003; Nudo 2007)
the common consensus has been that reactive plasticity is a likely mechanism for
observed post-injury functional recovery under at least some conditions. For
example, homotypic axonal sprouting and reactive synaptogenesis after
deafferentation of the hippocampus show a clear temporal correlation with
changes in hippocampus-dependent behavior (Reeves and Smith,1987).
Moreover, manipulations which affect synaptogenesis have been shown to
7

produce concomitant changes in behavioral outcomes (Phillips et al., 1997; Falo
et al., 2006). Rats tested in a learned alternation task, and mice tested in a water
maze—both measures of hippocampal-dependent spatial learning—showed
initial postlesion impairments which recovered along the same time course as
compensatory axonal sprouting (Loesche & Steward, 1977; Hardman et al.,
1997). A subsequent transection of the sprouted pathway in rats reinstated the
behavioral deficit (Loesche & Steward, 1977). Furthermore, progressive EC
lesions, an experimental manipulation known to accelerate the axonal sprouting
response, was also shown to accelerate the post-injury recovery of learned
alternation performance (Ramirez et al., 1996). However it is also clear that not
all reactive sprouting is equally supportive for behavioral recovery. Much
depends on the definition of “functional recovery” and the demands that the
particular behavioral test places on the damaged/sprouted pathways (Ramirez
2001). Animals given bilateral entorhinal lesions demonstrate sprouting of
heterotypic inputs to the hippocampus, which correlate with some measures of
recovery such as open-field locomotor activity (Lasher & Steward, 1981), but not
with other measures like the radial arm maze (Olton et al., 1978), water maze
(Skelton & McNamara, 1992), or operant non-matching to position task (Kirkby &
Higgins, 1998). Overall these data led Ramirez (2001) to suggest the ‘principle
of isomorphism’ as a guiding rule in the attempt to define the relationship
between reactive sprouting and behavioral recovery. This posits that the greater
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the similarity between the injured pathway and the sprouting pathway, the greater
the probability that sprouting will contribute to meaningful functional recovery.
Axonal sprouting is by nature a spatially limited process, so that
successful synaptogenesis following injury is most likely to occur when there are
intact fiber systems near the deafferented sites. Diffuse or multifocal brain
trauma is likely to damage some axons within a functional tract, while leaving
some adjacent fibers intact. Thus Steward noted in his comprehensive review on
injury-induced neuronal reorganization (1989) that in fact, the diffuse denervation
caused by TAI in the majority of naturally occurring brain traumata may be the
optimal type of insult for inducing successful sprouting—and, hopefully,
meaningful brain repair. Since the evidence points to a role for sprouting and
synaptogenesis in functional recovery after TBI, any therapeutic treatment
capable of directing or enhancing these processes would be worthy of attention.
Particular interest has arisen in the effects of the extracellular environment on
axonal sprouting and synaptic reorganization, with the idea that manipulations of
this environment could help support a functionally adaptive plasticity response.

Extracellular Matrix in the Brain
For much of the 20th century, the idea that an appreciable amount of
extracellular matrix (ECM) was present in the adult mammalian central nervous
system (CNS) remained out of favor among most neuroscientists. However with
improved histological and biochemical research techniques, it has now come to
9

be widely recognized that ECM not only comprises a significant portion of the
volume of brain and spinal cord, but also that it plays a vital role in the
development and normal functioning of the nervous system (Celio 1999).
Extracellular tracer diffusion studies have consistently demonstrated the volume
fraction of the extracellular space to be around 20% of mature brain (Nicholson &
Sykova, 1998). This space is occupied by an extracellular matrix that is secreted
by both neurons and glia, and is biochemically unique compared to the ECM of
other body tissues. Specifically, compared to the ECM of other organs, matrix in
the brain and spinal cord contains unusually low levels of fibrous proteins such
as collagen and elastin, and unusually high levels of glycosaminoglycans (GAGs;
Novak & Kaye, 2000).

ECM Composition and Structure
While the composition of nervous system ECM is highly complex and
heterogeneous, its major components may be considered in the framework of
three broad groups of molecules: hyaluronan, matrix proteins, and proteoglycans.
Hyaluronan is the simplest form of GAG, a linear chain of repeating disaccharide
units which may reach sizes up to 106 or 107 kilodaltons (kD). Hyaluronan is
believed to serve as a “backbone” in the structural organization of nervous
system matrix, binding and connecting other ECM components (Margolis et al.,
1975; Rauch 2004; see Figure 1.1). Matrix proteins comprise the second broad
group, including link protein, which stabilizes the bond between hyaluronan some
10

proteoglycans, and several glycoproteins such as tenascin, fibronectin, laminin,
thrombospondin, and reelin. The third group of ECM components, the
proteoglycans, are large multidomain molecules which exhibit a great amount of
structural diversity (Galtrey & Fawcett, 2007). Proteoglycans consist of a protein
core, to which some variable number of sulfated GAG chains are covalently
attached. Classification of proteoglycans rests on the type of attached GAGs.
Proteoglycans carrying chondroitin sulfate (CS) are the most abundant in brain
ECM, followed by heparin sulfate (HS), dermatan sulfate (DS), and keratan
sulfate (KS). Altogether, these proteoglycans, proteins, and hyaluronan chains
form a complex, interconnected structure surrounding the cellular components of
the nervous system. Both the physical parameters of the ECM (its volume
fraction and tortuosity), and its specific biochemical composition, are altered over
the course of development and after CNS injury (Pearlman & Sheppard 1996;
Oohira 2000; Grimpe et al. 2002; Garwood et al. 2002).

Proposed Functions of ECM in the CNS
ECM in the brain serves both a structural role and a cell signaling role. In
terms of its structural function, ECM influences the formation and stabilization of
the cytoarchitecture and synapses. Perineuronal nets (PNNs) are condensed
regions of extracellular matrix surrounding the cell bodies and proximal dendrites
of specific subsets of neurons in the brain and spinal cord (Celio & Blumcke,
1994; Celio et al., 1998). Important insights about the role of these discrete ECM
11

Figure 1.1 Proteoglycan Structure & Organization of Brain ECM
(A) Transmission electron micrograph showing the classical proteoglycan
structure where both protein core and GAG side chains are clearly visible. (B) In
vivo, proteoglycans are not typically found in isolation, but are bound to other
matrix molecules in complex aggregates. In brain ECM, hyaluronan is believed
to act as an organizing “backbone”, connecting many different proteoglycan
molecules. (C) Chemical structures of the disaccharide building blocks of GAG
chains.
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Figure 1.1
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structures came from a study by Pizzorusso et al. (2002) in the cat visual cortex.
This group showed that PNNs first appear in visual cortex at the end of the
critical period for developmental plasticity, and that dark-rearing the animals to
prolong the critical period also correspondingly delayed PNN formation. Finally,
they showed that an in vivo treatment to degrade the ECM of perineuronal nets
was able to re-activate developmental plasticity in adult animals. Thus PNNs
have been proposed to surround synapses in the mature CNS, where they serve
to stabilize synaptic cytoarchitecture (Fox & Caterson, 2002; Murakami &
Ohtsuka, 2003).
The cell signaling properties of ECM are initiated when a matrix molecule
binds to a specific receptor on the plasma membrane of a neuronal or glial cell.
This activates intracellular pathways which may influence a plethora of cellular
behaviors, including migration, differentiation, survival, neurite outgrowth,
fasciculation, synapse formation, and synaptic plasticity. Integrins, a class of
heterodimeric cell surface receptors which bind to molecules in the extracellular
matrix, may be responsible for mediating many of the signaling functions of ECM
in the CNS (Dityatev & Schachner, 2006). For example, the matrix glycoproteins
thrombospondin 1 and 2 (TSP1 and TSP2) are posited to induce synapse
formation through a mechanism that involves binding to neuronal integrins and
the intracellular activation of protein kinase C (Hama et al., 2004). TSP1 and
TSP2 were each shown to elicit formation of synapses in neuronal cultures, and
double knock-out mice develop about 30% fewer synapses than age-matched
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wild type mice (Christopherson et al., 2005). The many studies examining
knockout animals deficient in integrins or in various specific matrix components
have helped our understanding of the vital importance of ECM-integrin receptor
interactions for normal development and functioning of the CNS (Chan et al.,
2003; McCarty et al., 2005).

Regulation of ECM by Extracellular Proteolysis
Functions of ECM in the brain in vivo are under constant dynamic
regulation through the activity of extracellular proteases. These important
enzymes not only control constitutive turnover of matrix molecules, but also
actively sculpt extracellular microenvironments to allow for cell growth and
morphogenesis, and control the concentration and type of ECM constituents
which are made available to specific cells. Major classes of matrix-regulating
enzymes include the matrix metalloprotease (MMP) family and the plasminogen
activator/plasmin cascade.
MMPs are zinc-dependent proteases which constitute an ever-growing
family of now nearly 30 members (Ethell & Ethell, 2007). Together, the MMPs
are capable of degrading all components of the ECM. MMPs play a role in tissue
remodeling during development, and they are expressed by neural progenitor
cells and oligodendrocyte precursor cells (Agrawal et al., 2008; FrolichsthalSchoeller et al., 1999; Oh et al., 1999). Neurite extension through the
extracellular matrix is aided by secretion of MMPs at the leading edge of the
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growth cone (Yong et al., 2001). In the mature nervous system most MMPs are
expressed at very low levels, and once expressed there are multiple mechanisms
in place to ensure the precise regulation of their activity. First, MMPs are
secreted into the extracellular compartment as inactive zymogens, which must be
cleaved by either by plasmin or by other MMPs in order to be activated in situ.
Second, TIMPs (tissue inhibitors of metalloproteinases) are co-expressed with
MMPs in the nervous system. TIMPs bind MMPs in a one-to-one ratio,
occupying the active zinc-binding sites on MMPs to inhibit their activity (GomisRuth et al., 1997). Despite their low constitutive activity, MMP expression and
activity can be rapidly up-regulated by CNS insult or by degenerative diseases
such as Alzheimers disease (AD), multiple sclerosis (MS), many types of
invasive cancers, stroke, and brain trauma (Kim et al., 2005; Falo et al., 2006;
Vilalta et al., 2008; reviewed in Agrawal et al., 2008). Additional types of
proteases in the MMP family include the membrane-type MMPs (MT-MMPs),
ADAM (a disintegrin and metalloproteinase), and ADAMTS (ADAM proteins with
a thrombospondin-like domain). ADAMs are thought to be involved mainly in
proteolysis and ectodomain shedding of cell surface receptors in the brain, but
possible additional roles for these proteases are still emerging (Novak 2004;
Mayer et al., 2005; Yang et al., 2006).
Tissue plasminogen activator (tPA) is a plasma serine protease, best
known for its role in blood clot lysis through the conversion of plasminogen to the
active protease plasmin. However, tPA is also expressed in brain parenchyma,
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where it is posited that its primary role is not fibrinolysis but degradation of
specific substrates in the ECM. tPA is secreted by neurons and its ECMdegrading activity is thought to contribute to developmental neurite outgrowth
and plasticity-associated tissue reorganization (Pittman & Buettner, 1989;
Baranes et al., 1998). Like MMPs, the activity of tPA in normal CNS tissue is
tightly regulated, both at the level of restricted protein translation and posttranslationally. Neuroserpin is a endogenous inhibitor of tPA, which is coexpressed with tPA during development and in the adult (Yepes & Lawrence,
2004). While this helps to maintain low constitutive activity of tPA, expression
and activity can be rapidly increased under pathological conditions such as
seizures (Qian et al., 1993), ischemia and associated breakdown of the BBB
(Yepes et al., 2000, 2003), and MS (Teesalu et al., 2002). Also studies with
knockout animals have demonstrated that tPA can mediate excitotoxic cell death
through a plasmin-dependent cascade that involves cleavage of the endsubstrate laminin (Chen & Strickland, 1997). Plasmin generated by tPA can
activate MMP zymogens, thus providing a link between these two major
proteolytic systems in ECM of the nervous system (Lo et al., 2002).
While much progress has been made in the last two decades as interest in
CNS extracellular matrix has grown, much still remains to be learned about the
expression patterns, interactions, regulation, and precise functional roles of many
matrix components in the normal brain and in neuropathological conditions.
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Recently, the class of ECM molecules called the chondroitin sulfate
proteoglycans (CSPGs) has begun to attract particular attention.

Phosphacan/RPTPβ as Important Components of Nervous
System ECM
CSPGs are an abundant component of ECM in the brain and spinal cord.
As a group, CSPGs are generally considered inhibitory for neurite growth and
structural plasticity, yet there is also evidence to indicate that not all of these
proteoglycans are strictly inhibitory. Phosphacan is one example of a CSPG
whose functional role in the CNS appears to be more versatile (Faissner et al.
2003; Dobbertin et al. 2003). Phosphacan (also known as 6B4 proteoglycan, or
DSD-1 PG in the mouse) is a major component of adult brain ECM, comprising
approximately 20% of the total CSPG content (Rauch et al 1991). It has been
reported to both inhibit and promote neurite outgrowth under different conditions,
and studies have shown that phosphacan may be both upregulated and
downregulated in the injured CNS (Faissner et al. 1994; Garwood et al 1999;
McKeon et al 1999; Jones et al. 2003; Tang et al. 2003). Phosphacan and its
related splice variants will be described in detail below, including consideration of
structure, expression patterns, ligands, and putative functional roles of these
proteoglycans in the normal and injured CNS.
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Structural Characterization of RPTPβ Splice Variants
Molecular cloning studies have identified phosphacan as an alternative
splice variant of receptor protein tyrosine phosphatase beta (RPTPβ). The fulllength RPTPβ (also known as protein tyrosine phosphatase receptor type Z,
PTPRz, or PTPζ) is a single-pass transmembrane protein (see Figure 1.2 for a
structural comparison of RPTPβ splice variants). The extracellular domain of
RPTPβ contains an N-terminal carbonic anhydrase sequence (CA), followed by a
single fibronectin type III domain (FnIII), a 360 amino acid ‘spacer’ region, and an
intervening sequence (IS) of approximately 860 amino acids. Additionally,
RPTPβ has a short membrane-spanning domain and two intracellular tyrosine
phosphatase sites, termed D1 and D2 (Levy et al., 1993). All phosphatase
activity can be attributed to the membrane-proximal D1 site; the D2 domain is
rendered catalytically inactive by deletion of a single cysteine (Krueger & Saito,
1992). The shorter transmembrane splice variant (termed sRPTPβ) has most of
the IS region deleted (Levy et al., 1993). Phosphacan is the primary extracellular
variant, and is structurally identical to the entire extracellular portion of RPTPβ
(Maurel et al., 1994). Finally, another secreted extracellular isoform termed
phosphacan short isoform (PSI) has recently been identified. PSI corresponds to
the N-terminal portion of phosphacan but lacks the IS sequence and half of the
spacer region (Garwood et al., 2003). In this document we will use the term
"phosphacan/RPTPβ" to refer collectively to the three major splice variants
investigated in these studies: phosphacan, RPTPβ, and sRPTPβ.
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Figure 1.2 RPTPβ splice variants. The receptor-type protein tyrosine
phosphatase β (RPTPβ) gene is alternatively spliced into several different
isoforms. RPTPβ is a transmembrane receptor with an extracellular carbonic
anhydrase (CA) domain, a fibronectin type III (FnIII) domain, a spacer region (S),
and a membrane-proximal intervening sequence (IS) which contains many of the
predicted glycosaminoglycan (GAG) attachment sites. RPTPβ also has a short
transmembrane region and two intracellular tyrosine phosphatase domains, only
one of which is catalytically active. A shorter transmembrane splice variant,
sRPTPβ, retains the intracellular tyrosine phosphatase but lacks the extracellular
IS region. Phosphacan is the major secreted splice variant, and its structure is
identical to the entire extracellular domain of the full-length RPTPβ. Phosphacan
short isoform (PSI) is a secreted non-proteoglycan which contains the CA and
FNIII domains, and part of the S region. Figure modified from Harris et al., 2005.
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Figure 1.2
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Phosphacan splice variants are highly decorated with different types of
post-translational modifications. The extracellular IS region of 860 amino acids is
of particular importance since it contains most of the putative attachment sites for
the GAG chains. The isoforms which express this region—phosphacan and
RPTPβ—are heavily glycosylated with long, sulfated CS-GAG chains. Since
sRPTPβ lacks the IS region it is less heavily glycosylated, but still exists in
mature brain as a CSPG (Nishiwaki et al., 1998). Phosphacan and RPTPβ may
also sometimes carry KS-GAGs (Rauch et al., 1991; Maeda et al., 1995). All of
the phosphacan/RPTPβ splice variants also contain numerous sites for
attachment of small N- and O-linked oligosaccharides (Maeda et al., 1995).

Developmental Expression and Localization of Phosphacan/RPTPβ
Expression of all the RPTPβ variants is largely restricted to the nervous
system (Shintani et al., 1998; Engel et al., 1996; Meyer-Puttlitz et al., 1996). In
the rodent brain, phosphacan is first detectable in tissue homogenates at
embryonic day 20 (E20), with levels rising steadily thereafter to peak in the
second postnatal week. Phosphacan accounts for around 20% of the total
soluble CSPG in adult rat brain, and is thus a major component of mature
nervous system ECM (Rauch et al., 1991). Keratan sulfate is not present in
embryonic brain, but after birth it becomes detectable and its concentration
increases gradually to peak in the third postnatal week (Sakurai et al., 1996;
Meyer-Puttlitz et al., 1995; Meyer-Puttlitz et al., 1996). This increase in KS is
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believed to be attributable solely to chains attached to phosphacan; no other
KSPGs have been identified which are expressed postnatally in the nervous
system (Rauch et al., 1991; Maurel et al., 1994). Because KS concentration and
phosphacan concentration peak at different times, it appears that the GAGs
attached to phosphacan are regulated independently of the core protein during
development. In fact, many structural features of phosphacan/RPTPβ are altered
as the nervous system matures, including the number of GAG chains, their
length and sulfation pattern, and the number of N- and O-linked oligosaccharides
(Rauch et al., 1991; Meyer-Puttlitz et al., 1995; Mace et al., 2002). Since the
enzyme chondroitinase ABC (chABC), which is known to digest the CS chains
attached to proteoglycans in mature tissue, cannot efficiently digest CS on
embryonic and early postnatal phosphacan (Mace et al., 2002), it has been
suggested that the fine structure of these CS-GAGs may be altered during
development. Milev et al. (1998) found a developmental shift in the position of
sulfation on phosphacan CS chains, which may account for the difference in
susceptibility to degradation. Since specific functions of RPTPβ can be attributed
to distinct structural domains, the regulation of structural features suggests a
dynamic role for these molecules over the course of CNS development.
Immunostaining for phosphacan in the nervous system shows a wider
distribution than that shown by in situ hybridization, consistent with its
characterization as a secreted molecule which could be transported or
redistributed in the extracellular space. In the embryonic rodent CNS,
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phosphacan transcript is largely confined to areas of active cell proliferation, such
as the ventricular zone and ependymal layer surrounding the central canal of
spinal cord (Engel et al., 1996). Immunoreactivity for phosphacan core protein is
also very prominent in the ventricular zone, and diffuse staining is seen in many
areas of the cerebrum, brainstem, cerebellum, dorsal root ganglia, and in grey
and white matter of the spinal cord (Meyer-Puttlitz et al., 1996). Postnatally,
strong phosphacan staining is seen surrounding radial glia in the developing
cortex and Bergmann glia in the cerebellum (Meyer-Puttlitz et al., 1996; Rauch et
al., 1991). Since phosphacan is known to bind to numerous cell adhesion
molecules, it may assist in developmental migration of neurons along these glial
scaffolds.
The localization of the transmembrane variants appears to be less
widespread than phosphacan in the nervous system. RPTPβ and sRPTPβ are
detected predominantly in the subventricular zone in embryonic brain (Canoll et
al., 1996; Snyder et al., 1996). Expression of the full-length form all but
disappears postnatally, while expression of the short form sRPTPβ declines but
remains at steady lower levels in the adult CNS (Sakurai et al., 1996; Dobbertin
et al., 2003; Lorente et al., 2005).
Immunoblotting of primary cell cultures and in situ hybridization studies
have indicated that astroglia (Canoll et al., 1996; Engel et al., 1996) as well as
certain neuronal populations (Snyder et al., 1996; Hayashi et al., 2005; Shintani
et al., 1998) express sRPTPβ and phosphacan. 02A cells secrete high levels of
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phosphacan and RPTPβ, but expression of both disappears as these cells
differentiate into mature oligodendrocytes. While several cell populations appear
capable of producing phosphacan, astrocytes in culture were shown to secrete
much higher levels of this proteoglycan than other cell types (Snyder et al., 1996;
Canoll et al., 1996; Dobbertin et al., 2003). By contrast, O2A cells expressed
more RPTPβ than astrocytes or neurons (Dobbertin et al., 2003).
Recent investigations have also explored the ultrastructural localization of
RPTPβ family members. Electron microscopy revealed that sRPTPβ and
phosphacan are present on the surface of postmitotic migrating neurons and on
the surface of radial glia (Hayashi et al., 2005). In adult hypothalamus,
immunoreactivity for all variants was also seen surrounding axons and astrocytic
processes (Miyata et al., 2004). Cultured neurons from embryonic cortex first
express sRPTPβ and phosphacan on somata, axons, and dendrites. However,
as these cells mature in vitro, the staining selectively disappears from axonal
surfaces, suggesting that the cellular localization of RPTPβ/phosphacan may
shift during development, at least in some neuronal types (Hayashi et al., 2005).
While localization of the transmembrane forms at the plasma membrane is
anticipated, presumably the phosphacan immunostaining observed near the cell
surface was due to its interactions with membrane-associated molecules.
Binding partners of phosphacan include a number of surface cell adhesion
molecules (CAMs), which will be considered in detail below.
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Descriptions of RPTPβ/phosphacan localization in developing and adult
hippocampus have been contradictory. Some studies have reported that all
neuropil layers show gradually increasing immunoreactivity from birth, with the
strongest staining developing in the stratum lucidum of the CA subfields, and in
the polymorphic layer and middle third of the molecular layer in the dentate gyrus
(Bruckner et al., 2003; Wilson & Snow, 2000). In contrast, others have found a
distinct absence of immunoreactivity in the stratum lucidum, and the strongest
staining in the inner third of the molecular layer (Okamoto et al., 2001; Okamoto
et al., 2003). The discrepancies may be due to the use of antibodies recognizing
epitopes on different subsets of the RPTPβ family. Additionally, the substantial
changes in the GAG and oligosaccharide epitopes on phosphacan and RPTPβ
which occur during development could potentially alter antibody recognition sites
at different ages. Overall, the expression of phosphacan/RPTPβ is regulated on
many levels during development, and the spatial and temporal patterns of
expression suggest a potential involvement in cell migration, differentiation, and
synaptogenesis (Faissner et al., 2006).

Ligands of Phosphacan/RPTPβ
Extracellular Ligands
Studies over the last decade have identified a host of molecules which
bind to extracellular regions of the RPTPβ family. These may generally be
divided into three categories: cell surface-associated molecules, molecules of the
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extracellular matrix, and diffusable extracellular growth/differentiation factors.
The CA domain of the core protein, which is shared by all RPTPβ splice variants,
has been shown to bind to the cell surface adhesion molecule F3/contactin
(Peles et al., 1995), the transmembrane glycoprotein Caspr/paranodin (Peles et
al., 1997), and to the extracellular portion of voltage-activated Na+ channels.
The FnIII domain, also shared by all RPTPβ isoforms, binds to the ECM molecule
Tenascin-C (Adamsky et al., 2001). The S region, which is truncated in PSI but
present in all other isoforms, binds several members of the immunoglobulin
superfamily of cell adhesion molecules (Sakurai et al., 1997). In addition,
Tenascin-R and basic fibroblast growth factor (FGF-2) each bind to some part of
the extracellular core protein, but the specific binding sites have not been
identified for these ligands (Milev et al., 1998a; Milev et al., 1998b).
The chondroitin sulfate and keratan sulfate GAGs appear to be
responsible for modulating phosphacan/RPTPβ binding affinity to certain ligands.
Binding of phosphacan to FGF-2, for example, is reduced by 35% after in vitro
treatment with chABC to digest CS GAGs on phosphacan (Milev et al., 1998b).
The CS chains also serve as the primary binding sites for some ligands including
the adhesion molecule TAG-1/axonin-1, and the growth factors amphoterin,
midkine, and pleiotrophin/HB-GAM (Milev et al., 1996; Milev et al., 1998a; Maeda
et al., 1999). Small oligosaccharides attached to the CA and FnIII regions also
enhance binding affinity to N-CAM, Ng-CAM, and Tenascin-C, since treatment of
phosphacan with peptide N-glycosidase can substantially reduce binding to these
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molecules (Milev et al., 1995). Immunological studies have shown extensive
overlap between the expression of RPTPβ isoforms and expression of many of
the ligands discussed above, underscoring the biological importance of these
interactions in vivo. It should also be emphasized that in nervous system tissue,
rarely would phosphacan/RPTPβ encounter only one of these extracellular
binding partners in isolation. Rather, it is likely that the presence of certain
ligands can influence association of phosphacan with other binding partners,
possibly by steric alteration of binding sites, thereby adding another layer of
complexity to the interactions of phosphacan/RPTPβ in vivo.

Intracellular Ligands
While earlier studies focused on identifying ligands for
phosphacan/RPTPβ in the extracellular domain, a number of more recent reports
have described novel ligand interactions with intracellular regions of the receptor
forms. These ligands include both intracellular proteins and transmembrane
receptors. Intriguingly, many are enriched at post-synaptic profiles and have
been functionally linked to structural plasticity or synaptogenesis. Intracellular
binding partners of full-length and short RPTPβ include PSD-95 (Kawachi et al.,
1999), β-catenin (Meng et al., 2000), β-adducin (Pariser et al., 2005), p190
RhoGAP (Tamura et al., 2006), ErbB4 (Fujikawa et al., 2007), and TrkA (Shintani
et al., 2008). Most of the studies which identified these interactions have used in
vitro models to demonstrate that RPTPβ binding is linked to dephosphorylation of
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the ligands at tyrosine residues. For example, the D1 catalytic domain of RPTPβ
co-precipitates from glioblastoma cells with β-catenin, a key regulator of the
neuronal cytoskeleton (Meng et al., 2000). Furthermore, binding of pleiotrophin
to the extracellular domain of RPTPβ was shown reduce the intracellular
phosphatase activity and increase detection of phosphorylated β-catenin,
providing compelling evidence that β-catenin is a substrate for RPTPβ. RPTPβ
and sRPTPβ can also interact through their cytosolic D1 domain with voltagegated sodium channels (Ratcliffe et al., 2000). This interaction was shown to
regulate tyrosine phosphorylation of the sodium channel α subunit, and when
both α subunit and the intracellular portion of RPTPβ were co-expressed in tsa201 cells, an increase in whole-cell sodium current was observed. While an
interaction with sodium channels has yet to be demonstrated in neurons, these
findings suggest that RPTPβ phosphatase activity might be capable of
modulating cell excitability.

Interaction of RPTPβ Isoforms: Potential Competition for Common Ligands
Because of the sequence homology shared by RPTPβ variants, it is likely
that wherever multiple isoforms are co-expressed, they can compete for common
ligands. One could easily imagine a scenario where the transmembrane forms
respond to extracellular signals and activate intracellular signaling, while the
secreted forms regulate this activity by competing for ligand binding in the
extracellular space. In this context, there may be special significance in the
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relative spatial and temporal expression of the different RPTPβ splice variants.
Shifts in the relative expression of phosphacan/RPTPβ isoforms are likely to be
one way that these proteoglycans influence neuronal and glial adhesion,
migration, and neurite growth during CNS development and after injury.
An important way in which competition for common ligands might
influence cell behavior is through regulation of the tyrosine phosphatase activity
of full-length or short RPTPβ. It has been shown that pleiotrophin binding to the
extracellular domain of RPTPβ reduces the activity of the intracellular D1
phosphatase. Specifically, in both RPTPβ-expressing glioblastoma cells and Sf9
insect cells transfected with RPTPβ, application of pleiotrophin increased the
phosphorylation of the putative intracellular substrate β-catenin; this effect
appeared to be specific because β-catenin phosphorylation was unchanged in
untransfected Sf9 cells which do not express any RPTPβ variants (Meng et al.
2000). Since both phosphacan and RPTPβ can bind pleiotrophin, an increase in
extracellular phosphacan could increase competition and reduce binding of this
ligand to the transmembrane receptor. This would reduce ligand-induced
receptor inactivation and thus cause a net increase in phosphatase activity. One
in vitro study has suggested that such an increase in phosphatase activity might
support neuronal migration. Pleiotrophin stimulated migration of RPTPβexpressing neurons along coated glass fibers, and this effect was blocked by
application of soluble phosphacan to the culture medium (Maeda & Noda, 1998).
In the same assay, migration was blocked by tyrosine phosphatase inhibition,
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although it was unclear whether the halt in migration resulted from reduced
RPTPβ activity, or reduced activity of other tyrosine phosphatases.
Maeda and colleagues showed that adding phosphacan to neuronal
cultures caused a transient increase in phosphorylated-tyrosine on an 85kD
protein, which correlated closely with induction of neurite growth from these cells
(Maeda & Noda, 1996). In contrast with the experimental model described
above, in this case the data suggest that competition by phosphacan may reduce
phosphatase activity. An alternative interpretation is that phosphacan may
influence the phosphorylation of different effector molecules through multiple
pathways, including but not limited to its effects on RPTPβ phosphatase activity.
Another possibility is that different extracellular ligands may differentially
influence the catalytic activity of RPTPβ. Pleiotrophin binding is known to
suppress RPTPβ phosphatase activity, but it is conceivable that other yetunidentified ligands might have the opposite effect. If this is the case, then when
phosphacan competes with the transmembrane variants for ligands, the net
effect could be either an increase or a decrease in catalytic activity. Evidently,
further studies are needed to better characterize the influence of different ligands
on RPTPβ phosphatase activity, as well as the downstream effects on cellular
function. Figure 1.3 summarizes the potential effects of binding competition on
RPTPβ phosphatase activity and cell signaling.
The influence of the RPTPβ family on intracellular signaling pathways
could extend beyond simply those effectors which are altered directly via
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Figure 1.3 Potential effects of binding competition on RPTPβ phosphatase
activity and cell signaling. The structural similarity between phosphacan and
RPTPβ/sRPTPβ means that these splice variants share many common ligands.
In the mature brain, phosphacan is found in the extracellular space while
RPTPβ/sRPTPβ are primarily located on the surface of neuronal dendrites and
spines (Hayashi et al., 2005; see also Figure 2.3). Ligand binding to the
extracellular portion of RPTPβ/sRPTPβ may enhance or reduce activity of the
phosphatase and transduction of intracellular signals in postsynaptic neurons.
Phosphacan competition for ligand binding would modulate these effects. If the
ligand in question is a surface receptor on another cell (e.g. a CAM) then these
interactions could impact on bi-directional cell signaling in both the neuron
expressing RPTPβ and the neighboring cell expressing the CAM (CAM = cell
adhesion molecule; Figure modified from Sakurai et al., 1997).
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Figure 1.3
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dephosphorylation. A second way in which phosphacan/RPTPβ can affect cell
behavior is by modifying the activity of other cell surface receptors. This
influence may be direct, via cis or trans interactions of other receptors with an
RPTPβ isoform. For example, RPTPβ may influence the intracellular signaling
pathways initiated by transmembrane CAMs to which it binds. If soluble
phosphacan interacts with a surface adhesion molecule, it would generate a unidirectional signal from the extracellular ligand to the CAM-expressing cell.
However bi-directional signaling could also result from a trans interaction
between RPTPβ and CAMs on adjacent cells, when both of these receptors
transduce intracellular signals after binding (Peles et al., 1995; Oohira et al.,
2000; see again Figure 1.3).
Additionally, phosphacan/RPTPβ could influence cell signaling in a more
indirect manner, by altering the availability of soluble extracellular ligands.
RPTPβ and phosphacan are known to bind to various growth and differentiation
factors, which may bring these factors into closer proximity to their respective
surface receptors, thereby potentiating their effects. Indeed, it has been shown
that when phosphacan binds to FGF-2, the mitogenic effects of this growth factor
is nearly doubled (Milev et al., 1998). RPTPβ may not always augment growth
factor signaling, however. In some cases phosphacan in the ECM could
sequester growth factors, limiting their accessibility to receptors on the surface of
neurons (McKeon et al., 1999).
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In vitro Studies Suggest a Complex Influence of Phosphacan/
RPTPβ on Neuronal Behavior
Unlike many other CSPGs, which are generally considered to be inhibitory
to neuronal adhesion and axon growth (Davies et al., 1997; Fawcett & Asher,
1999), studies on the effects of phosphacan splice variants on neuronal function
in vitro have produced mixed results. As discussed above, phosphacan/RPTPβ
can interact with ligands through binding sites on the protein core, on the GAG
chains, and on the N- and O-linked oligosaccharides. With so many potential
interactions in vivo, it is perhaps not surprising that RPTPβ isoforms have been
implicated in many aspects of nervous system function, nor that the results of
different in vitro assays may at times appear contradictory.

Phosphacan/RPTPβ and Cell Adhesion
Since the RPTPβ family members are high-affinity ligands for a number of
different CAMs, it is logical to suggest that they might play a role in modulating
cell adhesion. In vitro studies have shown that phosphacan is a repulsive
substrate for cortical and thalamic neurons (Maeda & Noda, 1996) and for U373
astrocytoma cells (Lorente et al., 2005). Soluble phosphacan can interfere with
adhesion of neurons to Ng-CAM coated plates in a dose-dependent manner
(Milev et al., 1994). Moreover, it has been demonstrated that simply the purified
CS and KS epitopes of phosphacan are sufficient to prevent adhesion of
mesencephalic neurons (Mace et al., 2002). Interestingly though, the repulsive
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effect of CS as an isolated culture substrate stands in direct contrast to its effect
in an in situ assay where neurons were cultured on top of whole brain slices.
Neurons did adhere to the brain slice; however when the slice was pre-treated
with chABC, all neuronal adhesion to it was abolished, indicating that in this
experimental paradigm the CS acts as a permissive substrate (Mace et al.,
2002).
Adhesion experiments may report different results for phosphacan/RPTPβ
when different cell types are tested. For example, the isolated extracellular
domain of sRPTPβ is repulsive to U373 cells (Lorente et al., 2005) but
permissive for adhesion of neurons (Sakurai et al., 1997). Moreover, it appears
that details of the experimental protocol can affect the conclusions of in vitro
adhesion assays. Most adhesion studies use a traditional gravity assay where a
cell suspension is added to a flat substrate-coated plate and allowed to incubate
while gravity settles the cells onto the substrate. The plate is washed to remove
unbound cells, and those remaining are counted. By contrast, in a centrifugation
assay a cell suspension is added to a U-shaped well coated with substrate, and
centrifugation is the force which brings suspended cells briefly into contact with
the substrate-bound surface. After the centrifugation step, cells which have
adhered to the sides of the well are counted. The short-term centrifugation assay
is a better reflection of the strength of molecular interactions upon initial cell
contact, while the gravity assay reflects the capacity of a substrate to allow cell
spreading. Since phosphacan can bind to cells but also seems to exhibit some
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repulsive properties, a centrifugation assay would be more likely to identify it as
‘adhesive’ (e.g. Grumet et al., 1993) while a gravity assay is more likely to report
that no adhesion was observed (e.g. Maeda & Noda, 1996).

Phosphacan/RPTPβ and Neurite Outgrowth
Phosphacan has been found to promote neurite outgrowth from embryonic
cortical, mesencephalic, and hippocampal neurons (Faissner et al., 1994;
Garwood et al., 1999; Maeda et al., 1995; Dobbertin et al., 2003). PSI also
promotes neurite outgrowth from cortical neurons, though the effect is less potent
than that of phosphacan (Garwood et al., 2003). However in contrast with these
findings, are other studies showing that phosphacan inhibits neurite extension
from dorsal root ganglion explants (Garwood et al., 1999), retinal ganglion cells
(Inatani et al., 2001), neurons from embyronic chick brain (Milev et al., 1994),
and PC12D cells (Oohira et al., 1991). It may be that the inhibitory effect is due
to the core protein, while the promoting effect is due to an epitope present on the
CS chains. In support of this, outgrowth promotion is abolished by degradation
of CS-GAGs or by antibodies to the “DSD-1” epitope on CS (Faissner et al.,
1994; Garwood et al., 1999; Dobbertin et al., 2003). Conversely, inhibition of
neurite outgrowth is either unaltered or enhanced by removal of the CS chains
(Garwood et al., 1999; Inatani et al., 2001).
However, a model where CS is permissive and the protein core is
inhibitory is probably too simplistic. Instead, specific domains within the protein
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core may mediate different effects on neurite extension. A fusion protein
containing all extracellular regions of the short receptor form sRPTPβ can
promote neurite extension from chick tectal neurons (Sakurai et al., 1997), thus
suggesting that inhibitory epitopes may be contained within the IS region, which
sRPTPβ lacks. If different domains within phosphacan/RPTPβ can mediate
different effects on neurite outgrowth, then the presence of binding partners—
growth factors and cytokines, ECM molecules, and/or cell surface-associated
cues—may cause either promoting or inhibiting effects to dominate. Overall,
these findings from studies in vitro suggest that cell adhesion and axon guidance
are likely to be governed by a tightly regulated balance between the growthpromoting and growth-inhibiting influences of RPTPβ splice variants, along with
the influences of other ECM and cell-surface signals.

Phosphacan/RPTPβ in the CNS Injury Response
The role of RPTPβ splice variants has been studied in the context of
several different CNS injury models. As with the in vitro studies discussed
above, here too the results are complex. RPTPβ mRNA expression is induced in
rodent hippocampus after deafferentation by a knife lesion to the fimbria-fornix
and entorhinal cortex, while both phosphacan and RPTPβ transcript are
increased directly surrounding the lesion sites (Snyder et al., 1996). Nigrostriatal
axotomy, another type of mechanical deafferenting lesion which induces axonal
sprouting and glial scarring, produces an increase in both phosphacan core
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protein and KS-phosphacan (Moon et al., 2002). Animal models of
epileptogenesis induced by Pilocarpine and Domoate have also demonstrated
increases in RPTPβ and phosphacan in the hippocampus after seizure (NaffahMazzacoratti et al., 1999; Heck et al., 2004). Similarly, brain tissue resected from
human patients with intractable temporal lobe epilepsy showed elevated RPTPβ
staining compared to age-matched autopsy controls (Perosa et al., 2002). By
contrast, a reduction in phosphacan has been repeatedly demonstrated in
studies of kainate-induced seizures (Wu et al., 2000; Matsui et al., 2002;
Okamoto et al., 2003) and cortical stab wounding (Dobbertin et al., 2003).
Finally, in a filter implantation model to induce reactive gliosis, McKeon et al
(1999) found both an increase in phosphacan mRNA in the glial scar and a
simultaneous decrease in phosphacan protein.
The pathology of different injury models may involve significant variations
in the extent of cell loss, blood-brain barrier compromise, induction of cytokines
and other inflammatory factors, activation of microglia, astrocytes,
oligodendrocyte precursor cells (OPCs), and neuronal precursor cells (NPCs) are
activated. It seems likely that these injury variations can at least partially account
for the range of RPTPβ/phosphacan responses observed. Dobbertin and
colleagues (2003) showed that in vitro a number of inflammatory cytokines can
influence glial expression of RPTPβ isoforms. In particular, IFNγ and TNFα
cause astrocytes to downregulate phosphacan production, while EGF and TGFα
strongly upregulate production of phosphacan, RPTPβ, and sRPTPβ. Microglia
39

are a major source of TNFα in the injured nervous system, and lymphocytes
infiltrating at sites of BBB disruption are a major source of IFNγ (Uno et al., 1997;
Popko et al., 1997). However, injured neurons and astrocytes are known to
produce EGF and TGFα (Junier 2000). Therefore the relative activities of
microglia, lymphocytes, injured neurons, and astrocytes could influence ambient
levels of RPTPβ after nervous system insult.
Post-translational features of phosphacan/RPTPβ may be regulated
independently from the core proteins following injury. Dobbertin and colleagues
(2003) found that after a cortical stab injury, CS and KS GAG epitopes specific to
phosphacan exhibited a transient decrease (1-4 days) corresponding to a
decrease in phosphacan core protein. However, at later time points (7-28 days)
this parallel regulation diverged: the chondroitin sulfate epitope was increased
relative to phosphacan core, while keratan sulfate levels were decreased relative
to the core. Considering the influences of CS on ligand binding, such changes in
the GAG composition of phosphacan/ RPTPβ after injury could modify the
function of these proteoglycans.
Four enzymes have been identified which are expressed in the CNS and
can degrade phosphacan/RPTPβ in isolated in vitro assays. Interestingly, all of
these enzymes have been implicated in the pathobiology of brain injury. First,
MMP-3 can digest phosphacan in vitro (Muir et al., 2002) and is upregulated in
the hippocampus after traumatic brain injury (Muir et al., 2002; Kim et al., 2005;
Falo et al., 2006). MMP-3 is an extracellular protease which cleaves a range of
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ECM components including laminin, agrin, tenascin, and several CSPGs. It
appears that MMP-3 degradation of ECM components may contribute to an
environment which is permissive for morphological plasticity, since it is activated
in regions where synaptic plasticity occurs after traumatic brain injury. Moreover
this activation is reduced in animals treated with a pharmacological agent which
reduces cell death and degeneration after injury (Falo et al., 2006). Second,
plasmin can also degrade phosphacan in vitro (Wu et al., 2000). Plasmin is an
extracellular serine protease expressed in brain parenchyma, where its
substrates include the ECM components laminin and phosphacan (Tsirka et al.,
1997; Tsirka, 2002; Wu et al., 2000). In mice lacking the gene for plasminogen
(the inactive precursor to plasmin), aberrant accumulation of phosphacan was
found in hippocampus, coincident with an abnormal build-up of Timm-stained
mossy fiber terminals after KA-induced seizures. Further, in vitro assays showed
that mossy fibers would not grow across a border of native phosphacan, while
pre-incubating the phosphacan with plasmin abolished the inhibitory effect (Wu et
al., 2000). These data suggest that cleavage of phosphacan by plasmin may be
required for the mossy fiber growth and aberrant synaptic reorganization induced
by epileptic seizures. Finally, a recent study showed that the metalloproteinases
ADAM-17 and MMP-9 can also cleave long and short RPTPβ (Chow et al.,
2008). Both enzymes cleaved a membrane-proximal sequence of RPTPβ in
CHO cells, resulting in shedding of the receptor ectodomain. While relatively
little is known about ADAM-17 expression after TBI, increases in MMP-9 activity
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following brain injury have been well documented (Romanic et al., 1998; Wang et
al., 2000; Vilalta et al., 2008). It remains to be verified whether cleavage in vivo
by MMP-9, MMP-3, and/or plasmin might regulate phosphacan/RPTPβ following
brain injury.
Due to the complex and sometime contradictory results from previous
studies of phosphacan/RPTPβ following CNS injuries, it has been difficult thus far
to clearly define what role these important matrix components might play during
recovery from TBI. In order to investigate this question directly, we have
conducted a series of studies using unilateral entorhinal cortex lesion (UEC), a
model of injury-induced plasticity and adaptive synaptic recovery.

Unilateral Entorhinal Cortex Lesion
Many animal models have been developed to mimic the pathological
sequelae and cognitive effects of TBI in humans, and different models are useful
to researchers in different ways. Experimental models such as impact
acceleration (Marmarou et al., 1994), inertial acceleration (Gennarelli et al., 1982;
Ross et al., 1994), and fluid percussion injury (Dixon et al., 1987) reliably
reproduce many of the features of human closed-head injury including the TAI
frequently associated with it. However, the diffuse nature of this type of injury
makes it difficult to study the reactive axonal sprouting and synaptogenesis
induced by TAI. A more suitable experimental model which has been used to
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study the phenomenon of reactive synaptogenesis in a more targeted manner is
unilateral entorhinal cortex lesion (UEC; see Figure 1.4).
The entorhinal cortex (EC) provides approximately 90% of the afferents to
granule cells of the dentate gyrus, so that UEC produces a very significant
deafferentation of granule cell dendrites within the ipsilateral outer molecular
layer (OML). This lesion induces robust tissue restructuring, sprouting of axon
collaterals, and synaptogenesis which is spatially restricted to the OML, and
which has been well defined temporally in a number of detailed studies.
Specifically, reactive synaptogenesis occurs in a series of stages over
approximately the first two weeks following UEC. In the first 2 days post lesion,
synaptic boutons in the OML degenerate (Steward et al., 1976; Steward et al.,
1988) and the resulting cellular debris is cleared by activated microglia (Morgan
et al., 1993). We have designated this period the “degenerative phase” of
reactive synaptogenesis after UEC. The removal of afferent terminals induces
morphological changes in the postsynaptic granule cell dendrites in the
denervated OML, which first shrink and then reorganize to form new synaptic
contacts with axonal sprouts from the crossed entorhinal-dentate projection
(Cotman et al., 1977). Tissue remodeling and synaptogenesis continue for an
extended period, but the rate of plasticity sees its greatest rise at 7-8 days post
lesion (Steward et al., 1988). Thus we have termed 7 days after UEC to be the
“reorganization phase” of reactive synaptogenesis. By 15 days post lesion, the
rate of tissue reorganization has greatly declined and many of the newly formed
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synapses have begun to assume a stable, mature phenotype; thus we have
designated this period the “stabilization phase” of reactive plasticity after UEC.
These stages of degeneration, reorganization/regeneration, and recovery have
been documented with histological staining of the tissue, ultrastructural analyses,
electrophysiological recordings, and hippocampus-dependent behavioral testing
(Lynch et al., 1972; Matthews et al., 1976a,b; Steward et al., 1976; Reeves &
Steward, 1986; Loesche & Steward, 1977).
Importantly, the reactive synaptogenesis induced by UEC leads to
successful functional recovery. Physiological recordings have shown that the
amplitude of evoked potentials in the crossed temporo-dentate (CTD) projection
to the denervated OML increases in parallel with sprouting of CTD axon
terminals, and with recovery of T-maze behavioral performance (Steward et al.,
1976; Reeves & Smith, 1987). The capacity for LTP—thought to be a
physiological correlate of learning and memory—also emerges in the CTD
pathway around 2 weeks post-lesion as the newly sprouted synapses mature
(Reeves & Steward, 1986). In sum, the discrete and targeted nature of the
deafferentation in UEC, and the well-defined cell biology of each phase of the
ensuing reactive synaptogenesis, make this an ideal model to investigate the
role(s) of phosphacan/RPTPβ in adaptive plasticity after TBI.
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Figure 1.4 Unilateral entorhinal cortex lesion. (A) Diagram of a horizontal
section through hippocampus and adjacent entorhinal cortex. Entorhinal neurons
send projections to the outer molecular layer of the dentate gyrus, where they
synapse on granule cell dendrites. (B) Surgical ablation of the entorhinal cortex
deprives the outer molecular layer of approximately 90% of its normal input, and
induces sprouting of remaining intact afferents. (C) A horizontal section from one
of our rats 7 days after UEC, with visible necrosis, hemorrhage, and complete
severance of the entorhinal-hippocampal connections. (D) UEC lesion
placement. At each point marked, 1.5 mA current is passed through the
electrode tip for 30 seconds.
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Summary
In this introduction, we have framed the work to be presented herein within
the context of the ongoing search to better understand mechanisms of plasticity
and recovery after TBI. Extracellular matrix undoubtedly influences structural
plasticity and synaptogenesis, but many of the details regarding specific
functions of individual ECM components are still lacking. Phosphacan/RPTPβ is
an important CSPG in brain ECM which, unlike many other CSPGs, may not be
straightforwardly inhibitory for axon growth and plasticity. We have described the
structure of RPTPβ and its alternative splice variants, and their patterns of
expression during development. We have reviewed the putative functions of the
different RPTPβ variants in the nervous system, which include the regulation of
cell adhesion, neurite outgrowth, and a potential role in morphogenesis and
structural plasticity. Phosphacan/RPTPβ variants have been studied in neuronal
cultures and examined in animal models of epilepsy, penetrating brain injury, and
spinal cord injury. However, our understanding of how exactly these important
ECM components are involved in recovery from brain trauma remains unclear.
In the following chapters, we will take advantage of the unique features of the
UEC model to investigate the role of phosphacan/RPTPβ during the process of
injury-induced reactive plasticity. Through detailed protein and mRNA
quantification studies, immunohistochemistry, and qualitative ultrastructural
analyses, Chapter 2 will characterize the expression of phosphacan/RPTPβ
during synaptogenesis after UEC. In Chapter 3 we will examine an important
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methodological issue prompted by our quantitative mRNA studies, namely, the
identification of a valid approach to data normalization for real-time RT-PCR
studies of experimental TBI. Chapter 4 begins to explore mechanisms by which
sRPTPβ might influence the structural plasticity of dendritic spines during
reactive synaptogenesis, focusing on changes in the sRPTPβ substrate βcatenin. It is our hope that the findings in this dissertation will help improve our
understanding of how ECM influences recovery from brain injury, and will
therefore aid in the development of therapies to promote improved recovery in
TBI patients.
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CHAPTER 2

EVIDENCE FOR PHOSPHACAN/RPTPβ MEDIATION OF INJURYINDUCED SYNAPTOGENESIS

Introduction
Functional recovery after traumatic brain injury (TBI) requires axonal
sprouting and synaptic reorganization (Ramirez 2001; Stein & Hoffman, 2003;
Nudo 2007). There is increasing evidence that these processes are regulated by
molecules within the extracellular environment of the brain. The extracellular
matrix (ECM) in the brain is particularly enriched in proteoglycans, with a major
type being the chondroitin sulfate proteoglycans (CSPGs). Structurally, CSPGs
consist of a core protein containing variable number of chondroitin sulfate type
glycosaminoglycan (CS-GAG) side chains. As a group, CSPGs were initially
described as inhibitory regulators of axon growth and plasticity. For example,
they impede axon extension in vitro and in vivo (Snow et al., 1990; Oohira et al.,
1991; Grumet et al., 1993; Davies et al., 1999), and are major components of the
inhibitory glial scar which forms after lesions to the brain or spinal cord (reviewed
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in Properzi et al., 2003). More recently, it has been shown that enzymes which
degrade CS-GAGs enhance axon regeneration and synaptic plasticity (Moon et
al., 2001; Bradbury et al., 2002; Pizzorusso et al., 2002; Huang et al., 2006). By
contrast, some CSPG family members have been shown to interact in a positive
way with cell adhesion molecules and soluble growth factors, resulting in
enhanced axonal sprouting (Faissner et al., 1994; Sakurai et al., 1997; Bicknese
et al., 1994). These interactions may be complex and show that CSPG function is
not only growth inhibitory, but in some cases may serve to support regenerative
plasticity. The CSPG phosphacan and its related splice variants constitute one
group whose members may play a supportive role in neuronal plasticity
processes.
Phosphacan (6B4 proteoglycan, or DSD-1 proteoglycan in the mouse) is a
secreted alternative splice variant of the full length receptor protein tyrosine
phosphatase β (RPTPβ), a transmembrane receptor with intracellular tyrosine
phosphatase activity (Maurel et al., 1994). A third form of the CSPG, the short
transmembrane receptor (sRPTPβ), lacks the extracellular membrane-proximal
sequence but retains the full intracellular phosphatase. Recently, a fourth splice
variant, phosphacan short isoform, was identified (Garwood et al., 2003) as a
non-proteoglycan variant found in the extracellular space. Secreted phosphacan
and transmembrane sRPTPβ are the two most prominent forms found in adult
brain (Sakurai et al., 1996; Dobbertin et al., 2003). In vitro, phosphacan can
either inhibit or promote axon growth depending on the neuronal lineage
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(Garwood et al., 1999). Produced and secreted by both neurons and glia
(Snyder et al., 1996; Hayashi et al., 2005), phosphacan is a major component of
brain ECM. In normal brain, ultrastructural studies have shown the majority of
RPTPβ/sRPTPβ expression restricted to post-synaptic dendrites and spines
(Hayashi et al., 2005). The phosphacan splice variant is secreted into the ECM
and assumes a more diffuse distribution, observed surrounding synaptic profiles,
but absent from the synaptic active zone (Miyata et al., 2004).
In contrast to other CSPGs (e.g. neurocan, versican, NG2) which are upregulated after CNS trauma (Asher et al., 2000; Asher et al., 2002; Morgenstern
et al., 2002; Jones et al., 2003), phosphacan expression after injury can vary
significantly. For example, phosphacan is reduced acutely following spinal cord
injury (Jones et al., 2003; Tang et al., 2003), attenuated after cortical stab injury
(Dobbertin et al., 2003) and is lowered following filter implant-induced glial
scarring (McKeon et al., 1999). In contrast, other studies have reported
phosphacan increases after experimental stroke (Carmichael et al., 2005) and
fimbria/fornix lesion (Snyder et al., 1996). While one recent study did profile
phosphacan mRNA expression after deafferentation lesion (Snyder et al., 2008),
a systematic analysis of phosphacan splice variants during injury-induced
reactive synaptic plasticity has not been made. Phosphacan/RPTPβ expression
is clearly regulated following CNS trauma, and these molecules are well
positioned in the cytoarchitecture to potentially regulate axon regeneration and
synaptic recovery.
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Several recent studies support a role for RPTPβ in synaptic plasticity in
the uninjured mature brain. Hippocampal long term potentiation (LTP) and
hippocampus-dependent spatial learning are two processes which rely on
synaptic plasticity and appear to be influenced by phosphacan CSPGs. RPTPβ
knockout mice (lacking all phosphacan splice variants) display age-dependent
abnormalities in hippocampal LTP, as well as impairments in spatial learning and
contextual fear conditioning (Niisato et al., 2005; Tamura et al., 2006). A number
of intracellular targets for the RPTPβ phosphatase have been identified (Kawachi
et al., 1999; Meng et al., 2000; Pariser et al., 2005; Tamura et al., 2006), many of
which function in neurite morphogenesis, synapse regeneration, and/or
stabilization (e.g. β-catenin, β-adducin, PSD-95, p190 RhoGAP, etc.). These
results suggest that there may be multiple signaling pathways through which
RPTPβ can influence structural plasticity at synapses.
In the present study we have documented the spatial and temporal
expression of three phosphacan CSPG variants (phosphacan, RPTPβ and
sRPTPβ) during synaptic regeneration following brain injury. Here we will use
the term “phosphacan/RPTPβ” to collectively refer to all three of these splice
variants. We have used unilateral entorhinal cortex lesion (UEC), a wellcharacterized rodent model of reactive plasticity which leads to successful
functional recovery (Steward et al., 1988). One advantage of the UEC lesion
model is that a robust reactive synaptogenesis occurs within the ipsilateral outer
molecular layer (OML) of the dentate gyrus during the first two weeks post-lesion.
52

This temporal profile permits the examination of phosphacan splice variant
mRNA and protein change during three distinct post-lesion phases of injuryinduced plasticity: degeneration of perforant path axon terminals (2d), afferent
sprouting and establishment of new synaptic contacts (7d), and stabilization of
newly formed synapses (15d). We report that hippocampal sRPTPβ protein and
mRNA are persistently elevated over the first two weeks after UEC. In contrast,
phosphacan protein is elevated in whole hippocampus during the acute
degenerative phase (2d) and in ML-enriched samples during active synapse
regeneration (7d), while its mRNA is increased during sprouting and synapse
formation (7d). These results support a role for phosphacan/RPTPβ in both the
degenerative and regenerative phases of reactive synaptogenesis.

Methods
Animals and Surgical Procedures
Adult male Sprague-Dawley rats (300-390g) were subjected to entorhinal
cortical lesion after the method of Loesche and Steward (1977). Rats were
randomly divided into three experimental groups: 2d (n = 18), 7d (n = 23) and
15d (n = 12) survival. All animals were surgically prepared under isoflurane
anesthesia delivered via nose cone (2.25% in carrier gas of 70% N2O, 30% O2).
During all surgical procedures body temperature was maintained at 37°C. Rats
were placed in a stereotaxic frame and an area of skull was removed above the
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entorhinal cortex of the right hemisphere. Lesion current was passed (1.5 mA for
30 sec) through a Teflon-insulated wire electrode, 10° to perpendicular, at eight
stereotaxic sites: 1.5 mm anterior to the transverse sinus, 3mm lateral to midline,
at 2mm, 4mm, and 6 mm ventral to the brain surface; then 4mm lateral to midline
at 2mm, 4mm, and 6mm ventral; and finally 5 mm lateral to midline at 2mm and 4
mm ventral (see Figure 1.4). After lesions were completed, the electrode was
removed, the scalp was sutured closed, and topical antibiotic was applied to the
surgical site. Animals were placed in a warmed holding cage and monitored
during recovery, after which they were returned to their home cages. All animal
protocols were approved by the Institutional Animal Care and Use Committee.

Protein Extraction and Western Blotting
Two rapid dissection procedures were performed for isolation of ipsilateral
and contralateral samples. Whole hippocampi were removed from one subset of
animals at 2d (n = 6), 7d (n = 9), or 15d (n = 6) post-lesion, and a dentate
molecular layer enriched fraction was removed from a second subset of rats at
2d (n = 3) and 7d (n = 4) post-lesion. For the whole hippocampal tissue, a serial
extraction protocol was adapted from Dobbertin et al. (2003) in order to separate
soluble extracellular phosphacan from transmembrane RPTPβ and sRPTPβ.
Brains were removed from the skull, divided by a mid-sagittal cut, and whole
hippocampi (including dentate gyrus and Ammon's horn) were dissected from
each hemisphere. Each hippocampus was homogenized in 1.75 ml detergent54

free extraction buffer (50mM Tris, 150mM NaCl, 40mM Na Acetate) containing
protease inhibitors (Roche complete cocktail plus 2μg/ml Pepstatin).
Homogenates were centrifuged for 20 min at 100,000 x g and 4°C. Supernatant
was removed and stored at -80°C as the saline fraction. Pellets were rehomogenized in 1.75ml extraction buffer containing 1% Triton X-100, and
agitated for 1 h at 4°C prior to centrifugation for 20 min at 100,000 x g and 4°C.
Supernatant was removed and stored at -80°C as the detergent fraction. In order
to expose antigenic sites and maximize efficiency of antibody recognition, all
protein samples were treated with chondroitinase ABC (chABC; Seikagaku
America; East Falmouth, MA) to remove chondroitin sulfate GAG chains from
proteoglycans (see Appendix B). Aliquots of 540 ul for each sample were
removed, buffered to pH 8 by addition of 400 mM Tris, and mixed with an
additional protease inhibitor (Roche complete cocktail plus 2μg/ml Pepstatin).
The resulting preparation (600μl volume) was incubated with 0.3 U chABC for 3
h, shaking at 37°C. Reaction was stopped by returning samples to -80°C.
Protein concentration of the treated samples was determined by
spectrophotometry (Shimadzu UV-160; Shimadzu Scientific Instruments;
Colombia, MD). For phosphacan Western blots, samples were heat denatured in
XT sample buffer (Bio-Rad Laboratories; Hercules CA), 5μg separated on
Criterion XT 3-8% gels (Invitrogen; Carlsbad, CA) and protein transferred to
PVDF membrane. In Western blotting of RPTP-β/sRPTP-β, samples were heat
denatured in sample buffer and18μg separated on 3-8% gels (Bio-Rad
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Laboratories; Hercules CA) before transfer to PVDF membrane. Blots were
probed with monoclonal antibodies 3F8 (Developmental Studies Hybridoma
Bank; University of Iowa) or anti-RPTPβ (BD Biosciences; San Jose, CA).
A second subset of animals at 2d (n = 3) and 7d (n = 4) postlesion were
prepared for enriched molecular layer extraction. Fresh brain was rapidly
blocked into thick coronal sections, and the dentate molecular layer and adjacent
granule cell laminae were excised from the ventral leaf of the dentate gyrus.
These ML-enriched tissues were pooled from several adjacent thick sections,
homogenized in a 100μl volume of T-PER (Thermo Scientific; Waltham, MA), and
centrifuged for 5 min at 8,000xg and 4°C. Supernatant was removed and stored
at -80°C. As for the whole hippocampal protein extracts, 5μg of protein was
separated on Criterion XT 3-8% gels and transferred to PVDF membrane prior to
probing for phosphacan using the 3F8 antibody. Immunopositive bands on each
blot were detected using Supersignal West Dura (Pierce Biotechnology;
Rockford, IL) and images were captured with the G:Box ChemiHR system for
densitometric analysis using GeneSnap software (SynGene; Frederick, MD).
Measurements from tissue ipsilateral to UEC were compared to homologous
contralateral control regions and results expressed as percent of contralateral
value.
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Fluorescent Immunohistochemistry
At 2d (n = 3) or 7d (n = 3) post-lesion, groups of rats were deeply
anesthetized with sodium pentobarbital (60 mg/kg, i.p.) and sacrificed by
transcardiac perfusion of 0.9% saline, followed by 4% paraformaldehyde
(Electron Microscopy Sciences; Fort Washington, PA) in 0.1M phosphate buffer
(PB), pH 7.2. Brains were removed and post-fixed overnight at 4°C. Coronal
sections (40 μm) were collected in 0.1 M PB, and immunohistochemistry (IHC)
was performed for phosphacan (3F8 antibody; Developmental Studies
Hybridoma Bank) or RPTPβ and sRPTPβ (anti-RPTPβ, BD Biosciences) which
targets an intracellular domain common to both receptor forms. On some
sections, colocalization studies were performed with rabbit-anti-PSD-95
(Invitrogen; Camarillo, CA) or with rabbit-anti-GFAP (Dako North America Inc.;
Carpinteria, CA) to identify astrocytes as a possible source of phosphacan.
Since the binding site for 3F8 is partially masked by CS-GAGs attached to the
core protein (Dobbertin et al. 2003), we treated brain sections with chABC prior
to phosphacan immunodetection. These sections were incubated for 1 h at 37°C
with chABC (0.1 U/mL in Tris Acetate buffer; 100 mM Tris-HCl, 30 mM NaAcetate, pH 8.0), then washed 3 x 10 min in phosphate buffered saline (PBS;
Bio-Rad Laboratories) before subsequent immunodetection. Free-floating
sections were then blocked for 30 min in peroxidase, washed 3 x 10 min in PBS
and placed in blocking buffer (fish gelatin in PBS + 0.05% Triton X-100) for 30
min. Next, the tissue sections were incubated in primary antibody (3F8 1:100,
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anti-RPTPβ 1:500, or GFAP 1:5,000) overnight at 4°C. After primary antibody
exposure, sections were washed 3 x 10 min in PBS, blocked again for 30 min
and incubated with the appropriate fluorescent secondary antibody (Alexa 488
goat-anti-mouse, Alexa 594 goat-anti-chicken, or Alexa 594 donkey anti-rabbit;
Invitrogen; Carlsbad, CA) for 2 h. After a final series of PBS washes, sections
were mounted onto Probe On Plus glass slides (Fisher Scientific), and
coverslipped with Vectashield (Vector Laboratories). Minus primary controls
were processed in parallel to confirm signal specificity. Images were captured
with a Leica TCS-SP2 confocal microscope for qualitative analysis of protein
distribution.

EM Immunohistochemistry
At 7d, a subset of animals (n = 2) were deeply anesthetized with sodium
pentobarbital (60 mg/kg, i.p.) and sacrificed by transcardiac perfusion of 0.9%
saline, followed by mixed aldehyde fixative (4% paraformaldehyde and 0.2%
glutaraldehyde; Electron Microscopy Sciences) in 0.1M PB, pH 7.2. Brains were
removed and post-fixed overnight at 4°C. Coronal sections (40 μm) were
collected in 0.1 M PB and processed for immunostaining with anti-RPTPβ
antibody (BD Biosciences) as indicated above, or with MAB 5210 (Chemicon) to
detect all phosphacan splice variants. Antibody binding was visualized with DAB
as described previously (Phillips et al., 1994). Tissue was then placed in 1%
osmium (0.1M phosphate buffer, pH 7.2) and processed in resin prior to being
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flat-embedded on plastic slides. After the plastic had cured, sample regions of
mid-dorsal hippocampus containing the CA1 and dentate gyrus were excised and
a series of thick and thin sections cut on an Leica EM UC6i ultramicrotome (Leica
Microsystems). The thin sections were collected on membrane-coated slotted
grids and observed on a Jeol JEM-1230 electron microscope (Tokyo) equipped
with a Gatan UltraScan 4000SP CCD camera. The granule cell and molecular
layers of the dentate gyrus, both ipsilateral and contralateral to the lesion, were
systematically photographed at 5-10,000x magnification for qualitative analysis.

RNA Isolation and qRT-PCR
Whole hippocampi (including dentate gyrus and Ammon's horn) were
rapidly dissected from a subset of animals at 2d (n = 6), 7d (n = 5), or 15d (n = 6)
post-lesion, and RNA extraction was performed under nuclease-free conditions.
Each hippocampus (~100mg) was homogenized in 1ml Trizol Reagent
(Invitrogen), mixed with 0.2 ml chloroform, and centrifuged for 15 min at 12,000 x
g. RNA in the upper phase was removed and precipitated with 0.5 ml isopropyl
alcohol. After centrifugation for 10 min at 12,000 x g, supernatant was removed
and RNA pellets were washed in 75% ethanol. The pellets were dissolved in
PCR-grade water (Ambion) and incubated at 55°C for 10 min. All samples were
DNase treated (DNA-free DNase kit; Ambion) according to the manufacturer’s
protocol in order to remove residual DNA contamination and then stored at 80°C. Total RNA integrity and concentration was assessed with the Experion
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automated electrophoresis system (Bio-Rad). Electropherogram traces for all
samples indicated good quality RNA, with clear peaks at 18s and 28s and minor
RNA degradation. Sample concentrations measured with Experion were also
verified with spectrophotometry (ND-1000; Nanodrop Technologies). Equal
amounts of total RNA were prepared in PCR-grade water (Ambion) for
quantitative real time RT-PCR on the ABI prism 7900 Sequence Detection
system (Applied Biosystems). Taqman primers were designed with Primer
Express software (Applied Biosystems) to span exon-exon boundaries.
Sequences for specific primers and Taqman probes are shown Table 2.1.
Reactions were run in triplicate and relative mRNA quantities were derived from
CT values by the standard curve method. All reactions were found to have an
efficiency of >88% as determined by the slope of the standard curves. Negative
controls on each plate included no-amplification and no-template control
conditions. For subsequent data analysis, the mean of each mRNA triplicate was
calculated and ipsilateral values were expressed as percent of contralateral
controls for each gene. Four widely used reference genes (β-actin, cyclophilin A,
GAPDH, and 18s rRNA) were screened to assess their suitability as controls in
our injury paradigm. Only cyclophilin showed no differences in expression
between ipsilateral and contralateral hippocampi at any given time point, no
change over time postinjury, and the lowest variability of expression within each
group. Given these results, we grouped our RT-PCR data in two ways, first with
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target gene expression normalized to total RNA content, and second with
expression normalized to cyclophilin levels for each sample.

Statistical Analysis
The significance of densitometric values from Western blot immunobinding
was analyzed using the Student’s t-test. For quantitative RT-PCR data, both
normalized and non-normalized group means were analyzed using specific
planned comparisons between experimental groups, implemented using simple
main effects tests (SPSS v11 MANOVA syntax). A probability of less than 0.05
was considered statistically significant for all tests.
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Table 2.1 Taqman Sequences

gene

Oligo sequence

phosphacan forward

5’- GGGCATTCAGGAGTATCCAACA-3’

phosphacan reverse

5’- TCCGTGACTCTTCTATTTTTACTTTCAT-3’

phosphacan probe

5’- TCAGCACATCTCGTTCTATCCCTTTGCTCA-3’

RPTPβ forward

5’- GCAGAGGCCAGTAATAGTAGCCAT-3’

RPTPβ reverse

5’- TAGATGAGAATACCAACAAGAACCACTAG-3’

RPTPβ probe

5’- ACACGATCACAAGGGGTATAACCGCCTT-3’

sRPTPβ forward

5’-ACAATGAGGCCAGTAATAGTAGCCAT-3’

sRPTPβ reverse

5’- TAGATGAGAATACCAACAAGAACCACTAG -3’

sRPTPβ probe

3’- AGACACGATCACAAGGGGTATAACCGCCT -5’

cyclophilin A forward

5’- CTGTTTGCAGACAAAGTTCCAAA -3’

cyclophilin A reverse

5’- AGGAACCCTTATAGCCAAATCCTT -3'

cyclophilin A probe

5’- CAGCAGAAAACTTTCGTGCTCTGAGCACT -3'
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Results
Expression of phosphacan/RPTPβ protein after UEC
Western blot analysis of phosphacan in hippocampal homogenates
extracted without detergent (saline fraction enriched in soluble extracellular
proteins) was performed using the 3F8 antibody. In the untreated saline extracts
from 2, 7 and 15d cases, we observed a broad high molecular weight signal,
migrating at greater than 600 kD. After the samples were treated with chABC, a
discrete band at approximately 450 kD was resolved with the 3F8 antibody (see
Appendix B). This band, corresponding to the phosphacan splice variant
(Dobbertin et al., 2003), was significantly increased in the ipsilateral
hippocampus at 2d (Figure 2.1 A; 114.4 ± 6.9%, p<0.05), but was not different
from contralateral control samples at either 7 or 15d survival. By contrast, when
hippocampal homogenates extracted with 1% Triton (detergent fraction enriched
in transmembrane proteins) were probed for RPTPβ and sRPTPβ using antibody
to the intracellular c-terminal epitope, we observed a 250 kD band corresponding
to sRPTPβ (Dobbertin et al., 2003, which was significantly increased at 2, 7, and
15d after UEC (Figure 2.1 B; 116.6 ± 8.2%, p<0.05; 118.4 ± 9.5% and 120.2 ±
10.4%, p<0.001). Consistent with the reported low expression of full length
RPTPβ in adult brain, we failed to detect RPTPβ in our samples. These results
show that reactive synaptogenesis alters the protein expression of both
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Figure 2.1 Hippocampal phosphacan and sRPTPβ protein after UEC.
Protein was extracted from whole hippocampi at 2, 7, or 15d following UEC
lesion and Western blotting was performed for phosphacan (3F8 antibody) or
RPTPβ/sRPTPβ (anti-RPTPβ antibody). The developmentally prominent fulllength RPTPβ protein was not detected in our samples from adult brain. In (A)
phosphacan in the saline fraction (enriched in soluble extracellular proteins) is
increased in ipsilateral hippocampus at 2d post lesion (114.4 ± 6.9%, *p<0.02).
In (B) sRPTPβ in the detergent fraction (enriched in transmembrane proteins) is
persistently increased in ipsilateral hippocampus at 2, 7, and 15d post lesion
(116.6 ± 8.2%, *p<0.02; 118.4 ± 9.5% and 120.2 ± 10.4%, **p<0.001).
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phosphacan and sRPTPβ and that the temporal pattern of change is different for
the two proteins. Such differences suggest that phosphacan may selectively
affect an earlier phase of synapse reorganization after brain injury.

Phosphacan/RPTPβ immunohistochemistry
Having established the quantitative differences in phosphacan/RPTPβ
expression after UEC, we examined the cellular localization of these
proteoglycans with the same antibodies used in the Western blot experiments.
IHC analysis of phosphacan was focused on the acute 2d post-injury period,
where significant elevation in protein expression was observed. Diffuse low level
staining for phosphacan was evident in the contralateral molecular layer (ML),
with denser aggregates of the protein (arrows) surrounding the cell bodies of
dentate granule cells (Figure 2.2 A). By contrast, immunoreactivity specifically
within the outer ML (arrows) was upregulated ipsilateral to UEC when compared
to contralateral controls (Figure 2.2 B). Notably, the high intensity of
phosphacan staining within the granule cell layer was reduced on the
deafferented side (asterisk).
While Western blot results revealed a persistent increase in sRPTPβ
protein over the first 2 weeks after UEC, we chose to focus our IHC analysis of
sRPTPβ at 7d post lesion, the period corresponding to robust sprouting and
synaptic reorganization in the ML. Although our RPTPβ antibody recognizes an
intracellular domain common to both RPTPβ receptors, the low expression of full
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length RPTPβ in adult brain (Sakurai et al., 1996; Dobbertin et al., 2003) and lack
of detectable signal for the full length receptor in our WB studies strongly
suggests that our immunostaining with anti-RPTPβ primarily represents
distribution of sRPTPβ. We found a punctate staining pattern for sRPTPβ over
the entire ML, which appeared more intense on the deafferented side compared
to the contralateral control region (Figures 2.2 C, D).
When MAB5210 was used to localize phosphacan family members at the
ultrastructural level, we observed DAB reaction product in contralateral granule
cell cytoplasm (arrows; Figure 2.2 E), consistent with the distribution of both
proteins seen with confocal IHC. This label was verified as positive signal in
parallel unstained thin sections (see arrows in Figure 2.2 F). To investigate
whether astrocytes might express phosphacan/RPTPβ after UEC, we also
performed co-localization experiments with 3F8 or anti-RPTPβ and GFAP
antibody. Neither phosphacan nor sRPTPβ immunostaining were present within
astrocyte cell bodies and major processes (Figure 2.2 G, H), suggesting a
potential neuronal source, rather than glial, for these proteoglycans within the
deafferented dentate gyrus.
Since the distribution of sRPTPβ suggested potential synaptic localization,
we also performed double-label IHC for sRPTPβ and the post-synaptic density
marker PSD-95 at 7d after UEC. A subset of sRPTPβ positive puncta were
found adjacent to sites stained with PSD-95 (arrows in Figures 2.3 A, B), a
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Figure 2.2 Phosphacan/RPTPβ immunohistochemistry. (A) 3F8
immunostaining in contralateral hippocampus shows diffuse phosphacan
reactivity in the ML and denser aggregates surrounding granule cell bodies
(arrows). (B) Ipsilateral to lesion at 2 dpl, phosphacan staining intensity appears
reduced within the GCL (asterisk) and clearly increased in the outer ML (arrows).
(C) Anti-RPTPβ immunostaining reveals a diffuse distribution of sRPTPβ over the
contralateral ML, while ipsilateral to lesion (D) at 7dpl this immunoreactivity
appeared increased. In (E) MAB5210 was used to localize phosphacan/RPTPβ
at the ultrastructural level in the contralateral GCL 2 dpl. Reaction product can
be seen in granule cell cytoplasm, consistent with the distribution of phosphacan
in (A). In (F) a parallel thin section processed without uranyl acetate or lead
citrate counter-stain demonstrates specificity of the MAB5210 signal. Doublelabeling for phosphacan (green) and GFAP (red) at 2 dpl (G), and for sRPTPβ
(green) and GFAP (red) at 7dpl (H), shows that neither one of these
proteoglycans co-localizes with astrocytes in the deafferented zone after UEC.
In (I) a parallel section processed without primary antibodies demonstrates the
specificity of immunolabeling in these studies. ML=molecular layer; GCL=granule
cell layer; dpl=days post lesion. A-D bar=50µm; E,F bar=0.5µm; G-I bar=100µm.
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pattern suggesting contiguous distribution of the two proteins rather than colocalization. Moreover, the relative density of sRPTPβ again appeared greater in
the deafferented ML region when compared with the contralateral side (compare
Figure 2.3 B to 2.3 A). In order to further investigate whether this pattern might
represent pre- or post-synaptic localization of sRPTPβ, we performed electron
microscopic IHC on parallel 7d cases. At the ultrastructural level, sRPTPβ was
found within dendrites (asterisk in Figure 2.3 C), as well as in spines
(arrowhead) and adjacent to post-synaptic profiles (arrow), both illustrated in the
inset of Figure 2.3 C. This pattern of sRPTPβ distribution near synaptic
junctions was similar to that previously observed by Hayashi and colleagues in
embryonic cortical cells (2005). Post-synaptic localization in our experiments,
illustrated from a contralateral control molecular layer, was seen in both injured
and control ML at 7d post lesion.

Expression of Phosphacan/RPTPβ mRNA after UEC
Specific mRNA levels of phosphacan, RPTPβ, and sRPTPβ were
measured in deafferented and contralateral control tissue at 2, 7, and 15d post
lesion using qRT-PCR. Initially, we tested four commonly applied reference
genes for our hippocampal UEC samples and found that cyclophilin A transcript
was the most stably expressed (see Chapter 3). However, prior methodological
analysis of qRT-PCR shows that normalization to total RNA mass, rather than to
a specific reference gene, may be more accurate when assessing subtle shifts in
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Figure 2.3 sRPTPβ immunostaining indicates postsynaptic localization.
Double-labeling of sRPTPβ (green) and post-synaptic density marker PSD-95
(red) was performed at 7dpl. A subset of sRPTPβ positive puncta within the
contralateral ML (A) and the ipsilateral ML (B) are located adjacent to PSD-95
positive sites (arrows), suggesting a contiguous but non-overlapping distribution
of the two proteins. (C) In parallel 7dpl cases processed for ultrastructural
immunostaining, sRPTPβ is localized within dendrites (asterisk) and spines (see
inset) within the outer ML. Immunoreactivity was seen both near the base of
spines (arrowhead) and at the synaptic active zone (arrow). ML=molecular layer;
dpl=days post lesion; EM=electron microscopy. A,B bar= 25µm; C bar=0.5µm;
Inset bar=0.2µm.
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gene expression (Tricarico et al., 2002; Meldgaard et al., 2006). Given these
observations, we chose to analyze our qRT-PCR data in two ways: 1) normalized
to cyclophilin, and 2) normalized to total RNA content (Figure 2.4). Results with
the two normalization strategies show similar overall trends, but several
differences in the detection of significant effect were observed. When normalized
to cyclophilin, phosphacan mRNA was significantly increased at 7d (120.4 ±
3.0%; p<0.05), while mRNA for each transmembrane RPTPβ splice variant was
elevated at only at 15d (138.6 ± 20.8%, p<0.01 for RPTPβ; 134.6 ± 20.1% for
sRPTPβ, p<0.01). When mRNA expression was normalized to total RNA mass,
similar results were obtained for phosphacan, with significant transcript elevation
occurring only at 7d (113.6± 8.7%, p<0.05). By contrast, additional differences in
transcripts for both RPTPβ forms were detected. Specifically, full length RPTPβ
was significantly elevated at both 2 and 15d (122.8 ± 5.3% and 122.6 ± 7.8%;
p<0.001), while sRPTPβ was significantly elevated at 2, 7, and 15d post lesion
(111.7 ± 10.0% and 112.8 ± 5.6%, p<0.05; 118.8 ± 6.9%; p<0.01). These results
suggest that small shifts in cyclophilin gene expression following UEC introduce
enough variance into the reference gene normalization analysis to cause the loss
of some group differences. Interestingly, Bustin and colleagues (2006) have
proposed that reference gene normalization may not be necessary if RNA
sample quality is high (avoiding contamination effects on PCR reaction
dynamics), and if total RNA load concentration is accurately measured. Since
we rigorously assessed RNA quality by Experion LabChip analysis (see
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Appendix D) and confirmed sample concentrations by Nanodrop
spectrophotometry, we feel that these conditions are met in our protocol, and
predict that low variability of the PCR reaction was achieved in our experiments.
Based upon these criteria, and the fact that the temporal pattern of protein and
transcript are most closely matched using normalization to total RNA mass, we
believe that our results without reference gene normalization (Figure 2.4, right
column) are the more biologically relevant data.

Local Expression of Phosphacan in the Deafferented Molecular Layer
Given that observed shifts in phosphacan protein and mRNA at 2 and 7d
postlesion were not temporally matched, we investigated whether these
differences might be explained by sampling method. Our time course profiles for
phosphacan/RPTPβ were determined from whole hippocampal extracts, which
could potentially dilute injury effects specific to the deafferented ML. In fact, our
IHC results suggested that phosphacan within the ipsilateral dentate gyrus was
reduced over the granule cell layer and increased in the deafferented ML
following UEC. We examined phosphacan protein level in Western blots for both
2 and 7d samples enriched in the ML. At 7d, when qRT-PCR showed elevated
transcript, but no increase in whole hippocampal phosphacan, the isolated
deafferented zone revealed a significant increase in phosphacan protein
(129.9±4.9%; p<0.05; Figure 2.5). Interestingly, we found that phosphacan was
not increased in 2d ML enriched samples (3.7±3.6%; p>0.05), as compared with
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a clear increase seen in the whole hippocampal extracts (see also Figure 2.1).
This result might be explained by the observation that UEC appears to shift
phosphacan signal from granule cell layer to the deafferented outer ML (see
again Figure 2.2 A, B). Given that our ML enriched extracts are also likely to
contain some granule cell bodies (see dissection methods above), then the ML
enriched extracts from the ipsilateral and contralateral sides would have similar
overall amounts of phosphacan and show no relative change in WB signal.
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Figure 2.4 Phosphacan/RPTPβ mRNA after UEC. RNA samples extracted from
whole hippocampi at 2, 7, or 15d post lesion were analyzed for expression of
phosphacan, RPTPβ, or sRPTPβ transcript using qRT-PCR. The data were either
normalized to expression of the reference gene cyclophilin (left column) or normalized
to equal starting amounts of total RNA (right column). When normalized to cyclophilin,
phosphacan mRNA is significantly increased at 7dpl (120.4 ± 3.0%; *p<0.05), while
RPTPβ and sRPTPβ transcripts are each increased at 15dpl (138.6 ± 20.8% for
RPTPβ; 134.6 ± 20.1% for sRPTPβ; **p<0.01). Normalizing to equal total RNA
showed similar overall trends but revealed additional significant effects of injury. When
normalized to total RNA, phosphacan was increased at 7dpl (113.6± 8.7%, *p<0.05),
while RPTPβ showed significant elevation at both 2 and 15d (122.8 ± 5.3% and 122.6
± 7.8%; **p<0.001) and sRPTPβ showed persistent increase at 2, 7, and 15dpl (111.7
± 10.0% and 112.8 ± 5.6%, *p<0.05; 118.8 ± 6.9%; **p<0.01). Since the criteria for
accurate normalization to total RNA are met in our experiments (see text for details) we
propose that the qRT-PCR results normalized to total RNA represent the more
biologically relevant data.
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Figure 2.5 Phosphacan protein in the deafferented molecular layer. Protein
was extracted from ML-enriched hippocampal dissections at 2 and 7 dpl and
probed for phosphacan with the 3F8 antibody. Representative lanes show 3F8
Western blotting results from ipsilateral and contralateral hippocampi at 2 and
7dpl. At 7dpl, when whole hippocampal protein showed no change in
phosphacan compared to contralateral control (see also Figure 2.1A), MLenriched samples showed a significant increase in phosphacan (129.9±4.9%;
*p<0.05). This pattern is supported by the increase in phosphacan transcript we
observed at 7dpl (see Figure 2.4). Interestingly, the increase in whole
hippocampal phosphacan at 2 dpl (see also Figure 2.1A) is lost in the MLenriched dissection, suggesting differential distribution of phosphacan protein
within the hippocampus at 2 and 7d after UEC. I = ipsilateral; C= contralateral;
dpl = days post lesion.
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Discussion
The present study describes the expression of phosphacan/RPTPβ
isoforms during the time course of reactive synaptic plasticity in the deafferented
hippocampus. We focused on post-injury time intervals of synaptic degeneration
(2d), sprouting and synapse formation (7d), and synapse stabilization (15d). We
report that the protein and mRNA for phosphacan, full length RPTPβ, and
sRPTPβ are differentially expressed following UEC deafferentation. In whole
hippocampal tissue extracts, phosphacan protein was acutely upregulated 2d
after UEC, while transcript showed a later increase at 7d. When samples
enriched in the deafferented molecular layer were probed for phosphacan
protein, an increase was observed at 7d, showing that the injury response is subregion specific. By contrast, both protein and transcript for sRPTPβ were
persistently elevated at all three post injury time points. The mRNA for full-length
RPTPβ also increased after UEC lesion, but this change was limited to 2 and 15d
survival, and was not accompanied by detectable signal for the translated
protein. Phosphacan and sRPTPβ were each localized within granule cell bodies
and over the deafferented neuropil of the dentate ML, and increased in label
intensity at 2 and 7d post-lesion. Co-localization studies showed that reactive
astrocytes were not labeled for either phosphacan or sRPTPβ protein,
suggesting that they are not a primary source of the increased levels observed in
the deafferented zone. We also found that sRPTPβ and PSD-95 were expressed
in adjacent loci within the ML neuropil, and EM immunostaining showed sRPTPβ
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localization in ML dendrites and spines, suggesting post-synaptic proteins may
be targets of the tyrosine phosphatase during synaptogenesis. Taken together,
these results support the participation of phosphacan and its membrane bound
tyrosine phosphatase variants in each phase of reactive synaptogenesis.

Time Course of Phosphacan/RPTPβ Expression During Synaptogenesis
Our study provides new detail regarding the expression of extracellular
phosphacan and the transmembrane tyrosine phosphatase sRPTPβ during the
time course of reactive synaptogenesis. Overall, phosphacan showed increased
mRNA and protein expression in the earlier phases of synaptogenesis (2 and
7d), while the membrane bound sRPTPβ transcript and protein were elevated at
all time points examined, covering the degenerative, sprouting, and stabilization
phases. Notably, sRPTPβ showed a correlated rise in both transcript and
protein, while phosphacan did not.
Prior to the present study, two other investigations have explored
expression of phosphacan isoforms at single time points after UEC. First, Deller
and colleagues (1997) reported an increase in phosphacan immunostaining 6d
after UEC. However, this study used an antibody directed toward a CS epitope
attached to phosphacan. Since post-translational modifications may alter CS
epitopes, causing them to be regulated independently from the core protein
(Rauch et al., 1991; Meyer-Puttlitz et al., 1995; Dobbertin et al., 2003), changes
detected by this antibody may not fully reflect the impact of UEC on phosphacan
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protein level. The second study employed in situ hybridization to show induction
of phosphacan and full-length RPTPβ mRNA in hippocampus 20d after a
combined UEC and fimbria/fornix lesion (Snyder et al. 1996). Unfortunately, the
single long-term time point examined did not allow for conclusions to be drawn
about the specific role(s) of these transcripts during the full time course of
hippocampal synaptic reorganization.
In our study we sampled three key postinjury intervals and report an
increase in both sRPTPβ and full-length RPTPβ transcript after UEC. For
sRPTPβ, protein and mRNA were concurrently elevated at 2, 7, and 15d survival,
remaining remarkably stable throughout the different phases of reactive
synaptogenesis. Transcript for the long form of RPTPβ was increased at the
acute 2d and later 15d period. Notably, the increase in full-length RPTPβ mRNA
reported by Snyder and colleagues is consistent with our 15d data showing
transcript elevation for both long and short receptor forms during the synaptic
stabilization phase. Because full-length RPTPβ is primarily a developmental
isoform, and the protein is not routinely detectable in our adult samples, the
functional significance of UEC-induced changes in RPTPβ transcript remains
unclear. Since we have applied the standard curve method for relative transcript
quantification (Bond et al. 2002), we could not derive an absolute copy number of
RPTPβ mRNAs. Given that qRT-PCR is a sensitive technique capable of
detecting mRNAs with very low copy number, it is possible that the significant
increases in full-length RPTPβ detected in the present study reflect a low copy
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number shift, which may or may not be directly relevant to the process of reactive
synaptogenesis. Further examination of this RPTPβ isoform will be required to
establish its possible role in the acute and long-term phases of synaptic
reorganization.
In addition, our results differ from those of Snyder and colleagues in that
we did not observe increased hippocampal phosphacan message at 15d after
UEC. As we found with phosphacan protein analysis, this may be due to dilution
of effect by sampling whole hippocampus rather than enriched ML zones. In fact,
the study by Snyder et al. (1996) showed that increased tissue signal was
focused over the stratum lacunosum-moleculare and stratum radiatum, dendritic
regions targeted by their combined injury paradigm. It is also possible that
hippocampal deafferentation produces elevation of phosphacan message at both
7 and 20d postinjury, indicating a biphasic transcriptional response, and
suggesting multiple roles for this proteoglycan during synaptic recovery.
While more recent studies have included phosphacan in a detailed
analysis of CSPG family transcription during reactive synaptogenesis (Schafer et
al., 2008), we believe that the present study is the first to report the pattern of
both protein and transcriptional regulation for three major phosphacan splice
variants over the time course of reactive synaptogenesis leading to adaptive
recovery. Our current findings with respect to UEC lesion add to the
understanding of how phosphacan and sRPTPβ contribute to synaptic
reorganization within the injured CNS.
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Asynchrony of Phosphacan Expression During Synaptogenesis
In the current study some interesting differences in phosphacan
expression were revealed from whole hippocampal extracts. Specifically a 2d
increase in protein was not matched by mRNA elevation, while a 7d increase in
transcript was not accompanied by a rise in protein. While less frequently
observed, differing patterns of transcript versus protein expression have been
reported for proteoglycans in other studies of CNS injury. For example, spinal
cord contusion caused an increase in phosphacan protein while transcript
remained essentially unchanged (Iaci et al., 2007). Conversely, experimental
stroke caused an induction of phosphacan mRNA while staining for phosphacan
protein was reduced in peri-infarct cortical regions (Carmichael et al., 2005).
Such differences between phosphacan protein level and mRNA
transcription might be explained in several ways. When increased protein is
observed without transcript change, as we have shown for phosphacan at 2d
after UEC, one possibility would be that a stable pool of mRNA is translated at an
accelerated rate after injury. One mechanism by which this effect might occur
could be through the induction of elongation factor 1α (EF1α), a key component
of the translational machinery, in granule cell dendrites when reactive plasticity is
induced. Increased EF1α has been demonstrated in association with the
hippocampal plasticity produced by LTP of the medial perforant path (Huang et
al., 2005). Molecules like EF1α are also upregulated by mGluR activation,
mediating protein expression by driving dendritic mRNA translation without new
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transcription (Huang et al., 2005; Huber et al., 2000). Changes in proteins which
regulate translation have also been reported following fluid percussion injury
(FPI). For example, mammalian target of rapamycin (mTOR) and cytoplasmic
polyadenylation element-binding protein (CPEB), both mediators which help
promote protein translation, are reported to be transiently increased after FPI
(Atkins et al., 2006; Chen et al., 2007). Clearly, multiple pathologies which
constitute focal brain lesion might activate molecules which alter the rate of
protein translation. Alternatively, the difference we report in phosphacan protein
and transcript at 2d could be due to an injury-induced effect on antibody binding.
In this case, the efficacy of antibody recognition could be altered by injuryinduced changes in the target protein, including changes in binding partners,
protein conformation, or post-translational modifications. Such post-injury
changes in phosphacan conformation or post-translational modifications could
potentially enhance detection of protein by immunological methods, in the
absence of change in transcript.
In contrast to 2d post injury, at 7d we observed an elevation in
phosphacan transcript without concurrent increase in protein. Several different
scenarios could explain this type of difference. First, despite the evidence
suggesting accelerated protein translation at 2d, it is possible that post-injury
conditions at the 7d time point could cause translation of phosphacan protein to
be suppressed. On the other hand, the observed transcript elevation without
change in protein levels could occur if the protein products of new mRNA
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transcripts are successfully translated, but then rapidly degraded in vivo. This
could result from activation of one or more extracellular proteases known to
degrade phosphacan. In particular, the metalloproteinase MMP-3 has been
shown to cleave phosphacan in vitro (Muir et al., 2002) and its expression is
upregulated in hippocampus after UEC (Falo et al., 2006). The tPA/plasmin
proteolytic pathway could also degrade phosphacan during injury-induced
synaptogenesis, since plasmin has been shown to degrade phosphacan in the
hypothalamus during physiologically induced synaptic plasticity (Miyata et al.,
2005).
Our exploration of the role of tissue sampling revealed a more direct
potential explanation for these differences between phosphacan mRNA and
protein expression. In extracts from whole hippocampus, phosphacan protein
increased only at 2d post lesion. When the deafferented ML was more directly
examined using dentate-enriched protein fractions, phosphacan was no longer
elevated at 2d, but rather at 7d post lesion, the period when sprouting and
synapse formation is initiated. This ML result was consistent with our
observation that increased transcription of hippocampal phosphacan mRNA was
restricted to 7d after UEC. With careful examination of correlative phosphacan
IHC (describe in detail below), the absence of ML increase in protein expression
at 2d appears to be associated with phosphacan redistribution from the granule
cell body lamina to dendritic zones (see again Figure 2.2 A, B). Thus,
comparison of our lesioned and control extracts would produce no detectable
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differences. By contrast, at 7d, when ipsilateral ML expresses higher levels of
phosphacan by WB analysis, the IHC pattern shows uniform elevation of the
protein over the entire deafferented dentate ML (see again Figure 2.2 C, D). In
this case, our ML enriched extracts revealed significant elevation of phosphacan
on the lesioned side. Given the differences between whole hippocampal and ML
enriched extracts, it is clear that UEC produces a complex phosphacan response
and that accurate interpretation of phosphacan expression requires sampling of
tissue sites specific to the biological process being investigated.
Finally, we cannot rule out the possibility that the examination of other
time points not included in the present study would provide tighter correlation
between mRNA and protein profiles. For example, phosphacan transcript levels
may be elevated prior to 2d and their translation may be responsible for the
significant increase in phosphacan protein we find at 2d. The asynchrony in
phosphacan mRNA and protein levels after UEC illustrates the fact that transcript
does not always accurately predict changes in protein content. In fact, others
have urged caution in interpreting studies of proteoglycan expression after CNS
trauma, particularly where mRNA quantification is the sole endpoint (Iaci et al.
2007).

Distribution of Phosphacan/RPTPβ During Synaptogenesis
We also investigated the in vivo localization of phosphacan splice variants,
to address whether the changes observed in protein extracts were supported by
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a tissue distribution consistent with the adaptive synaptogenesis induced by
UEC. IHC for hippocampal phosphacan and sRPTPβ was performed focusing
on 2 and 7d post injury, intervals when differences in protein expression for each
splice variant were detected by Western blot.
IHC for phosphacan revealed a diffuse, uniform staining of the neuropil in
the control samples, consistent with its role as a matrix proteoglycan. We also
observed a dense staining pattern surrounding neuronal somata in the
hippocampal GCL. At 2d post lesion, immunoreactivity for phosphacan appeared
as a strong band in the deafferented outer ML and was notably decreased in the
GCL compared to contralateral controls. At 7d post lesion the same relative
distribution of phosphacan between ML and GCL was observed, however the
intensity of antibody signal was reduced overall (data not shown). A similar
pattern of elevated proteoglycan over the deafferented outer ML was reported
using antibodies to tenascin-C and a CS epitope on phosphacan (Deller et al.,
1997). However, one notable difference shown in our study was a strong GCL
localization of phosphacan which appeared to shift into the deafferented dendritic
regions after UEC. It is possible that 3F8 antibody recognition of the phosphacan
protein core revealed cell body sites not recognized with the DSD-1-PG IgM
antibody used by Deller’s group.
By contrast, IHC with antibody to sRPTPβ revealed a punctate staining
pattern, which at 7d showed elevation over the hippocampal ML compared to
contralateral controls. Anti-RPTPβ targets an intracellular epitope common to
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both receptor variants, so that this staining could represent the long as well as
short receptor form of the protein. However, since other studies have
demonstrated that full-length RPTPβ is primarily a developmental isoform
(Sakurai et al. 1996; Dobbertin et al 2003), and we failed to detect it in our
Western blot samples from adult brain, it seems likely that our anti-RPTPβ IHC
signal represents primarily the short receptor form. Thus, the enhanced IHC
signal observed at 7d supports the increase in ML sRPTPβ detected at that same
time interval with Western blotting. Furthermore, the increased sRPTPβ tissue
signal is located in the region of active synaptogenesis at 7d after UEC, the
period when the rate of collateral sprouting and synapse formation is most rapid.
This supports the hypothesis that sRPTPβ may interact with the local ML
environment to influence the development of presynaptic terminals and the
reorganization of postsynaptic dendrites after UEC. A similar role for RPTPβ has
been proposed during dendritic morphogenesis of cerebellar Purkinje cells in
vitro, where direct inhibition of RPTPβ results in aberrant, disoriented dendritic
structure (Tanaka et al., 2003). It would be interesting to examine such
manipulations of sRPTPβ in UEC or other TBI models to establish a direct link
between the tyrosine phosphatase and synaptic recovery following brain injury.
Because the punctate pattern of sRPTPβ staining was suggestive of a
potential synaptic distribution, we performed co-localization studies with the postsynaptic density marker PSD-95. We found that a subset of sRPTPβ puncta in
the outer ML were localized immediately adjacent to, but not overlapping with,
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PSD-95 signal, suggesting that this tyrosine phosphatase is positioned near the
reorganizing postsynaptic sites to regulate protein phosphorylation in tandem
with local synaptic kinases. A similar patchy localization of RPTPβ along
dendritic shafts and cell body membranes of cerebellar Purkinje cells was
reported by Fukazawa et al. (2008) using both confocal and EM methods. In the
present study we have also used EM immunohistochemistry, and our results
confirm the localization of sRPTPβ within ML postsynaptic spines and dendrites.
Such a pattern is consistent with the postulated role for sRPTPβ in modulating
postsynaptic protein distribution (Kawachi et al., 1999; Fukazawa et al., 2008)
and in the regulation of phosphorylation-directed positioning of receptors in the
postsynaptic membrane (Tezuka et al., 1999). Supporting this interpretation,
other EM studies also show anti-RPTPβ immunostaining on dendrites and
postsynaptic profiles of pyramidal neurons in cortex and hippocampus (Miyata et
al., 2004; Hayashi et al., 2005).
Finally, we have utilized dual label confocal IHC combining antibody to
phosphacan or sRPTPβ with antibody to GFAP, to determine whether reactive
astrocytes contribute significantly to the increased expression of these proteins in
the deafferented ML. Surprisingly, we failed to find co-localization of either of
these phosphacan splice variants within the cell bodies and primary processes of
ML reactive astrocytes, either at 2 or 7d after lesion. This observation contrasts
with documented astrocytic expression of phosphacan following spinal cord
contusion (Vitellaro-Zuccarello et al., 2008), ischemic brain injury (Beck et al.,
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2008), and a filter implant-induced model of chronic glial scarring (McKeon et al.,
1999). Our results suggest that such a pattern is not reproduced in the UEC
model, where astrocytes do not appear to be the primary source for phosphacan
or sRPTPβ production during reactive synaptogenesis. Neurons themselves
may be the major regulators of phosphacan response during adaptive synaptic
recovery.

Phosphacan/RPTPβ Expression Differs as a Function of Injury Type
Based on previous studies in multiple models of brain and spinal cord
injury, phosphacan regulation in the injured CNS appears to be quite complex.
While many other CSPGs such as neurocan (Asher et al., 2000), versican (Asher
et al., 2002), and NG2 (Tang et al., 2003), all undergo rapid upregulation after
CNS injury, phosphacan appears to be unique in that its response to injury may
be mixed. For example, acute reductions in phosphacan (1-4 days) have been
documented after cortical stab injury (Dobbertin et al., 2003; Matsui et al., 2002),
kainic acid induced seizures (Matsui et al., 2002; Okamoto et al., 2003), spinal
cord contusion (Jones et al., 2003), and spinal cord stab injury (Tang et al.,
2003). On the other hand, increased phosphacan expression has been reported
as well, generally at later time points (2 weeks - 2 months), after spinal cord
contusion, spinal cord stab injury, and seizures induced by intra hippocampal
glutamate agonist injection (Jones et al., 2003; Tang et al., 2003; Heck et al.,
2004). In some cases, both increases and decreases in phosphacan occur
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concurrently within different sub-regions after injury. For example, phosphacan
immunostaining 2d after spinal cord stab injury is reduced in the lesion core but
increased at the lesion margins (Tang et al., 2003). Additionally, in a rodent
model of stroke, phosphacan immunostaining was increased in the region of glial
scarring closely bordering the infarct, but was markedly reduced in a broader
band of peri-infarct tissue where axonal sprouting is known to occur (Carmichael
et al., 2005). Clearly injury-induced changes in phosphacan expression can
depend upon the type and severity of tissue damage, the location sampled, and
the post-injury interval examined.
The present results serve as a good example of how assessment of
phosphacan expression can be dependent on multiple factors. We found that,
during UEC-induced synaptogenesis, the temporal profile of phosphacan: 1)
differs from other types of cortical injury, 2) may exhibit asynchronous mRNA and
protein change, and 3) will show significant increase or decrease depending
upon the proximity to the site of synaptic plasticity. It seems likely that variance
in phosphacan expression after CNS injury can be attributed, in large part, to
physical differences between the injuries induced. Compared to other injury
paradigms, one unique feature of the UEC model is that the lesion site is some
distance away from the deafferented region, allowing separation between
processes associated with tissue degeneration and those associated with
adaptive synaptic plasticity (Deller et al., 2000). In particular, the lack of
extensive cell death and typical glial scarring (as would be generated by lesions
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such as stab wounds) might contribute to the novel pattern of phosphacan
regulation we have observed in the UEC deafferented hippocampus. Since
neurons express phosphacan, lower expression would be expected following
injuries with more extensive cell loss, as has been observed in spinal cord
contusion (Jones et al., 2003) and stab injury (Tang et al., 2003). Conversely,
paradigms like UEC lesion, which reduce neuronal activity in the deafferented
region, might lower expressional inhibition for proteins like phosphacan/RPTPβ.
Studies which apply systemic stimuli to activate supraoptic magnocellular
neurons have shown an inverse relationship between cell activity and levels of
phosphacan/RPTPβ expression (Miyata et al., 2004).
Differences in the extent of reactive gliosis across injury models could also
affect phosphacan since reactive astrocytes have been shown to alter their
expression of phosphacan splice variants after experimental brain injury,
including knife lesion of the perforant path (Snyder et al., 1996), and cortical stab
lesions (McKeon et al., 1999; Dobbertin et al., 2003). With focal brain lesions like
stab wounds, phosphacan may be more closely linked to the local astrocytic
scarring response than other CSPGs. This possibility is supported by a recent
study where experimental attenuation of the astroglial response to spinal cord
contusion reversed the injury-induced rise in phosphacan, while elevated
expression of other CSPGs (e.g. versican, neurocan, and brevican) remained
unaltered (Vitellaro-Zuccarello et al., 2008). Further, astrocyte expression of
phosphacan splice variants is influenced by a number of soluble growth factors
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and cytokines (Dobbertin et al., 2003; Smith and Strunz, 2005), many of which
are altered with CNS injury. Two of these molecules, epidermal growth factor
(EGF) and transforming growth factor α (TGFα), both EGF receptor ligands,
enhance astrocytic phosphacan expression in vitro. Astrocytes have also been
shown to up-regulate EGF receptors and ligands including TGFα in vivo after
lesions to the anterior hypothalamus or hypoglossal nerve (Junier et al., 1991;
Junier et al., 1993; Lisovoski et al., 1997). Thus, activation of EGF receptors on
astrocytes may be one pathway responsible for increased phosphacan protein
levels in some types of injury. Interestingly, after UEC we found no evidence of
significant astroglial phosphacan synthesis, at least during the 2-7d postinjury
period. While it remains possible that astrocytes produce and release
phosphacan prior to 2d after UEC, this seems unlikely since the ML reactive
astrocytic response peaks between 2-4d post lesion without appreciable scar
formation. Given these conditions, our results suggest that induction of astrocytic
phosphacan may depend upon whether or not a barrier scar interface is required
after injury.
Phosphacan may be degraded by matrix metalloproteinase 3 (MMP-3),
part of a family of extracellular enzymes (Muir et al. 2002). Therefore,
differences between injury models in activation of MMPs (Kim et al 2005; Falo et
al. 2006) could also account for some of the variance in phosphacan expression
levels seen after different types of injury. Specifically, these studies have shown
a significant increase in MMP-3 transcript, protein, and enzyme activity at 2d
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after UEC, with reduction toward control values at 7d postlesion. If MMP-3
contributes to the regulation of phosphacan protein levels after injury, the
temporal pattern of early activation and later reduction would fit with the ML
profile of phosphacan expression observed in our study.
Compared to the extensive literature on phosphacan and other
extracellular proteoglycans, studies describing the response of receptor splice
variants RPTPβ or sRPTPβ to CNS injury are rare. In one of these studies,
Dobbertin and colleagues (2003) described the expression of both receptor
variants after cortical stab injury in rodents. There, injury did not alter expression
of sRPTPβ protein or transcript, and caused a reduction in full-length RPTPβ
mRNA. A different result was found with the evaluation of sclerotic hippocampal
tissue from epileptic patients, where an increase in anti-RPTPβ immunoreactivity
was associated with gliosis and mossy fiber sprouting in the inner molecular layer
(Perosa et al. 2002). Our results after UEC also showed an elevation in sRPTPβ
mRNA and protein, which persisted throughout the period of reactive plasticity.
Similar to temporal lobe epilepsy, UEC induces axonal sprouting in the
hippocampus. The present results support an association between this sprouting
response and increase of sRPTPβ mRNA and protein, as well as full-length
RPTPβ mRNA. Again, it appears that this splice variant is associated with
neuronal structures, as we see little evidence of significant astrocytic production
of sRPTPβ. A stab injury, in contrast, would likely be associated with more
discrete tissue damage, blood-brain barrier disruption, astroglial scarring, and
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notably less compensatory plasticity. If sRPTPβ is supportive for synaptic
remodeling, then this lack of plasticity following stab lesion correlates well with
the lack of change in sRPTPβ. Thus, as with phosphacan, it appears that the
expression of RPTPβ after injury is sensitive to differences in injury pathogenesis
across different models.

Mechanisms of Phosphacan/RPTPβ Regulation of Synaptic Plasticity
How might phosphacan/RPTPβ isoforms influence synaptic reorganization
after brain injury? These proteoglycans are large molecules with many functional
domains which may carry out different and even opposing functions depending
on the presence of specific binding partners in the immediate proximity. We
propose that the effects of phosphacan on plasticity are due to interactions
occurring in the extracellular compartment, while sRPTPβ effects on plasticity
can be attributed largely to interactions within the intracellular domain. For
phosphacan, relevant binding partners may include cell adhesion molecules
(CAMs), ECM molecules, and growth factors. For sRPTPβ, functional
intracellular targets may include a number of post-synaptic scaffolding proteins
and regulators of the neuronal cytoskeleton.
It is well established that endogenous growth factors can promote
sprouting and plasticity in the injured CNS (Nieto-Sampedro & Bovolenta, 1990;
Cui 2006; Deller et al., 2006). Similar to other ECM molecules, phosphacan
binds to a unique array of growth factors including basic fibroblast growth factor
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(FGF-2), pleiotrophin, amphoterin, and midkine (Milev et al., 1998a; Milev et al.,
1998b; Maeda et al., 1999). This binding may help localize these signals to sites
of sprouting, or to sequester them for mobilization at the appropriate point during
regeneration. In particular, FGF-2 has been shown to be important for
synaptogenesis induced by hippocampal deafferentation, since antibodies
against FGF-2 caused a marked reduction in compensatory cholinergic sprouting
(Fagan et al., 1997).
CAMs are another class of molecules known to regulate the sprouting and
outgrowth of axon collaterals after injury (Deller et al., 2006). Phosphacan may
block neuronal binding to CAMs, which would be adaptive during the early phase
of reactive synaptogenesis, when axons must “release” their contacts with
adjacent cells in order to reorganize. The acute (2d) shift in phosphacan to
deafferented dendritic regions and the overall elevation of phosphacan within the
dentate gyrus at the initiation of sprouting (7d) could serve as mechanisms to
generate an open and permissive environment for adaptive synaptic
reorganization in the ML.
In contrast to phosphacan, sRPTPβ may affect injury-induced plasticity
primarily through its interactions with binding partners in the intracellular domain.
sRPTPβ has a cytosolic tyrosine phosphatase domain, and binding of
extracellular ligands such as pleiotrophin and midkine has been shown to induce
a conformational change which regulates phosphatase activity and triggers signal
transduction (Maeda et al., 1996; Maeda et al., 1999; Sakaguchi et al., 2003). A
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role for the receptor splice variants in the morphogenesis of post-synaptic
structures has been proposed in the context of cerebellar Purkinje cell
development (Tanaka et al., 2003). In that study, disruption of
pleiotrophin/RPTPβ signaling by RPTPβ antibodies, chondroitinase treatment,
exogenous CS, or inhibition of phosphatase activity resulted in aberrant dendritic
morphology. The cellular mechanisms underlying structural plasticity in
development, and in learning and memory in adults, share many similarities with
those that drive reactive plasticity after brain injury. Therefore, these
developmental studies offer further support for our hypothesis that sRPTPβ is
involved in regulating the structural plasticity of dendrites after UEC.
RPTPβ knockout mice have also provided additional insight into the role of
sRPTPβ during synaptic plasticity in the uninjured adult brain. While the
knockouts (lacking all splice variants derived from the RPTPβ gene) showed no
gross anatomical abnormalities, they did display abnormal synaptic plasticity as
evidenced by enhanced LTP and impaired spatial learning (Niisato et al. 2005).
One mechanism to explain the observed effects on learning, memory, and LTP in
RPTPβ-null mice proposes that structural plasticity is impaired due to altered
phosphorylation of p190 RhoGAP (Niisato et al., 2005). This GTPase activating
protein is a substrate of sRPTPβ in wild-type mice, and is known to regulate
neuronal morphogenesis and synaptic plasticity through its downstream effectors
Rho and ROCK. In addition to p190 RhoGAP, the sRPTPβ phosphatase also
targets a number of other proteins involved in cytoskeletal regulation and spine
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morphogenesis, including β-catenin, β-adducin, Fyn, GIT1, PSD-95, and ErbB4
(Meng et al., 2000; Pariser et al., 2005a; Pariser et al., 2005b; Kawachi et al.,
2001; Kawachi et al., 1999; Fujikawa et al., 2007; see full list in Appendix E). Of
these sRPTPβ targets, at least two are directly associated with cell damage in
TBI paradigms. Dying neurons show an elevation in ErbB4 after closed head
injury (Erlich et al., 2000) and regions of cortical contusion exhibit reduced PSD95 expression up to 4d postinjury (Ansari et al., 2008). Together, these
observations suggest that sRPTPβ can act through multiple signaling pathways
after brain injury to alter the phosphorylation state of synaptic proteins and
influence synaptic structural plasticity.

In summary, the data presented here provide new evidence that
phosphacan and sRPTPβ play a role in the reactive synaptic plasticity that
occurs after brain injury. These two isoforms are differentially regulated over
time after UEC. Phosphacan protein is increased at 2 and 7d as a function of
sampled subregion, with transcript increasing only at 7d. By contrast,
hippocampal sRPTPβ protein and transcript are both elevated throughout the
time course of reactive synaptogenesis. These changes appear to be primarily
associated with neuronal structures. The earlier increase in extracellular
phosphacan could be adaptive if it helps concentrate plasticity-promoting growth
factors in the outer ML, or it could modulate the physical aspects of synaptic
structural reorganization by blocking neuronal binding to CAMs. The prolonged
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increase in sRPTPβ after UEC suggests that this isoform may be involved in
spine morphogenesis and/or stabilization of new synapses, acting through
intracellular substrates that control cytoskeletal reorganization. In order to
promote recovery after TBI, it will be essential to gain a better understanding of
the many interacting signals in the extracellular environment which contribute to
the inhibition, or to the promotion, of axonal regeneration and synaptogenesis in
the injured CNS. Understanding how components of brain ECM influence
synaptic reorganization will be key to defining the difference between injuries
where recovery is successful, and those where recovery fails.
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CHAPTER 3
QUANTIFYING GENE EXPRESSION IN RODENT
MODELS OF TBI: NORMALIZATION STRATEGIES

Introduction
Real-time quantitative RT-PCR (qRT-PCR) has come to be a widely
preferred method for the sensitive measurement of mRNA in tissue. The number
of studies using real-time to quantify gene expression after injury to the central
nervous system (CNS) has grown immensely over the past decade. Technical
details have been described elsewhere (Heid et al., 1996; Gibson et al., 1996)
but the basic concept of qRT-PCR is centered, like traditional endpoint RT-PCR,
around the design of forward and reverse oligonucleotide probes to anneal to a
specific mRNA of interest. Unlike traditional RT-PCR however, TaqmanTM qRTPCR also uses a TaqmanTM probe designed to anneal to the target mRNA
downstream of one of the primers. This probe contains a fluorescent reporter
dye and a quencher dye, whose proximity suppresses the fluorescent emission
through fluorescence resonance energy transfer (FRET). When the target
sequence is replicated, both dyes are released by the 5’ endonuclease activity of
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Taq DNA polymerase, terminating FRET and allowing the reporter dye to
fluoresce. Thus each time a target mRNA is replicated, one fluorophore is
released. The increase in total fluorescence intensity is proportional to the
amount of amplicon produced, and can be measured in “real time.”
Considering the many sequelae of a traumatic brain injury (TBI)—reactive
gliosis, inflammation, activation of cell death pathways, neuroplasticity,
regeneration—it can be said that every one of these processes relies on altered
gene expression. The quantitative assessment of specific mRNAs is therefore
an essential tool in TBI research, and an important complement to techniques
which measure protein expression. There are several advantages of using qRTPCR to assess mRNA transcripts, compared to other techniques (Reviewed in
Giulietti et al., 2001; Bustin, 2002; Nolan et al., 2006). It offers rapid, highthroughput screening of genes with less opportunity for RNA contamination than
other quantification methods. It also enables the use of small amounts of starting
material, an advantage which is not only critical for analysis of precious biopsy
tissue from patients, but which may also present new opportunities for TBI
studies in animals. For example, Dash and colleagues (2004) used qRT-PCR to
assess mRNA from small ‘punches’ of cortical tissue harvested at varying
distances from the injury core, permitting high spatial accuracy in their analysis of
injury-induced gene expression. Further, qRT-PCR is a more sensitive approach
for measuring gene expression levels than other semi-quantitative assays (e.g.
northern blots, microarrays, or in situ hybridization), in that it permits detection of
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smaller changes in genes of interest. Real-time RT-PCR was recently shown to
be more accurate than microarrays for determining <2-fold changes in gene
expression (Wang et al., 2006). This sensitivity may be especially important in
the field of TBI research, where significant differences in gene expression can
often occur within a <2-fold range. One study by Li et al. (2004) used microarray
to screen for transcript changes after TBI and compared results for selected
genes with qRT-PCR assessment. This comparison showed that the two
approaches produce comparable results for many genes, but for some genes
measurement by real-time was far more sensitive, detecting for example a 1.5fold increase in HSP70 while microarray showed no change.
Despite the many advantages of qRT-PCR, the increasingly frequent use
of this technique in neuroscience research has brought to light certain technical
issues and concerns. In particular, the identification of suitable reference genes
has been an topic of focus in recent reviews (Dheda et al., 2004; Bustin et al.,
2005; Huggett et al., 2005; Meldgaard et al., 2006; Johansson et al., 2007;
Coulson et al., 2008). qRT-PCR data are typically normalized to a
“housekeeping” or reference gene, to control for nonspecific variation due to
sample-to-sample differences in RNA quality and reaction efficiency. Some
commonly used reference genes include cyclophilin A (also known as PPIA), βactin, glyceraldehyde phosphate dehydrogenase (GAPDH), and 18s or 28s
rRNA. In order to serve as a reliable nonspecific control, an ideal reference gene
should be stably expressed across all tissues, developmental stages, and
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experimental conditions. Of course, such an ideal does not exist in real practice.
Prior studies have shown that expression of widely used reference genes is
altered in models of hypoxia/ischemia (Zhong et al., 1999; Bond et al., 2002;
Kobayashi et al., 2004), seizure activity (Chen et al., 2001), hippocampal
deafferentation (Phillips et al., 1987; Phillips & Steward, 1990), and
demyelination (Meldgaard et al., 2006). On the other hand, in some
experimental contexts these same reference genes are invariant and can serve
as reliable standards for data normalization. For example, GAPDH and
cyclophilin were found to be stably expressed in the first 24 hours after middle
cerebral artery occlusion in rats (Harrison et al., 2000).
Normalization to total RNA mass has also been considered as an
alternative to the use of a reference gene control (Bustin 2005). This approach
depends on the ability to recover high quality RNA from tissue, and to accurately
measure its concentration and integrity. Several studies have shown that if these
conditions are met, normalization to total RNA can produce viable experimental
results (Tricarico et al., 2002; Dheda et al., 2004; Bustin 2005; Meldgaard et al.,
2006). Normalization to multiple reference genes is another option, and several
mathematical approaches to this strategy have been proposed (Vandesompele
et al., 2002; Pfaffl et al., 2004; Anderson et al., 2004). However, the identification
of three or more best reference genes requires testing the suitability of many
candidate genes—a process which requires more time, resources, and tissue
sample than may be practically feasible.
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While two recent articles have critically examined the practice of qRT-PCR
normalization in acute post traumatic analyses (Thal et al., 2008; Rhinn et al.,
2008), the unique issues surrounding the application of this technique to the
range of pathology generated in rodent TBI models have not been fully
considered. TBI presents a particular challenge for the accurate and reliable
quantification of mRNA due to heterogeneous cell populations in injured tissue,
multiple components of TBI pathology (primary tissue damage, progressive
secondary degeneration, ischemic/hypoxic damage, edema, hemorrhage,
inflammation, etc.), and variability of individual animal responses to brain injury.
Each of these parameters may impact the expression of common qRT-PCR
reference genes.
In this study we have examined the expression of four widely used
reference genes in two rodent models of brain injury. Moderate central fluid
percussion injury (cFPI) was used to model diffuse closed-head trauma, while
unilateral entorhinal cortex lesion (UEC) served as a model of targeted
deafferentation and reactive plasticity induced by traumatic axonal injury.
Transcripts for β-actin, cyclophilin A, GAPDH, and 18s ribosomal RNA were
measured at long term survival intervals (2, 7, or 15 days) in order to investigate
the pattern of reference gene expression during these well-defined periods of
synaptic recovery. We examined RNA extracted from hippocampus after UEC,
and from both hippocampus and parietotemporal cortex after cFPI. Results were
analyzed for gene expression at each time point, comparing injured samples to
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contralateral control tissue (for UEC), or to sham control tissue (for cFPI).
Change in expression relative to controls was also assessed over time postinjury. Finally, the within-group variability of gene expression was measured by
calculating the coefficient of variation (CV) for each experimental group.
Here we show that none of the four common reference genes tested was
invariant across all tissues, time points, and types of experimental injury. For
studies focusing on the rodent hippocampus after UEC, cyclophilin may be an
appropriate reference gene. In the hippocampus subjected to cFPI, β-actin was
the most stable control gene. Within the parietotemporal cortex, each of the
tested reference genes showed significant alteration over time after cFPI, making
them unsuitable controls for time course studies. However, some of the
reference genes tested may be appropriate for investigations confined to a single
post-injury time point. We further suggest that normalization to total RNA content
may be a reasonable approach, particularly where measurement of smaller
changes in gene expression is desired. The present data provide a starting point
for the identification of appropriate reference genes in studies of postinjury
recovery following experimental TBI. In this context, we outline considerations
for validating a qRT-PCR normalization strategy in models of brain injury, and we
stress the importance of reference gene validation for each TBI paradigm and
each set of experimental conditions.
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Methods
Experimental Animals
Adult male Sprague-Dawley rats (300-390g) were used for each injury
model in this study. Rats were randomly divided into three experimental groups:
unilateral entorhinal lesion (UEC; n = 17), central fluid percussion injury (cFPI; n
= 30) and sham-injured (n = 16). Rats were housed in pairs within individual
cages having food and water ad libitum, subjected to a 12hr dark-light cycle at
22°C. All protocols for injury and use of animals were approved by the
Institutional Animal Care and Use Committee of Virginia Commonwealth
University.

Unilateral Entorhinal Cortex Lesions
Rats were subjected to unilateral entorhinal cortex lesion (UEC) after the
method of Loesche and Steward (1977). All animals were surgically prepared
under isoflurane anesthesia delivered via nose cone (2.25% in carrier gas of 70%
N2O, 30% O2). During all surgical procedures, body temperature was maintained
at 37°C via a thermostatically controlled heating pad (Harvard Apparatus,
Holliston MA). Rats were placed in a stereotaxic frame, and an area of skull was
removed above the entorhinal cortex of the right hemisphere. Lesion current was
passed through a Teflon-insulated wire electrode angled at 10o from vertical.
Current was delivered (1.5 mA for 30 sec) at a total of eight stereotaxic sites: 1.5
mm anterior to the transverse sinus, 3mm lateral to midline, at 2mm, 4mm, and 6
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mm ventral to the brain surface; then 4mm lateral to midline at 2mm, 4mm, and
6mm ventral; and finally 5 mm lateral to midline at 2mm and 4 mm ventral (see
Figure 1.4). After lesions were completed, the electrode was removed, the scalp
was sutured closed over the surgical site, and topical antibiotic was applied.
Animals were placed in a warmed holding cage and monitored during recovery
from anesthesia, after which they were returned to their home cages.

Central Fluid Percussion Injury
Adult male Sprague-Dawley rats (300-390 gm) were subjected to central
fluid percussion injury (cFPI) as previously described (Dixon et al., 1987). 24
hours before cFPI, each animal was surgically prepared under isoflurane
anesthesia delivered via nose cone (2.25% in carrier gas of 70% N2O, 30% O2).
During all surgical procedures, body temperature was maintained at 37°C via a
thermostatically controlled heating pad (Harvard Apparatus; Holliston, MA). Rats
were placed in a stereotaxic frame and an incision was made to expose the skull
from bregma to lambda. A fluid percussion injury hub was prepared as follows.
Two shallow 1 mm holes were drilled in the left frontal and right occipital bones, 1
cm rostral and caudal to bregma and lambda respectively. A 4.8 mm circular
craniotomy was then made, centered on the sagittal suture midway between
lambda and bregma, taking care not to disturb the underlying dura. A Luer-Loc
syringe hub was cut away from a 20-gauge needle and affixed to the craniotomy
site with cyanoacrylate glue. After verifying the integrity of the seal between the
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hub and the skull, two fixation screws were inserted into the 1 mm holes (round
machine screws, 3/16 in. long). Dental acrylic (Coltene/Whaledent, Inc.;
Cuyahoga Falls, OH) was then applied around the hub and over the screws to
provide stability during induction of the injury. After solidification of the dental
acrylic, skin over the hub was sutured and the animal was placed in a warmed
recovery cage and monitored until fully recovered from anesthesia. The animal
was then returned to the home cage and allowed to recover for 24 hours. Prior
to the induction of fluid percussion injury, anesthesia was induced by placing the
animal in a bell jar with 4% isoflurane in 70% N2O and 30% O2 for 4 min. An
incision was quickly made to expose the craniotomy site, and the male end of a
connector tube was inserted into the hub. After filling the hub-spacer assembly
with 0.9% normal saline, the female end of the spacer was inserted into the male
end of the fluid percussion apparatus, taking care to ensure that no air bubbles
were introduced into the system. The animal was then injured at a magnitude of
2.00 ± 0.10 ATM, representing an injury of moderate severity (Dixon et al., 1987).
The pressure pulse measured by the transducer was displayed on an
oscilloscope (Tektronix 5111; Beaverton, OR) and the peak of the pressure curve
was recorded.
Following injury, the hub was removed and scalp incision rapidly sutured,
prior to recovery of consciousness. Animals were monitored for spontaneous
respiration, and if necessary, artificially ventilated to ensure adequate postinjury
oxygenation until spontaneous respiration was recovered. Recovery of
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consciousness was monitored by recording the length of time it took for each
animal to recover the following reflexes: tail pinch, toe pinch, corneal blink,
pinnal, and righting. Following recovery of the righting reflex, animals were
placed in a warmed holding cage and monitored during recovery, after which
they were returned to their home cages. For animals in the sham injury group, all
of the above procedures were followed with the exception of the release of the
pendulum for actual transduction of fluid percussion injury.

RNA isolation and quantitative real time RT-PCR
Rats were sacrificed 2d (n = 6), 7d (n = 5), and 15d (n = 6) after UEC
lesion, or 2d (n = 6), 7d (n = 5) and 15d (n = 3) after cFPI. Sham-injured animals
for cFPI comparison were sacrificed at 7d (n = 5). Fresh brains were rapidly
removed from the skull and a mid-sagittal cut was made to separate the two
hemispheres. For UEC rats, whole hippocampi (including dentate gyrus and
Ammon's horn) were dissected from each hemisphere. For cFPI animals, both
hippocampi and tissue blocks of parietotemporal cortex were removed (see
Appendix C). Tissue samples (~100mg) were homogenized in 1ml Trizol
Reagent (Invitrogen; Carlsbad, CA), mixed with 0.2 ml chloroform, and
centrifuged for 15 min at 12,000 x g. RNA in the upper phase was removed and
precipitated with 0.5 ml isopropyl alcohol. After centrifugation for 10 min at
12,000 x g, supernatant was removed and RNA pellets were washed in 75%
ethanol. The pellets were then dissolved in PCR-grade water (Ambion; Austin,
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TX) and incubated at 55°C for 10 min. All samples were rigorously treated with
the DNA-free DNase kit (Ambion; Austin, TX) according to the manufacturer’s
protocol in order to remove residual DNA contamination. DNase treated RNA
samples were stored at -80°C. Total RNA concentration and integrity were
assessed with the Experion automated electrophoresis system (Bio-Rad
Laboratories; Hercules, CA). Electropherogram traces for all samples indicated
good quality RNA, with clear peaks for 18s and 28s rRNA and very low signal
indicative of sample degradation (see example in Appendix D). RNA
concentrations measured with Experion were further verified with
spectrophotometry (ND-1000, NanoDrop Products; Wilmington, DE). Equal
amounts of total RNA were prepared in PCR-grade water for quantitative real
time RT-PCR on the ABI prism 7900 Sequence Detection system (Applied
Biosystems; Foster City, CA). Taqman primers for all reference genes and two
test transcripts of interest (phosphacan and sRPTPβ) were designed with Primer
Express software (Applied Biosystems; Foster City, CA) to span exon-exon
boundaries. Sequences for specific primers and Taqman probes are listed in
Table 3.1. Reactions were run in triplicate and relative mRNA quantity values
were derived from CT values by the standard curve method. Reactions were
found to have an efficiency of >88% as determined by the slope of the standard
curves. Negative controls on each plate included no-amplification and notemplate control conditions.
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Table 3.1 Taqman sequences

gene
GAPDH forward
GAPDH reverse
GAPDH probe

Oligo sequence
5' AATGTATCCGTTGTGGATCTGACA 3'
5' CTCGGCCGCCTGCTT 3'
5' CCTGGAGAAACCTGCCAAGTATGATGACATC 3'

cyclophilin forward
cyclophilin reverse
cyclophilin probe

5' CTGTTTGCAGACAAAGTTCCAAA 3'
5’ AGGAACCCTTATAGCCAAATCCTT 3'
5’ CAGCAGAAAACTTTCGTGCTCTGAGCACT 3'

β-actin forward
β-actin reverse
β-actin probe

5' CCCTGGCTCGCACCAT 3'
5' GAGCCACCAATCCACACAGA 3'
5' ATCAAGATCATTGCTCCTCCTGAGCGC 3'

18s rRNA

18S rRNA was measured using a Taqman pre-developed assay
reagents kit containing 18s primers and probe (Applied
Biosystems)

phosphacan forward
phosphacan reverse
phosphacan probe

5' GGGCATTCAGGAGTATCCAACA 3'
5' TCCGTGACTCTTCTATTTTTACTTTCAT 3'
5' TCAGCACATCTCGTTCTATCCCTTTGCTCA 3'

sRPTPβ forward
sRPTPβ reverse
sRPTPβ probe

5' ACAATGAGGCCAGTAATAGTAGCCAT 3'
5' TAGATGAGAATACCAACAAGAACCACTAG 3'
5' AGACACGATCACAAGGGGTATAACCGCCT 3'
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Protein Extraction and Western Blotting
Rats were sacrificed 2d (n = 6), 7d (n = 6), or 15d (n = 4) after cFPI, and
paired sham-injured controls at 2d (n = 4), 7d (n = 4), or 15d (n = 3). Whole
hippocampi (including dentate gyrus and Ammon's horn) were dissected from
fresh brain, rapidly homogenized in a 250 μl volume of T-PER (Thermo Scientific;
Rockford, IL) and centrifuged for 5 min at 8,000xg and 4°C. Supernatant was
removed and stored at -80°C. Protein concentration of each sample was
determined using the Bio-Rad Protein Assay Reagent and spectrophotometry
(Shimadzu UV-160; Shimadzu Scientific Instruments). 5 μg of protein from each
sample was mixed with reduced sample buffer and electrophoresed on 4-12%
Bis-Tris Criterion XT gels (200V, 45 min.) and subsequently transferred to PVDF
membrane. Membranes were blocked in 5% milk-TBST (Tris buffered saline
containing 0.05% Tween 20) for 1h before being probed with mouse monoclonal
antibody raised against phosphacan (3F8; Developmental Studies Hybridoma
Bank, University of Iowa) in milk-TBST (1.5 μg/mL) overnight at 4°C. Blots were
subsequently washed with milk-TBST and then incubated for 1h at room
temperature in peroxidase conjugated goat anti-mouse secondary antibody
(1:20,000; Rockland; Gilbertsville, PA). The blots were then washed in TBST
and immunopositive signal visualized using Super Signal West Dura Extended
Duration Substrate (Thermo Scientific; Rockford, IL) and imaged digitally with the
G:Box ChemiHR system for densitometric analysis using GeneSnap software
(SynGene; Frederick, MD). Measurements from tissue ipsilateral to UEC were
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compared to homologous contralateral control regions and results expressed as
percent of contralateral value.

Statistical Analysis
For all qRT-PCR data, group means were analyzed using specific planned
comparisons between experimental groups, implemented using simple main
effects tests (SPSS v11 MANOVA syntax). The significance of densitometric
values from Western blots were analyzed using the Student’s t-test. A probability
of less than 0.05 was considered statistically significant for all tests. In order to
assess within-group variability of reference gene expression, the coefficient of
variation (CV) was calculated for each group, generated from the ratio of
standard deviation to group mean. CV is a dimensionless parameter which
permits the comparison of variability of gene expression between groups with
different mean values.

Results
Reference gene expression is differentially altered after UEC and cFPI
Transcripts for β-actin, GAPDH, 18s ribosomal RNA, and cyclophilin A
were measured in tissue collected 2, 7, or 15 d after UEC or cFPI. We examined
RNA from whole hippocampi following UEC, and compared relative gene
expression ipsilateral to lesion to gene expression in contralateral controls. β114

actin was significantly increased in ipsilateral hippocampus at 2d after UEC
(145.1 ± 25.4%, p<0.05; Table 3.2; Figure 3.1). GAPDH expression was highly
variable after UEC in both ipsilateral and contralateral hippocampi (see CV
values in Table 3.2; scatterplot in Figure 3.1). While 18s rRNA showed lower
variability and no significant difference between ipsilateral and contralateral
expression at any post-injury time point (Table 3.2), there was increase of 61±
28% in 18s rRNA between 2 and 15d after UEC (Figure 3.1). Only cyclophilin
showed stable expression after UEC and relatively low variance (Figure 3.1;
Table 3.2), making this the best choice of reference gene among the four we
tested in this injury paradigm.
Following cFPI, we examined reference gene expression in both
hippocampus and parietotemporal cortex, two brain regions known to be affected
in this injury model. Because of the midline injury location, hippocampi or cortical
blocks dissected from both hemispheres were pooled for analysis. Reference
gene expression was assessed at each time point, comparing injured samples to
sham control tissue. β-actin was significantly increased in cortex at 2 and 7d
after cFPI (173.9 ± 36.0%; 153.9 ± 38.5%, p<0.05). By contrast, expression of βactin in hippocampus remained remarkably stable after injury at all time points
sampled (Figure 3.2; Table 3.2). Thus β-actin may be a good reference gene
choice in hippocampus but not in cortex following cFPI. GAPDH expression was
increased in both cortex and hippocampus 7d after injury (132.5 ± 6.8% and
128.7 ± 6.5%, p<0.05; Table 3.2). 18s rRNA was lower than control values in
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both hippocampus and cortex 2d after cFPI (84.0 ± 8.2%; 82.9 ± 17.3%) and
later increased in hippocampus and cortex 7d after cFPI (138.7 ± 16.4%; 190.0 ±
26.6%, p<0.01). However because of group differences in variability, these
changes only reached statistical significance for hippocampus and for cortex at
7d (Table 3.2). Finally, cyclophilin mRNA was reduced in both hippocampal and
cortical tissue at 2 and 7d post-injury (84.5 ± 13.4%, p<0.01, and 90.6 ± 4.6%,
p<0.05 for hippocampus; 87.3 ± 13.5%, p<0.01, and 76.2 ± 4.6%, p<0.05 for
cortex; Table 3.2).
We believe the reference gene regulation we have described represents
specific changes in gene expression following injury, since the four candidate
reference genes are differentially altered in the same tissue samples. If
expression differences were due to a nonspecific factor (for example, if some
tissue samples contained a higher concentration of an endogenous PCRinhibiting compound), then we would expect to see a parallel shift in expression
of all genes measured in these samples. However our results do not show
parallel changes; for instance in hippocampus 7d after cFPI we have observed
an increase in GAPDH, a reduction in cyclophilin, and no change in expression of
18s or β-actin compared to sham controls. This supports the conclusion that
these findings represent specific, injury-induced alterations in expression of each
reference gene.

116

Table 3.2 Reference genes after experimental brain injury: variability and
change relative to control. Where present, arrows represent significant change
in expression of a reference gene compared to contralateral control hippocampus
for UEC, or compared to sham injured tissue for cFPI (p < 0.05). Numerical
values represent coefficient of variation (CV; standard deviation divided by mean)
for expression of each reference gene at 2, 7, or 15 days after injury. These
provide a measure of within-group variability of gene expression at a given time
point, tissue, and injury type. An ideal reference gene should not be altered with
injury, and should have a low CV value indicating stable expression among
individuals in a group. We emphasize however that CV is a relative measure; an
acceptable level of variance cannot be defined a priori but must be determined
for each particular experiment.
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UEC hippocampus
2d
β-Actin

↑

0.175

7d

15d

0.144

0.233

GAPDH

0.317

0.415

0.454

18s

0.149

0.151

0.235

Cyclophilin

0.145

0.120

0.256

cFPI hippocampus
2d

7d

15d

β-Actin

0.149

0.092

0.114

GAPDH

0.159

18s

0.092

Cyclophilin

↓

↑

0.051
0.120

↓

0.201

0.050

0.071
0.108
0.123

cFPI cortex
2d
β-Actin

↑

7d

0.207

15d

↑

0.250

0.018

GAPDH

0.154

↑

0.061

0.046

18s

0.209

↑

0.138

0.054

↓

0.051

0.160

Cyclophilin

↓

0.213

Table 3.2
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Figure 3.1 Reference gene expression after UEC. Each point represents the
mean hippocampal gene expression for one animal, while bars represent group
means. Y-axes show arbitrary quantity units based on the standard curves
generated for each set of primers. 18s rRNA shows no significant difference
between ipsilateral and contralateral expression at any time point. However, the
overall level of gene expression increases over time post-injury, so 18s is not a
suitable control. β-actin is both increased ipsilateral to lesion at 2 days after UEC
(145.1 ± 25.4%, p < 0.05) and shows high variance at 15d, and is thus is also a
poor control. The variability of GAPDH expression is very high, particularly at 7
and 15d after UEC, so GAPDH is not a suitable control. Only cyclophilin is a
good candidate reference gene in this injury paradigm, showing both stable
expression at all time points after UEC and low variability within groups.
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Figure 3.1
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Figure 3.2 Regional differences in reference gene expression after cFPI.
Compared to a sham-injured control group, β-actin shows increased expression
in parietotemporal cortex 2 and 7 days after central fluid percussion injury (173.9
± 36.0% and 153.9 ± 38.5%; p < 0.05). By contrast, β-actin expression in
hippocampus remains stable over time after cFPI. However it should be noted
that sham control variance in hippocampus is relatively high, possibly
contributing to the lack of detectable difference between groups. These results
suggest that in this injury model β-actin is a poor choice of reference gene for
studies of cortical tissue, but could be an appropriate choice for studies of
hippocampus.
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Figure 3.2
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Normalization approach can affect qRT-PCR study conclusions
To investigate the effect of different normalization approaches, we ran
qRT-PCR for two genes of interest, phosphacan and sRPTPβ, in hippocampus
following UEC. We compared results for phosphacan and sRPTPβ when
normalized to 18s rRNA (a poor control in this injury model due to increased
expression over time; see Figure 3.1), normalized to cyclophilin (a stable control
in this injury model), or normalized to total RNA content. Results show that the
choice of reference gene may significantly affect qRT-PCR results for a gene of
interest (Figure 3.3).
Phosphacan normalization to cyclophilin and to total RNA produce a
similar overall pattern of regulation, showing no change relative to contralateral
control at 2d and 15d, but significantly elevated expression at 7d, (120.4 ± 3.0%,
p<0.05 with cyclophilin; 113.6 ± 8.8%, p<0.05 with total RNA; Figure 3.3). By
contrast, normalizing phosphacan to 18s shows trends toward elevation at all
three postinjury intervals, however none of the differences reached statistical
significance. Since phosphacan normalized to cyclophilin or total RNA
corresponds to the temporal changes in phosphacan after UEC detected by
immunohistochemistry (IHC; Harris et al., 2006; see also Chapter 2), this
suggests that either of these normalization strategies may be acceptable for
phosphacan analysis.
For the analysis of sRPTPβ expression, all three normalization strategies
produced somewhat different results. Analysis with cyclophilin showed no
123

change at 2d, and a trend toward elevation over control at 7d, which reached
significance at 15d (134.6 ± 20.0%; p<0.01; Figure 3.3). Normalizing sRPTPβ
expression to total RNA showed a steady significant increase over control at 2, 7,
and 15d post injury (111.7 ± 10.0% , p<0.05;112.8 ± 5.6%, p<0.05; 118.8 ± 6.9%;
p<0.01). By contrast, 18s normalization showed significant increase only at 15d
(151.1± 5.4%; p<0.05). Here the pattern of sRPTPβ transcript normalized to total
RNA best reflects the changes in sRPTPβ protein observed after UEC by
Western blotting (WB; Harris et al., 2008), suggesting that total RNA may be the
most accurate normalization approach for sRPTPβ analysis.
Even when a potential reference gene meets initial criteria for stability over
time postinjury and low CV, normalization using that reference gene may not be
optimal if there is high variance in the control group against which it is compared.
We compared hippocampal phosphacan transcript after cFPI, normalized to βactin and normalized to total RNA. We show that phosphacan normalized to βactin shows no change after cFPI, while the same data using total RNA as a
standard reveals a significant elevation in phosphacan transcript at 7d postinjury
(138.9 ± 6.02%, *p<0.05; Figure 3.4 A, B). When these results are compared
with hippocampal phosphacan levels determined by Western blotting (Figure 3.4
C), the increase in transcript at 7d seen with total RNA normalization is
supported by a 3-fold rise in phosphacan protein at 7d (2d- 144.3 ±14.3%,
*p<0.05; 7d- 370.2 ± 53.4%, **p<0.01; 15d- 61.7 ± 4.0 %, **p<0.01). The
difference in phosphacan qRT-PCR results depending on normalization
124

approach is most likely a result of variance of β-actin expression in the sham
control group (see Figure 3.2). When considering selection of a reference gene,
variability of gene expression under control conditions may be just as important
as variability after injury. Even in the absence of reference gene change under
experimental conditions, when qRT-PCR data are compared to a variable control
group, differences in subsequent injury to control comparisons may be lost.
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Figure 3.3 Normalization approach can significantly affect experimental
conclusions. Expression data for two genes of interest, phosphacan and
sRPTPβ, are compared when normalized to cyclophilin, 18s rRNA, or total RNA
content. 18s is a poor choice of reference gene dues to increasing expression
after UEC, while cyclophilin is stably expressed and may be an appropriate
reference gene (see Figure 3.1). These comparisons show that the applied
normalization strategy can significantly affect experimental results. We suggest
that, beyond initial consideration of reference gene changes with injury and CV
values, consideration of correlative data on the gene of interest can help guide
selection of a normalization approach. In (A) phosphacan normalized to either
cyclophilin or total RNA shows peak transcript elevation at 7d postinjury, a result
which best matches the temporal elevation of phosphacan protein in the
deafferented hippocampus detected by IHC (see Chapter 2). In (B) the
consistent increase in sRPTPβ transcript normalized to total RNA best reflects
the consistent increase in sRPTPβ protein seen in WB analysis of hippocampus
after UEC (see again Chapter 2).
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Figure 3.3
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Figure 3.4 Reference gene choice must consider variance in all groups
sampled. Even when a potential reference gene meets initial criteria for stability
over time postinjury and low CV, normalization using that reference gene may
not be optimal if there is high variance in the control group against which it is
compared. In (A) hippocampal phosphacan mRNA normalized to β-actin shows
no change after cFPI, while the same data using total RNA as a standard (B)
reveals a significant elevation in phosphacan transcript at 7d postinjury (138.9 ±
6.02%; *p<0.05). When these results are compared with hippocampal
phosphacan levels determined by WB (C), the more than 3-fold rise in
phosphacan protein at 7d (370.2 ± 53.4%; *p<0.05) supports the increase in
transcript at 7d with total RNA normalization. These differences between A and
B are most likely a result of variance of β-actin expression in the sham control
group (see Figure 3.2). When considering selection of a reference gene,
variability of gene expression under control conditions may be just as important
as variability after injury. Even in the absence of reference gene change under
experimental conditions, when qRT-PCR data are compared to a variable control
group, differences in subsequent injury to control comparisons may be lost.
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Figure 3.4
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Discussion
In the present study we describe the postinjury time course of mRNA
expression for four common reference genes (GAPDH, β-actin, cyclophilin A, and
18s rRNA) in two models of brain injury, (UEC and cFPI). Nearly all qRT-PCR
studies of TBI have used one of these reference genes for quantitative evaluation
of gene expression (Rhinn et al., 2008). When a reference gene is used to
normalize RT-PCR data, it is often assumed that the expression of this gene in
the target tissue is unchanged by experimental treatments. Any variations
observed in reference gene levels should then only reflect differences in sample
quality and technical differences in RT-PCR runs (Bond et al., 2002; Wilson,
1997). However, we report that every one of the four reference genes we tested
was specifically altered following focal deafferentation and/or diffuse brain injury,
demonstrating that CNS trauma does result in reference gene modulation. First,
18s rRNA expression increases over time after UEC in both deafferented
ipsilateral and contralateral control hippocampi. Further, 18s expression is
increased in parietotemporal cortex following cFPI. Second, GAPDH expression
is increased in hippocampus and cortex 7d after cFPI. Third, the commonly used
reference gene β-actin showed an increase in mRNA transcript in cortex after
cFPI (2d and 7d), and in hippocampus after UEC (2d). Finally, cyclophilin is
decreased in both hippocampus and cortex 2d and 7d after cFPI. Together,
these results show that selection of appropriate qRT-PCR reference genes in the
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context of experimental TBI must take into consideration model type, brain region
sampled, and postinjury survival interval.

Reference gene expression may be altered under numerous physiological
or pathological conditions in the CNS
Accumulating evidence has indicated that physiological and pathological
events in the brain are capable of influencing the expression of traditional
reference genes. One recent report showed that normal aging and dietary
restriction altered expression of reference genes including 18s rRNA in the
rodent hippocampus and cortex (Tanic et al., 2007). Synaptic plasticity also
appears to be associated with altered expression of traditional control genes.
The hippocampal dentate gyrus is known to exhibit a robust synaptic
reorganization during the time points we sampled following UEC. Our finding
that 18s rRNA is elevated during this period of synaptic plasticity is supported by
a previous study which showed increased rRNA after UEC by in situ hybridization
(Phillips et al., 1987). The widely used reference gene cyclophilin A is also
altered during synaptic plasticity, showing reduced expression during
reorganization of the feline visual cortex following retinal lesions (Arckens et al.,
2003). We have similarly observed reduced cyclophilin in hippocampus following
cFPI; however we did not see significant changes in hippocampal cyclophilin
expression after UEC. Differences in species or region-specific cell types may
account for these results. The precise role of cyclophilin A in lesion-induced
131

plasticity remains to be clarified. GAPDH may also be altered during injuryinduced plasticity, though the details of its regulation are not yet clear. A
previous study showed reduced GAPDH expression during synaptic
reorganization of mouse hippocampus after a mechanical lesion of the perforant
path (Meldgaard et al., 2006). In the denervated rat hippocampus, we have
identified GAPDH as a poor choice of reference gene due to high variability of
expression after UEC.
It has also been reported that the expression of β-actin and GAPDH is
rapidly upregulated in rodent models of cerebral ischemia (Harrison et al., 2000;
Kobayashi et al., 2004). Secondary ischemia is frequently a component of TBI
pathogenesis, and in our FPI studies β-actin was acutely increased in cortex but
not hippocampus at the earliest time point we assayed (2d). The lack of change
in β-actin in hippocampus was surprising, since hippocampal regions such as
CA3 are selectively vulnerable to global TBI and ischemic injury. Notably, the
variability of β-actin gene expression in sham-injured hippocampus was relatively
high (see Figure 3.2), which may have contributed to the failure to detect injuryinduced expressional changes.
Finally, two recent studies have both explored reference gene regulation
in the acute response to mouse models of brain trauma. In the first study, Thal
and colleagues (2008) examined expression of candidate reference genes at the
site of contusion over the first 24 hours after controlled cortical impact (CCI).
This study identified cyclophilin A and β-2-microglobulin as the best controls,
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while GAPDH and β-actin were among the worst normalization factors due to
increased and highly variable expression in injured tissue. Interestingly, in the
second study by Rhinn et al. (2008) GAPDH was one of the least variable genes
at the site of injury over the first 48 hours after weight drop TBI, and was
identified as a top choice for normalization of gene expression. This group also
reported that 18s rRNA and total cDNA content were good normalization choices
following weight drop injury. As in the CCI model, β-actin expression was
increased after weight drop injury, and thus was identified as an inappropriate
control. Both of these studies focused on the early post-injury period, compared
to the more protracted postinjury time course we report here, which may help
account for the differences between these studies and our results. Furthermore,
both previous studies examined gene expression at the site of tissue lesion,
while we have sampled hippocampus and cortical regions in a diffuse head injury
model which does not cause frank contusion and cavitation. Species differences
could also potentially contribute to the differences in our results in rodents and
theirs in mice. In contrast to the two mouse TBI studies, we have shown β-actin
to be stably expressed in hippocampus after cFPI. However, β-actin may not be
a good control because of variable expression in sham controls (see Figure 3.2).
Like the conclusions of Thal et al. with CCI, our results showed cyclophilin to be
a good reference gene choice after UEC, while GAPDH expression was
regulated and highly variable in our injured tissues.
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Given the many examples of physiological and pathological changes that
can influence reference gene expression, our present finding that traditional
controls are differentially regulated following UEC and cFPI is not surprising. The
present study in combination with the two recent reports on reference genes in
mouse TBI models should underscore the fact that choice of appropriate qRTPCR controls is specific to the brain region, survival time, and specific
pathological components of a given TBI paradigm.

Validation of candidate reference genes
The question remains for researchers wishing to use the present
investigation as a starting point for selecting reference genes in future TBI
studies: what are the criteria for reliable validation of a candidate reference
gene? First, a valid reference gene is one which remains unaltered under the
varying experimental conditions of a study. In the specific context of TBI studies,
this means no difference in injured tissues versus sham-injured (or other control)
at any single time point, no changes over time post-injury, and no changes
between experimental treatment groups (i.e. drug-treated) and controls.
Additionally, researchers should bear in mind that injury effects on gene
expression may be tissue specific; a reference gene which is deemed
appropriate for studies of one brain region cannot be assumed to be stably
expressed in a different region under the same injury paradigm.
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Second, our results suggest that expressional differences between
experimental groups are not the only concern in identifying a valid reference
gene. Variability of reference gene expression within each group (CV value) is
also an important consideration, and this has received somewhat less attention in
recent studies and reviews. For example we show that after UEC, mean GAPDH
expression is no different between ipsilateral and contralateral hippocampi, and
that expression levels do not change over time. However, GAPDH expression is
highly variable in both ipsilateral and contralateral groups (Figure 3.1) and thus
GAPDH is not a good reference gene choice after UEC. We emphasize that the
acceptable level of variability cannot be defined a priori but must be dictated by
the degree of resolution required for each particular experiment. This will
primarily depend on the magnitude of injury effect on the gene of interest. If a
gene of interest exhibits a large change, study conclusions may only be
minimally impacted by control gene variability. However, for a gene of interest
showing lower levels of change, study conclusions are more likely to be seriously
affected by the additional noise introduced to the analysis by a variable reference
gene. Variability of reference gene expression should be considered not only in
injured groups, but in control groups as well. We have shown that β-actin
expression remains stable in hippocampus following cFPI, and considering this
information alone, one might conclude that β-actin is an appropriate control in
this injury paradigm. However, the high variability of β-actin mRNA in sham-
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injured tissue causes significant effects in injured-to-sham comparison to be lost
(see Figure 3.2; Figure 3.4).

Potential outcomes of using an unvalidated reference gene
Results of qRT-PCR studies can depend heavily on the choice of
reference gene (Dheda et al., 2005; Thal et al., 2008; Bonefeld et al., 2008).
Three types of errors can potentially be introduced when an unvalidated
reference gene is used: the first two arise from use of a poor control which is
altered by experimental treatments, while the third can arise from a poor control
which exhibits highly variable expression. First, if the reference gene and the
gene of interest are both altered by injury in the same direction (i.e. both are
increased or both are decreased), normalization can produce a false negative
result, since one cancels out the effect of the other. Second, if the reference
gene is altered after injury but the gene of interest is not, normalization can lead
to a false positive result (Bond et al., 2002). For example if the gene of interest is
stably expressed while the reference gene increases, normalized expression
(gene of interest divided by reference gene) would indicate an apparent decrease
in the target gene. Third, when expression of a reference gene is highly variable
(high CV) then normalization will introduce additional noise to the assay so that
relatively small changes in the gene of interest lose statistical significance
(Dheda et al., 2005; also see Figure 3.4). Depending on the overall distribution
of data, small increases or decreases in a gene of interest may be no less
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biologically significant than large quantitative changes (Bond et al., 2002).
Therefore careful validation of a normalization strategy is especially crucial for
genes of interest which undergo smaller quantitative changes following TBI.

Experiment-specific considerations can help in selecting a qRT-PCR
normalization approach
Specific knowledge about the biology of an injury paradigm could be used
to help guide candidate reference gene selection. For example, in injuries known
to induce a significant increase in the population of non-neuronal cells, a
neuronally expressed gene might be a good choice of reference (e.g. Chen et al.,
2001). Conversely, in an injury known to induce selective neuronal loss, a
reference gene expressed by glial cells might be a more attractive candidate.
However, most brain injuries are likely to exhibit both neuronal loss and
significant influx of astrocytes and microglia, rendering the identification of
suitable control genes particularly challenging. In tissues undergoing complex
changes associated with TBI pathology and recovery, total RNA levels may be
less volatile than expression of most individual genes (Bustin et al., 2002; Bustin
& Nolan, 2004). We propose that future TBI studies consider the possible use of
total RNA as a normalizing factor, when high quality of RNA samples (lacking
significant degradation or contaminating DNA) can be demonstrated and when
total RNA concentration can be accurately measured.
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Additionally, we suggest that correlative experiments such as measuring
protein expression are likely to help complete the 'biological picture' and assist in
the interpretation of meaningful qRT-PCR data following experimental TBI.
Protein expression levels may often predict similar alterations in mRNA. In
Figure 3.4, we show hippocampal phosphacan expression normalized to β-actin
and normalized to total RNA content after cFPI. β-actin was the most stable of
the four reference genes we tested in this injury paradigm, while total RNA is a
reasonable alternative normalization approach given the low degradation of our
RNA samples. We show that phosphacan transcript normalized to total RNA is
supported by the profile of phosphacan protein regulation after UEC, but
phosphacan transcript normalized to β-actin follows a very different pattern.
Thus the protein data strongly supports the use of total RNA rather than β-actin
as a normalization factor in this experimental context. The different result seen
with β-actin normalization is probably due to high variance of β-actin expression
observed in the sham control group, as described above. While correlative
studies cannot substitute for thorough validation of reference gene selection as
detailed above, they can provide valuable additional information which may
further support a chosen normalization approach.
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Recommendations for qRT-PCR normalization in studies of experimental
TBI
Based on the results presented here, we propose that cyclophilin A may
be a good candidate reference gene for studies of injury-induced plasticity in the
deafferented rodent hippocampus. For studies of hippocampal response to fluid
percussion brain injury, β-actin may be an appropriate reference gene provided
that other correlative outcome measures are concurrently applied. However, in
cortical tissue following fluid percussion, none of the four genes we tested was
stably expressed. Additional research is needed to identify suitable reference
genes for TBI time course studies and analyses of different brain regions.
Microarrays might be a useful tool to initially screen a broad array of mRNA
transcripts to identify those which change the least under the conditions of the
proposed experiment. Finally, since we have shown that 18s rRNA was
significantly altered in each of the brain regions we examined after UEC and
cFPI, we recommend that 18s, although commonly used as a reference gene in
qRT-PCR studies, may not be an appropriate control for brain injured tissues.
Conclusions from real-time RT-PCR data can be highly dependent on the
reference gene selected for normalization (Dheda et al., 2005; Bonefeld et al.,
2008). The results presented here are meant to establish a groundwork for
guiding the selection of controls in future TBI studies using real-time RT-PCR.
However for each new set of experimental conditions it is essential that validation
of one or more candidate reference genes be performed. Knowledge about the
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pathobiology of specific injury paradigms may be used to help guide selection of
candidate reference genes for validation. A validated reference gene will be
stably expressed across all experimental conditions (sham vs. injury, treatment
vs. control, between survival time points) and will have low CV within each group
(defined as low enough not to introduce confounding noise to study results).
In addition, researchers should bear in mind that in some cases
normalization to a single reference gene may not be the only valid approach. If
quality of extracted RNA is high and concentration can be accurately measured,
normalization to total RNA mass can be a good alternative (Tricarico et al., 2002;
Meldgaard et al., 2006; see also Chapter 2 Results). If time and resources
permit, normalization to multiple reference genes may also be a preferable
alternative to use of a single control gene (Kobayashi et al., 2004; Bonefeld et al.,
2008). In conclusion, qRT-PCR is a powerful and essential tool for TBI research,
but it will be most useful only when technical considerations such as data
normalization are carefully addressed. Data from qRT-PCR assays will always
provide the most meaningful biological picture when combined with other
approaches such as in situ hybridization and measures of corresponding protein
expression.
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CHAPTER 4

sRPTPβ AND REACTIVE PLASTICITY: EVIDENCE FOR EFFECTS
ON POSTSYNAPTIC STRUCTURES THROUGH SUBSTRATE
β-CATENIN

Introduction
Two chief components of the pathobiology of traumatic brain injury (TBI)
are neuronal cell death and traumatic axonal injury. Both of these have the
important downstream effect of deafferenting target tissues. Injury-induced
deafferentation in the CNS is known to induce axonal sprouting and structural
reorganization of neuronal connections in many brain regions (Raisman 1969;
Lund & Lund, 1971; Steward 1976). However, in many cases, naturally occurring
plasticity after brain trauma is limited, and varies with injury type and severity.
Since reactive plasticity after brain injury may contribute to functional recovery
(Ramirez 2001; Stein & Hoffman, 2003; Nudo 2007), elucidating the factors that
control injury-induced plasticity is of particular interest.
Injury-induced neuronal restructuring is supported by the dynamic
regulation of cytoskeletal proteins. One important mechanism for regulating the
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interactions of cytoskeletal proteins is their phosphorylation and
dephosphorylation via the coordinated activity of tyrosine kinases and
phosphatases. Short receptor protein tyrosine phosphatase beta (sRPTPβ) is a
neuronal tyrosine phosphatase which appears well positioned to potentially
regulate plasticity of post-synaptic structures after TBI. An alternative splice
variant of the proteoglycan phosphacan/RPTPβ, sRPTPβ is a transmembrane
receptor protein primarily localized on dendrites and spines in the mature brain
(Kawachi et al., 1999; Hayashi et al., 2005; see also Chapter 2). We have
recently provided evidence that sRPTPβ may be involved in synaptic
reorganization following brain injury, reporting that sRPTPβ expression is
persistently upregulated following unilateral entorhinal cortex lesion (UEC), a
classic model of injury-induced axonal sprouting and synaptogenesis. sRPTPβ
protein and mRNA expression were increased in the denervated rat
hippocampus at 2, 7 and 15 days after UEC (Harris et al., 2008; see also
Chapter 2). Since the tyrosine phosphatase domain of sRPTPβ is constitutively
active (Meng et al., 2000), we hypothesized that increased protein expression
might correspond to a more dynamic regulation of intracellular sRPTPβ
substrates important for the reactive plasticity process.
A number of intracellular substrates of sRPTPβ have been identified,
including both cytosolic proteins and transmembrane receptors (reviewed in Paul
& Lombroso, 2003). Notably, many of these substrates are enriched at
postsynaptic sites, and all of them have been functionally linked to processes
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important to successful synaptogenesis. For example, β-catenin, β-adducin,
Fyn, and P190Rho/GAP are cytoskeletal regulators involved in neuronal
morphogenesis (Takeichi & Abe, 2005; Pariser et al., 2005a; Pariser et al.,
2005b; Brouns et al., 2000), the neuregulin receptor ErbB4 plays a role in the
maturation of excitatory synapses (Li et al., 2007), and PSD-95 is important for
synapse stabilization (Ehrlich et al., 2007). Moreover, the actions of several
sRPTPβ substrates are known to be regulated by phosphorylation on tyrosine
residues. One of the best-studied examples is β-catenin. β-catenin is a 92 kD
intracellular protein which orchestrates structural changes in dendritic spines by
reversibly linking surface cadherins to the actin cytoskeleton. When
dephosphorylated, β-catenin binds to α-catenin and the resulting complex
associates with both cadherin and actin filaments. However when tyrosinephosphorylated, β-catenin dissociates from this complex and relocates to the
base of spines (Murase et al., 2002). sRPTPβ is one of several tyrosine
phosphatases which may balance the actions of kinases to maintain a dynamic
regulation of β-catenin in spines (Lilien & Balsamo, 2005). Since excitatory
projections from the entorhinal cortex terminate almost exclusively on spines in
the hippocampal molecular layer, spine retraction and reformation is a central
part of reactive plasticity after UEC (Matthews et al., 1976; Reeves & Steward,
1986). Given the role of β-catenin in spine morphogenesis, we chose to explore
this sRPTPβ target during injury-induced synaptogenesis.
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In the present study we examined whether β-catenin might play a role in
injury-induced synaptic restructuring. We used Western blotting to track βcatenin protein in hippocampus after UEC, selecting survival intervals which
correspond to three phases of reactive plasticity: degeneration of perforant path
axon terminals (2d), afferent sprouting and synapse regeneration (7d), and
synapse stabilization (15d). We show that the profile of β-catenin protein shifts in
kD during the three post injury time intervals examined, generating fragments
which may be consistent with calpain proteolysis. Moreover, when phosphatase
activity was inhibited within parallel tissue extracts, the same β-catenin fragments
produced during reactive synaptogenesis were not detected by Western blot
analysis. We discuss the implications of this finding for understanding the role of
sRPTPβ in reactive synaptogenesis.

Methods
Experimental Animals
Adult male Sprague-Dawley rats (300-390g) were used for each injury
model in this study. A randomly selected group of rats (n = 19) were subjected to
unilateral entorhinal cortex lesion under isoflurane anesthesia delivered via nose
cone (2.25% in carrier gas of 70% N2O, 30% O2). During all surgical procedures
body temperature was maintained at 37°C. Rats were housed in pairs within
individual cages having food and water ad libitum, subjected to a 12hr dark-light
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cycle at 22°C. All protocols for injury and use of animals were approved by the
Institutional Animal Care and Use Committee of Virginia Commonwealth
University.

Unilateral Entorhinal Cortex Lesion
Adult male Sprague-Dawley rats (300-390g) were subjected to unilateral
entorhinal cortex lesion (UEC) after the method of Loesche and Steward (1977).
All animals were surgically prepared under isoflurane anesthesia delivered via
nose cone (2.25% in carrier gas of 70% N2O, 30% O2). During all surgical
procedures, body temperature was maintained at 37°C. Rats were placed in a
stereotaxic frame, and an area of skull was removed above the entorhinal cortex
of the right hemisphere. Lesion current was passed (1.5 mA for 30 sec) through
a Teflon-insulated wire electrode angled at 10o from vertical. Current was
delivered at a total of eight stereotaxic sites: 1.5 mm anterior to the transverse
sinus, 3mm lateral to midline, at 2mm, 4mm, and 6 mm ventral to the brain
surface; then 4mm lateral at 2mm, 4mm, and 6mm ventral; and finally 5 mm
lateral at 2mm and 4 mm ventral (see also Figure 1.4). After lesions were
completed, the electrode was removed and the scalp was sutured closed.
Topical antibiotic was applied to the surgical site, and animals were placed in a
warmed holding cage and monitored during recovery. Following recovery from
anesthesia animals were returned to their home cages.
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Protein Extraction and Western Blotting
Rats were sacrificed at 2d (n = 7), 7d (n = 8), or 15d (n = 4) after lesion.
Brains were rapidly removed from the skull and a mid-sagittal cut was performed
to separate the hemispheres and expose hippocampi. Whole hippocampi
(including dentate gyrus and Ammon's horn) were dissected from each
hemisphere, homogenized in a 125 μl volume of T-PER (Thermo Scientific), and
centrifuged for 5 min at 8,000xg and 4°C. Supernatant was removed and stored
at -80°C. Protein concentration of each sample was determined using the BioRad Protein Assay Reagent and spectrophotometry (Shimadzu UV-160;
Shimadzu Scientific Instruments). 20 μg of protein from each sample was mixed
with reduced sample buffer and electrophoresed on 4-12% Bis-Tris Criterion XT
gels (200V, 1h) and subsequently transferred to PVDF membrane. Membranes
were blocked in 5% milk-TBST (Tris buffered saline containing 0.05% Tween 20)
for 1h before being probed with mouse monoclonal antibody raised against βcatenin (BD Transduction Laboratories; Franklin Lakes, NJ) in milk-TBST
(1:1000) overnight at 4°C. Blots were subsequently washed with milk-TBST and
then incubated for 1h at room temperature in secondary antibody (peroxidase
conjugated goat anti-mouse IgG; Rockland). The blots were washed in TBST
and immunopositive signal visualized using Super Signal West Dura Extended
Duration Substrate (Thermo Scientific) and imaged digitally with the G:Box
ChemiHR system for densitometric analysis using GeneSnap software
(SynGene). Measurements from tissue ipsilateral to UEC were compared to
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homologous contralateral control regions and results expressed as percent of
contralateral value.

Protein Extraction with Phosphatase Inhibition
In a subset (n = 2) of the 2d UEC samples , whole hippocampi were
homogenized in the same buffer system as indicated above, except that
PhosStop (1:10 dilution; Roche Applied Science; Indianapolis, IN) and complete
protease inhibitor cocktail (1:25 dilution; Roche Applied Science) were added to
the 125 μl volume of T-PER. After protein determination, 20 μg volumes were
separated on the same 4-12% Bis-Tris Criterion XT gel system and transferred to
PVDF membranes. Blots were then subjected to the same protocol for β-catenin
Western blotting and visualization as described above. Densitometric analysis of
band intensity was again determined with SynGene software and injury effect
expressed as percent of contralateral control.

Statistical Analysis
The significance of percent change in densitometric values from Western
blot immunobinding was analyzed using the Student’s t-test. A probability of less
than 0.05 was considered statistically significant for all tests.
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Results
Expression of β-catenin During Time Course of Reactive Synaptogenesis
Western blot analysis was performed on hippocampal homogenates from
2, 7 and 15d post lesion using anti-β-catenin antibody. In contralateral control
tissues we observed a primary band at 92 kD at all time points sampled. In
ipsilateral hippocampus, signal intensity for this 92 kD band was reduced at 2
and 7d (Figure 4.1; 39.1 ± 2.9%, p<0.01 and 37.8 ± 6.5%, *p<0.05) returning to
control levels by 15d. By contrast, two lower bands at 90 kD and 75 kD were
barely detectable in contralateral control tissue and were significantly increased
after UEC (Figure 4.1; 90 kD-2d 270.5 ± 19.1%, *p<0.01; 7d 258.8 ± 32.0%,
*p<0.05; 15d 157.6 ± 13.8%, *p<0.05; 75 kD-2d 379.6 ± 69.5%, *p<0.05; 7d
390.1 ± 29.5%, *p<0.05; 15d 175.3 ± 11.4%, *p<0.05). These results show that
reactive synaptogenesis alters the protein profile of β-catenin in hippocampus.
The shift in molecular weight of β-catenin may reflect increased proteolytic
processing and/or a shift in phosphorylation due to altered balance of
phosphatase and kinase activity following injury.

Expression of β-catenin is Altered by Phosphatase Inhibition
We added PhosStop phosphatase inhibitor (Roche) to a small subset of
hippocampal homogenates extracted at 2d. When we performed Western
blotting on these tissues, the injury-induced shift in β-catenin was abolished
(Figure 4.2). In contrast to untreated ipsilateral samples, PhosStop treated
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Figure 4.1 The protein profile of β-catenin is altered in hippocampus after
UEC. Western blotting of β-catenin revealed a primary band at 92 kD in
contralateral control tissue. In ipsilateral hippocampus, UEC produced a shift in
molecular weight of β-catenin, with reduced signal in the 92kD band and
increased signal in additional bands at 90kD and 75 kD. These changes were
evident at 2 and 7dpl. At 15dpl there was a trend toward return to contralateral
baseline, with the 92kD band equal to control levels and expression of the lower
bands still elevated, but markedly reduced compared to earlier post-injury time
points (i = ipsilateral; c = contralateral).
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Figure 4.1
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Figure 4.2 Phosphatase inhibition abolishes the UEC-induced shift in βcatenin. In a small subset of animals, hippocampi were collected at 2d post
lesion and PhosStop phosphatase inhibitor was added to the protein
homogenates. Compared to untreated samples at 2d, PhosStop treated samples
no longer showed reduction in the 92 kD band ipsilateral to UEC. Appearance of
the lower 90kD and 75 kD bands ipsilateral to injury was also abolished in the
PhosStop treated samples. (I = ipsilateral; C = contralateral).
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samples ipsilateral to injury showed no reduction in the 92kD band and a
disappearance of the lower 90 and 75 kD bands. This finding suggests that the
shift in β-catenin after UEC is dependent on phosphatase activity, and suggests
a potential role for sRPTPβ or other phosphatases (such as calcineurin) in
regulating β-catenin function during reactive synaptogenesis.

Discussion
In the present study we have examined the post-injury expression profile
of β-catenin, a substrate which may mediate the downstream effects of sRPTPβ
on injury-induced structural reorganization of synapses. Western blotting of
hippocampal β-catenin after UEC revealed a shift in the molecular weight of βcatenin bands. Compared to contralateral controls, a 75kD and 90kD band were
each enhanced at 2, 7, and 15d postinjury, while the primary 92kD band was
reduced at 2 and 7d after UEC. Inhibiting phosphatases in the tissue
homogenates abolished the injury-induced shift in β-catenin bands, supporting
the hypothesis that phosphatase activity may regulate the function of β-catenin
during reactive synaptogenesis.

β-catenin Cleavage After UEC
From our initial experiments it is clear that different forms of β-catenin are
generated during the time course of UEC reactive synaptogenesis. While the
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cellular mechanism(s) responsible for producing these fragments cannot be
determined from the present data, at least three possibilities are suggested.
These include either a shift in phosphorylation state, proteolytic cleavage, or
some combination of the two. If sRPTPβ is directly altering the profile of βcatenin, it would most likely be involved with the generation of the 90kD
fragment, resulting in a 2kD shift due to extensive dephosphorylation of tyrosine
residues. It is also possible that sRPTPβ activity might indirectly alter the
structure of β-catenin to facilitate specific proteolysis, similar to what has been
suggested for the interaction of β-catenin and other protein tyrosine
phosphatases with the Wnt signaling pathway (Welters et al., 2008). If sRPTPβ
and other enzymes work in concert after UEC, then the 75 and 90 kD bands
immunoreactive for β-catenin would most likely represent cleavage products of
the full-length 92kD form. Calpain cleaves β-catenin after NMDA receptor
activation in hippocampal neurons (Abe & Takeichi, 2007), generating stable
truncated forms at 85 and 75 kD. Since UEC has been shown to induce calpain
activity in the denervated regions (Seubert et al., 1988), one or both of the
fragments we have observed could be calpain cleavage products.
Alternatively, β-catenin can also be degraded by caspase-3, though in this
case several different fragment sizes have been reported (Steinhusen et al.,
2000; Brancolini et al., 1997; Van de Craen et al., 1999). Because of this
variability, it is generally concluded that the pattern of β-catenin breakdown
products generated by caspase-3 may depend on cell type and/or the extent of
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enzyme activation. Peptides at 90 kD and 76 kD were among the caspasemediated fragments observed in cultured epithelial cells undergoing apoptosis
(Steinhusen et al., 2000), which were of similar molecular weight as those we
observed following UEC. Furthermore, since entorhinal lesion has been shown
to induce acute caspase-3 activation (24-36 hours) in a subset of dentate granule
cells (Kovac et al., 2004), the β-catenin fragments we find in our hippocampal
extracts could be generated by caspase-3, within a population of granule cell
neurons undergoing transneuronal cell death after UEC.

Potential Injury Effects on β-catenin Function in Spines
β-catenin is known to influence the structural integrity of spines depending
on its tyrosine phosphorylation (Takeichi & Abe, 2005). Dephosphorylated βcatenin associates with α-catenin, and stabilizes synapses by linking surface
cadherins to the actin cytoskeleton. By contrast, tyrosine-phosphorylated βcatenin dissociates from this complex and accumulates in dendritic shafts
(Murase et al., 2002). In neurons, multiple tyrosine kinases and phosphatases
work together to control β-catenin phosphorylation, and their relative
contributions in regulating the cytoskeletal role of β-catenin are not yet fully
understood (Lilien & Balsamo, 2005). However, the neuronal phosphatase
sRPTPβ is ideally positioned to influence the plasticity of dendritic spines through
β-catenin after UEC. sRPTPβ dephosphorylates β-catenin on tyrosine, is
specifically enriched at postsynaptic sites, and expression of sRPTPβ is
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increased over the same post-injury time course described in the present study
(Harris et al., 2008; see also Chapter 2). Since the intracellular phosphatase
domain of sRPTPβ is constitutively active, it can reasonably be presumed that
increased protein expression corresponds to increased dephosphorylation of
sRPTPβ substrates. During reactive plasticity, enhanced sRPTPβ activity may
modulate the effects of tyrosine kinases in dendritic spines, resulting in a more
dynamic regulation of β-catenin. This would be consistent with the active
cytoskeletal reorganization that underlies spine retraction (2d) and reformation
(7d) after UEC (Steward 1989).
In addition to the morphological effects, an increased rate of sRPTPβmediated dephosphorylation could have several additional consequences in
postsynaptic spines. For example, tyrosine-phosphorylated β-catenin is known
to dissociate from N-cadherin, rendering N-cadherin more susceptible to
ubiquitination and degradation (Huber et al., 2001; Lilien & Balsamo, 2005).
Thus, increased sRPTPβ activity could promote the association of β-catenin and
N-cadherin, reducing N-cadherin turnover and protecting the stability of cadherin
mediated synaptic adhesions. Further, recent evidence has suggested a novel
role for β-catenin in maintaining excitatory synaptic strength by regulating the
abundance of functional postsynaptic AMPA receptors (Okuda et al., 2007). This
raises the possibility that sRPTPβ effects on β-catenin could modulate
physiological responses of deafferented ML dendrites after UEC.
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It is unclear whether the β-catenin fragments generated after UEC would
have implications for altered cytoskeletal stability. Steinhusen et al. (2000)
showed that fragments generated by caspase-3 in MCDK cells could still interact
with both α-catenin and cadherin. On the other hand, Brancolini et al. (1997)
reported that caspase-cleaved β-catenin did not associate with α-catenin in
apoptotic NIH3T3 and MDCK cell lysates. Also Abe and Takeichi (2007) showed
that fragments generated by NMDAR-dependent calpain cleavage in neurons
could not stably associate with cadherin. In order to determine the impact of βcatenin cleavage on injury-induced plasticity, future studies will first have to
determine whether the β-catenin fragments that appear in hippocampal
homogenates after UEC are generated in intact, reorganizing dentate granule
cells (DGCs) or in apoptotic DGCs.

Potential Injury Effects on the Transcriptional Function of β-catenin
In addition to its role as cytoskeletal regulator, β-catenin also plays an
important role in the neuronal cell body as a transcription factor. This
transcriptional function can be activated through the canonical Wnt pathway
(Moon et al., 2002), or through an activity-dependent NMDAR-calpain pathway
(Abe & Takeichi, 2007). If the β-catenin fragments generated in the denervated
hippocampus after UEC are the product of calpain, then these may retain
transcriptional activity and potentially alter gene expression to influence synaptic
recovery (Abe & Takeichi, 2007). Conversely, if these are caspase-derived
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fragments, they may have reduced or inactivated transcription potential
(Steinhusen et al., 2000). To date, it remains unclear whether these
transcriptional modifications would positively or negatively affect synaptogenesis
after brain injury. The complexity of such transcriptional change is illustrated by
a recent study, where calcineurin, a serine-threonine phosphatase which can
also target tyrosine (Chernoff et al., 1984; Pallen et al., 1985), has been shown to
mediate nuclear translocation of the transcription factor proline-rich tyrosine
kinase 2 (Faure et al., 2007). Following TBI, calcineurin inhibition is
neuroprotective, suggesting that, in certain cases, attenuation of phosphataseinduced transcriptional change would be beneficial. Future studies will need to
define whether β-catenin and other phosphatase substrates indeed act as
transcription factors after TBI and what genes they may target to affect synaptic
plasticity.
As discussed above, when β-catenin in spines is tyrosine-phosphorylated,
it dissociates from α-catenin and cadherin and moves away from the synapse to
the base of spines. Is this pool of unbound β-catenin then available to move to
the nucleus and act as a transcription factor? Recent reviews have posed the
question of whether the cytoskeletal and transcriptional functions of β-catenin are
served by two separate pools of proteins, or a single common pool (Nelson &
Nusse, 2004; Harris & Peifer, 2005). A study from Brembeck and colleagues
(2004) suggested that in cultured fibroblasts, β-catenin can translocate from the
plasma membrane to the nucleus to serve either function, with the switch
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mediated by tyrosine phosphorylation and the co-factor BCL9-2. When
dephosphorylated on Y142, β-catenin binds α-catenin and cadherin to stabilize
cell adhesions. When phosphorylated, β-catenin dissociates from α-catenin, and
is then able to bind BCL9-2 and translocate to the nucleus. It is yet unclear
whether a similar mechanism might work in neurons. If so, this raises the
possibility that changes in the balance of kinase and phosphatase activity after
injury could affect not only the cytoskeletal function of β-catenin, but also its
transcriptional activity. Specifically, increased phosphatase activity could
decrease β-catenin availability to move to the nucleus and activate transcription.
In conclusion, the results presented here lend support to the hypothesis
that sRPTPβ may function through its intracellular substrates to influence
reorganization of postsynaptic structures after injury. We have focused on βcatenin, showing that the protein profile of this substrate is altered after UEC at
the same post-injury time points when sRPTPβ is upregulated. Exactly how the
observed generation of β-catenin fragments may be related to the presumed
increase in sRPTPβ-mediated dephosphorylation after injury is still
undetermined. However it is clear that changes in proteolysis and
phosphorylation can influence the structural and transcriptional functions of βcatenin, and we propose that sRPTPβ is ideally positioned to affect these
changes.
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Notably, β-catenin is just one of several candidate sRPTPβ substrates
which could potentially direct synaptic reorganization after brain injury. Like βcatenin, the role of other substrates (e.g. β-adducin, P190 RhoGAP) in regulating
cytoskeletal structure can be directly altered by tyrosine phosphorylation and
dephosphorylation (Pariser et al. 2005; Tamura et al., 2006). Further
investigation of additional substrates will help better elucidate the mechanism by
which elevated sRPTPβ could affect cytoskeletal fluidity during spine retraction,
spine regeneration, establishment of new synaptic contacts with sprouted axons,
and stabilization of these newly formed synapses. It is our hope that a better
understanding of the factors which control reactive synaptogenesis will help to
identify therapeutic approaches which will support adaptive plasticity after TBI,
and ultimately, will enhance recovery.
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CHAPTER 5
GENERAL DISCUSSION

Summary of Results
In these studies we have investigated the role of phosphacan/RPTPβ
variants, major components of brain ECM, in synaptic plasticity following brain
injury. In Chapter 2, we provided a detailed characterization of the spatial and
temporal expression of three phosphacan splice variants (phosphacan, RPTPβ
and sRPTPβ) during reactive synaptogenesis. We used unilateral entorhinal
cortex lesion (UEC), a well-characterized rodent model of reactive plasticity
which leads to successful functional recovery. UEC allowed us to track mRNA
and protein throughout the course of reactive sprouting and synapse formation in
the ipsilateral dentate gyrus (DG) during the first two weeks post-lesion. We
focused on three post-injury time points corresponding to three distinct phases of
the adaptive plasticity response: degeneration of perforant path axon terminals
(2d), afferent sprouting and establishment of new synaptic contacts (7d), and
stabilization of newly formed synapses (15d). We show for the first time that
hippocampal sRPTPβ protein and mRNA are persistently elevated during all
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three phases of synaptogenesis after UEC. In contrast, we have demonstrated
that hippocampal phosphacan protein is elevated during the acute degenerative
phase (2d in whole hippcampus) and during sprouting and synapse formation (7d
in isolated molecular layer). Phosphacan transcript was also increased at 7d
post injury. Immunolocalization studies suggested that sRPTPβ is localized on
dendrites and spines in the OML, while phosphacan is found more diffusely in the
neuropil, particularly in spaces surrounding granule cell bodies. These results
support a role for phosphacan/RPTPβ splice variants in both the degenerative
and regenerative phases of injury-induced synaptogenesis.
As we began our study to measure mRNA levels of phosphacan/RPTPβ
after UEC, we turned our attention to the technical limitations of qRT-PCR for
resolving the small-but-consistent changes we observed in our genes of interest.
In particular, we had some initial difficulty identifying a suitable reference gene
which was stably expressed and unaffected by the applied brain lesion. Chapter
3 therefore sought to systematically compare the expression of four widely used
reference genes (β-actin, GAPDH, cyclophilin, 18s rRNA) in hippocampus after
UEC, in order to determine their suitability as normalization factors. Beyond the
immediate applicability of these results to our qRT-PCR studies following UEC,
selection of a normalization strategy is a critical issue for TBI researchers in
general. qRT-PCR is now the method of choice for measuring mRNA, and the
choice of reference gene can significantly affect final experimental results.
Unfortunately, many currently published studies still fail to appropriately validate
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their qRT-PCR normalization strategy. Therefore we have also evaluated these
candidate reference genes in hippocampus and cortex following central fluid
percussion injury (cFPI), a widely used model of brain trauma in rodents. Nearly
all TBI studies using qRT-PCR in the last 5 years have utilized one of these four
genes for data normalization (Rhinn et al., 2008). In Chapter 3 we report that
none of the reference genes we tested shows invariant expression across all
tissues, time points, and experimental injury models. However, we have
identified certain reference genes which may be reasonable choices for
normalization within a defined experimental context (for example, cyclophilin in
hippocampus after UEC). From these studies it is clear that endogenous
reference gene expression can be modulated by injury-induced tissue
denervation and closed-head trauma. Since our findings regarding appropriate
normalization choices differ significantly from the findings of two recent studies of
reference genes in mouse TBI models (Rhinn et al., 2008; Thal et al., 2008) we
emphasize the critical importance of reference gene validation for each new TBI
model and each set of experimental conditions. We define a 'validated' reference
gene as one whose expression does not change under the varying experimental
conditions of a study and whose intrinsic variability of expression (within-group
coefficient of variation) is low. Normalization to multiple reference genes may be
preferable to a single control, when resources permit extensive screening of
reference gene candidates. Normalization to total RNA is another alternative,
which may be the best option in cases when extensive screening of reference
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genes is not practically feasible or when a suitably stable reference cannot be
found.
In Chapter 4, we began to investigate the potential functional significance
of the increased sRPTPβ expression observed during the course of reactive
synaptogenesis. These studies have shown for the first time that β-catenin, a
substrate of sRPTPβ and a critical cytoskeletal regulator protein, is altered during
reactive plasticity after UEC. We have described a shift in the protein profile of βcatenin on Western blots, including reduced signal for full-length β-catenin and
increased signal for two shorter immunoreactive bands. These may reflect
proteolytic degradation by calpain or caspase. Exactly how these β-catenin
fragments may be related to the presumed increase in sRPTPβ-mediated
dephosphorylation of β-catenin remains to be determined. However sRPTPβ is
known to target β-catenin, and is specifically enriched on postsynaptic spines
where β-catenin regulates the stability of the actin cytoskeleton. Since
expression of sRPTPβ is increased after injury at time points when dendritic
reorganization is known to occur, we suggest that sRPTPβ is ideally positioned to
influence the reactive plasticity of dendritic spines through β-catenin.

Source of Elevated Phosphacan Expression
While these studies have provided a detailed characterization of
phosphacan/RPTPβ expression at the protein and mRNA levels during injuryinduced synaptic plasticity, some key questions remain. For instance, the source
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of increased phosphacan expression after UEC is still undetermined. While a
number of studies have described phosphacan expression by astrocytes in vivo
and in vitro (Canoll et al.,1993; Milev et al.,1994; Engel et al., 1996; MeyerPuttlitz et al., 1996; McKeon et al., 1999; Beck et al., 2008), we did not detect
any co-localization of astrocytic marker GFAP and 3F8 immunostaining for
phosphacan in our tissues. It is still possible that astrocytes are the source of the
increased phosphacan expression after UEC, but that the redistribution of
phosphacan once secreted into the extracellular space precludes detection of
colocalization by immunohistochemical means. Astrocytes have been shown to
contain phosphacan mRNA (Engel et al., 1996; Canoll et al., 1996; McKeon et
al., 1999) and probing for phosphacan with in situ hybridization after UEC could
be a straightforward way to answer this question.
Neurons could also be the source of elevated phosphacan following UEC.
We did not try co-localization of 3F8 immunostaining with neuron-specific
markers, but it is possible that as with astrocytes, phosphacan antibodies would
not co-localize with neuronal markers because of diffusion or redistribution once
it is secreted. Phosphacan mRNA has been detected in granule and pyramidal
neurons of the hippocampal formation in adult rodents (Snyder et al., 1996). Our
IHC results with confocal microscopy showed phosphacan staining in the granule
cell layer, while qualitative EM analysis showed reaction product for
phosphacan/RPTPβ in granule cell bodies. Again, in situ hybridization of the
denervated dentate gyrus could definitively address whether neuronal
165

populations increase production of phosphacan after injury. Notably, the DG is
one of the few brain regions known to undergo continued neurogenesis
throughout adult life, and EC lesion enhances neurogenesis in the DG (Gama
Sosa et al., 2004). Since neural progenitor cells (NPCs) express high levels of
CSPGs including phosphacan (Kabos et al., 2004), dividing neural progenitors
could be another potential source of increased phosphacan after UEC, at least
within the GCL.

Signals Responsible for Phosphacan/RPTPβ Induction
Another question which remains unresolved is the nature of the upstream
signals which induce the observed changes in phosphacan and sRPTPβ with
injury. A recent study by Beck et al. (2008) demonstrated that the transcription
factor Egr-1 binds to the phosphacan promoter and activates phosphacan
transcription both in primary astrocyte cultures and in vivo. In a mouse model of
experimental stroke, Egr-1 expression was increased as early as 12 hours postinjury and co-localized with increased phosphacan in the zone of infarct. Also
Egr-1-null mice expressed less phosphacan and sRPTPβ after stroke than wildtype animals. This is the first transcription factor which has been shown to
directly influence expression of phosphacan splice variants. Egr-1 is considered
an immediate-early gene which undergoes rapid, transient activation in response
to growth factors, vascular injury, hypoxia, or mechanical perturbation
(Khachigian et al., 1996). It would be interesting to examine the expression of
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Egr-1 in different brain injury paradigms, and the extent to which this correlates
with induction of phosphacan/RPTPβ expression. If the concentration of Egr-1,
or the mechanical or molecular signals which induce its expression, prove to vary
in different injury models, this could potentially account for the range of
phosphacan responses to different types of injury which have been reported by
different groups (see discussion in chapters 1 and 2).

Function of Phosphacan May Depend on the Presence of
Co-factors
Whereas some previous studies have reported reduced phosphacan after
injury (Jones et al., 2003; Dobbertin et al., 2003; Tang et al., 2003), we have
observed increases in phosphacan expression after UEC, including an increase
in whole hippocampal protein at 2d, an increase in ML protein at 7d, and an
increase in mRNA transcript at 7d. Thus our results, along with those from
previous studies, suggest that the role of phosphacan in CNS injury is complex,
and may be dependent on injury type, severity, and location. Given that
phosphacan can interact with so many extracellular binding partners, the
functional role of phosphacan after injury may be contextual; that is, it may
depend on an array of co-factors whose concentration might vary considerably in
different microenvironments. Growth factors (GFs) and cell adhesion molecules
(CAMs) are two groups of phosphacan ligands of particular interest in this
respect.
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GFs are known to promote sprouting and adaptive structural plasticity
after brain injury (Nieto-Sampedro & Bovolenta, 1990; Cui 2006; Deller et al.,
2006). The binding of phosphacan to GFs including FGF-2, pleiotrophin,
amphoterin and midkine, may help to localize or sequester these molecules
during tissue reorganization and synaptogenesis. In particular, FGF-2 is known
to be important for normal reactive plasticity in the dentate gyrus. FGF-2 mRNA
was increased in hippocampus during the degenerative and regenerative phases
of reactive synaptogenesis, while intracerebroventricular (ICV) infusion of FGF-2
antibodies attenuated the sprouting response (Fagan et al., 1997). Furthermore,
intravenous infusion of FGF-2 after entorhinal lesion led to enhanced sprouting of
the septodentate fibers (Ramirez et al., 1999). Importantly, the increase in FGF2 staining observed by Fagan and colleagues was confined to the OML after the
denervating lesion and apparently associated with astrocytes. Since the
plasticity-promoting function of FGF-2 requires secretion and extracellular
binding to FGF receptors (Reuss et al., 2003), it is possible that once astrocytes
secrete this factor, phosphacan, enriched in the OML after UEC, binds to it and
helps ensure its strict confinement to the region of sprouting.
CAMs mediate neuronal adhesion, and these molecules are important
regulators of structural reorganization and synaptogenesis after brain injury.
Phosphacan/RPTPβ interaction has been reported for several neuronal CAMs
including contactin/F3 (Peles et al., 1995), axonin-1/TAG-1 (Milev et al., 1996),
Nr-CAM (Sakurai et al., 1997), Ng-CAM/L1, and N-CAM (Milev et al., 1994).
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Binding of the transmembrane RPTPβ variants to CAMs may directly mediate
cell adhesion (Peles et al., 1995; Sakurai et al., 1996). By contrast, binding of
phosphacan to CAMs may interfere with cell adhesion by competing with the
receptor forms or with other CAMs for binding sites (Milev et al., 1994; Sakurai et
al., 1997). This hypothesis has been supported by cell culture experiments, but it
is unclear whether such interactions occur in the dentate gyrus after EC lesion.
We have observed sRPTPβ localization on granule cell dendrites and spines
within the OML. Axons in the molecular layer have been shown to express NgCAM/L1, while reactive astrocytes in the denervated region increase N-CAM
expression after UEC (Styren et al., 1995; Jucker et al., 1995, 1996). It is
therefore possible that sRPTPβ on dendrites mediates adhesion to CAMexpressing axon terminals and/or glial cells in the deafferented hippocampus,
and that phosphacan in the extracellular space serves to modulate these
interactions. Such a scenario would place great importance on the temporal
regulation of phosphacan protein levels after injury. The enhanced phosphacan
expression we have observed at 2d (in whole hippocampal tissue) and 7d (in
molecular layer enriched samples) could represent an adaptive response to
injury. During these early post-injury phases, sprouting terminals and dendritic
spines must release their contacts with neighboring cells in order to allow
structural reorganization and establishment of new synaptic contacts. Increased
extracellular phosphacan might bind to adhesion molecules to facilitate such a
release. In contrast, a more prolonged phosphacan elevation (which we have
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not observed after UEC, but which has been reported in some other studies, e.g.
Carmichael et al., 2005) could be maladaptive, since prolonged interference with
cell adhesion would impair synapse stabilization and maturation. Future studies
which manipulate sRPTPβ binding in vivo could test these hypotheses. For
example, infusion of purified phosphacan should increase competition for CAM
binding and enhance synaptic reorganization if administered early after injury,
while later treatment should impair successful synapse formation. Treatment
with antibodies to the CAM-binding region of sRPTPβ would also disrupt
sRPTPβ-CAM interactions and should have a similar effect.

Multiple Intracellular Targets of sRPTPβ May Be Involved at
Different Post-Injury Stages
In Chapter 4 we evaluated post-injury changes in β-catenin, a substrate of
sRPTPβ known to play an important role in cytoskeletal regulation and spine
morphogenesis. However β-catenin is just one of several sRPTPβ substrates
which could potentially influence structural reorganization after brain injury. Like
β-catenin, the functional interactions of other substrates have been shown to be
directly altered by tyrosine phosphorylation and dephosphorylation. One
example is β-adducin, a neuron-specific cytoskeletal regulator also targeted for
dephosphorylation by sRPTPβ (Pariser et al., 2005). β-adducin caps actin
filaments and works with α-adducin to promote stabilization of actin-spectrin
junctions near the plasma membrane (Gardner & Bennett ,1987). Tyrosine
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phosphorylation of β-adducin alters its subcellular distribution, suggesting
changes in its association with the actin-spectrin complex (Gotoh et al., 2006).
Interestingly, β-adducin-deficient mice show abnormalities in LTP maintenance
and generalized learning deficits on spatial and cued memory tasks, supporting
the idea that β-adducin is involved in the synaptic plasticity underlying learning
and memory (Rabenstein et al., 2005).
p190 RhoGAP is another sRPTPβ substrate which has been implicated in
plasticity required for hippocampus-dependent learning. In behavioral studies
comparing wild-type mice with RPTPβ knockouts, fear conditioning induced
dephosphorylation of p190 RhoGAP in wild-types, while RPTPβ-deficient mice
showed no change in phosphorylation of p190 and impaired learning ability
(Tamura et al., 2006). Tyrosine dephosphorylation of p190 RhoGAP is known to
inhibit its interaction with Rho, thus promoting Rho GTPase activity. Therefore in
the absence of sRPTPβ-mediated dephosphorylation, the learning defects in
knockout mice were attributed to reduced activation of Rho GTPase. Rho
GTPases are known to be important for neuronal morphogenesis and structural
plasticity (Luo 2002). It would be interesting to examine whether RPTPβ
knockout animals exhibit altered capacity for reactive plasticity after brain injury,
and whether this could be correlated with differences in substrate
phosphorylation. Tamura and colleagues (2006) have developed an antibody
specific to tyrosine-phosphorylated p190 RhoGAP which would be useful for this
kind of investigation. If such a correlation could be established, this would
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provide strong evidence that sRPTPβ influences structural plasticity following
injury at least in part through targeting the substrate p190 RhoGAP.
The most recently identified sRPTPβ substrate is the receptor tyrosine
kinase TrkA (Shintani & Noda 2008). Unlike the intracellular proteins discussed
above, this substrate is a transmembrane receptor which mediates signaling for
outgrowth and plasticity of both axons and dendrites in response to nerve growth
factor (NGF; Huang & Reichardt, 2001). Shintani and Noda showed that
sRPTPβ dephosphorylates TrkA and inhibits its activation, leading to attenuated
neurite outgrowth in NGF-stimulated PC12D cells. The fact that sRPTPβ
reduced but did not completely attenuate neurite outgrowth in these studies
suggests a modulatory role for sRPTPβ in growth factor-induced plasticity.
Importantly, NGF expression is increased in the OML after EC lesion (Conner et
al., 1994) and intraventricular treatment with NGF antibodies inhibits regenerative
sprouting (Van der Zee et al., 1992). If sRPTPβ interacts with TrkA in the
denervated hippocampus, then it is possible that elevated sRPTPβ expression
after injury could modulate growth factor-induced synaptic reorganization.
Altogether, it is likely that change in expression of sRPTPβ after injury
coordinately regulates the function of multiple intracellular substrates, by altering
their steady-state tyrosine phosphorylation. Since we have shown that sRPTPβ
is persistently upregulated in the zone of sprouting and synaptogenesis after
UEC, actions of different downstream targets may mediate distinct functions of
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sRPTPβ during the early, intermediate, and later phases of injury-induced
plasticity.

sRPTPβ in the Context of Other Phosphatases and Kinases
The tyrosine phosphorylation state of proteins in the nervous system is
typically maintained by the balanced activity of multiple kinases and
phosphatases (Johnson & Van Vactor, 2003; Paul & Lombroso, 2003). While
injury-induced sRPTPβ changes have the capacity to alter the steady-state
tyrosine phosphorylation of intracellular targets, we cannot rule out the possibility
that changes in other tyrosine phosphatases and kinases after brain injury could
counteract or augment the effect of sRPTPβ alone. Other neuronal tyrosine
phosphatases share partially overlapping substrate specificity with sRPTPβ. For
example PTP1B and LAR-PTP also act on β-catenin (Balsamo et al., 1998;
Kypta et al., 1996) and PTPσ dephosphorylates TrkA (Faux et al., 2007).
Neuronal tyrosine kinases which may work to counteract the effects of sRPTPβ
activity include the EGF family of receptor tyrosine kinases and the Src family of
intracellular kinases, e.g. Fyn, Src, and Abl (Murase et al., 2002; Roura et al.,
1999). Interestingly, Fyn is itself dephosphorylated by sRPTPβ (Pariser et al.,
2005). This raises the possibility that sRPTPβ may regulate steady-state levels
of tyrosine phosphorylation both directly (by dephosphorylating substrates), and
indirectly by altering tyrosine kinase activity.
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While it is difficult to directly assess activity changes in an individual
phosphatase protein after injury, it would be interesting to perform a phosphatase
assay to investigate overall changes in tyrosine phosphatase activity in brain
tissue at different post-injury time points. This would determine whether the
expressional changes we have observed in sRPTPβ occur in parallel with
generalized changes in tyrosine phosphatase activity after brain injury. Clearly
the factors controlling tyrosine phosphorylation after injury are complex, and
understanding the contributions of multiple kinases and phosphatases to the
structural reorganization that occurs after brain injury remains a major challenge
for the future.

Potential Modulation of sRPTPβ Phosphatase Activity
We have thus far assumed that increased expression of sRPTPβ would
directly correspond to increased effects of the constitutively active intracellular
phosphatase. However, there are at least two ways in which this constitutive
enzymatic activity may be modulated following TBI. First, sRPTPβ phosphatase
activity can be regulated by interaction with the growth factor pleiotrophin (PTN).
PTN has been shown to inactivate the phosphatase upon binding to the
extracellular domain of sRPTPβ (Meng et al., 2000). In normal adult brain PTN is
expressed by a subset of neurons, but its expression by astrocytes and
macrophages is greatly upregulated after acute ischemic injury (Yeh et al., 1998).
If PTN is also increased following traumatic brain injury, this could potentially
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suppress activity of the sRPTPβ phosphatase and its downstream effects on key
intracellular substrates. Second, a recent study has reported that reactive
oxidative species (ROS) specifically target the conserved cysteine residues in the
catalytic domain of protein tyrosine phosphatases, rendering them inactive (Wu &
Terada, 2006). Brain injury is well known to induce oxidative stress in surviving
neurons (Juurlink & Paterson, 1998; Bayir et al., 2006). Thus, even if sRPTPβ
protein levels are increased following injury, this might not correspond to
increased phosphatase activity if the phosphatase is inactivated in cells
undergoing oxidative stress. Alternatively, in the face of phosphatase
inactivation by PTN and/or ROS, the increase in sRPTPβ expression we have
observed after brain injury could be an adaptive response in order to maintain
homeostasis.

Clinical Considerations
Relevance of Findings in UEC to Clinical TBI
Each year, TBI affects at least 1.5 million people in the U.S and millions
more around the world. There is mounting evidence to indicate that TBI induces
axonal sprouting of spared axons and subsequent synaptogenesis, and that
these processes can support functional recovery. However the natural extent of
reactive synaptic plasticity achieved after most brain injuries is limited.
Identifying the factors that regulate injury-induced sprouting and synaptogenesis
is an important challenge of current TBI research. UEC, as applied in the
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present studies, is a targeted lesion known to induce robust, localized sprouting
and synaptogenesis which can be directly examined. The discrete nature of EC
lesion allows researchers to identify molecules and define mechanisms involved
in adaptive synaptic reorganization after injury. However, it is important to
recognize that UEC also has its limitations. In particular, its relative lack of many
complicating pathologies common to human TBI (e.g. neuroexcitatory insult,
vascular damage, edema, hypoxia, inflammation) could lead to difficulty in
translating research findings and experimental treatments to successful
application in brain-injured patients. While other TBI models which more
specifically reproduce the pathologic features of human closed-head injury do
induce a limited degree of post-injury sprouting (Erb & Povlishock, 1991;
Christman et al., 1997), the diffuse nature of reactive synaptogenesis in these
models makes further study difficult. One reasonable strategy would be to
contrast the adaptive response to a targeted UEC lesion with that generated in a
TBI model which does not lead to successful synaptic recovery. This approach
has been taken in studies which compare UEC to a combined insult model which
pairs bilateral UEC lesion with central fluid percussion injury, generating a
maladaptive synaptic plasticity consistent with clinical TBI outcome (Phillips et
al., 1994; Phillips et al, 1997; Zhu et al., 2000; Phillips & Reeves, 2001; Falo et
al., 2006). Thus, having the option to design studies which compare the adaptive
synaptogenesis following UEC with insults which do not lead to successful
recovery is another powerful benefit of the UEC injury paradigm.
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ECM Manipulations Can Promote Sprouting and Recovery after Injury
Exciting new studies have garnered much attention by showing that in vivo
treatment with chondroitinase ABC (chABC), an enzyme which digests the CSGAG side chains of matrix CSPGs, can promote axon sprouting and recovery
after CNS injury. These studies provide important proof-of-concept that the ECM
influences plasticity following injury, and that manipulations to render the
extracellular environment more permissive can significantly affect anatomical,
physiological, and behavioral measures of recovery (Reviewed in Crespo et al.,
2007; Del Rio & Soriano, 2007). However, chABC is a non-specific treatment; it
degrades both hyaluronan and the CS portion of all extracellular CSPGs. The
functional significance of hyaluronan (HA) digestion by chABC is just beginning
to be appreciated. Since HA serves to link many ECM components, it has been
suggested that its degradation leads to a more widespread disruption of ECM
structure than digestion of CS alone, and this may be important for the effect of
chABC on plasticity and recovery (Crespo et al., 2007).
In addition, the mechanism(s) by which degradation of CS on CSPGs can
enhance recovery are not well understood. It is well documented that the
expression of CSPGs is upregulated by reactive glia in response to CNS injury
and that this contributes to inhibition of adaptive axon growth and plasticity
(McKeon et al., 1991; Davies et al., 1999). As discussed in Chapter 1, CSPGs in
the nervous system constitute a large group of molecules which exhibit
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substantial structural and functional diversity. The removal of CS is therefore
likely to reduce the inhibitory effects of some, but not all, CSPGs. Notably, one in
vitro study reported that chABC-mediated digestion of CS on phosphacan
significantly enhanced its inhibitory effect on neurite outgrowth from retinal
ganglion cells (Inatani et al., 2001). This increased inhibition of neurite outgrowth
after CS removal from phosphacan could be due to a loss of interaction with
growth and plasticity-promoting factors, since CS chains are the sites where
several GFs bind to phosphacan (Milev et al 1998; Maeda et al 1999). We have
hypothesized that the increased phosphacan observed in reorganizing OML after
UEC could support recovery by concentrating GFs in the denervated region. If
this is the case, then treatment with chABC after UEC would eliminate GF
binding and possibly impair recovery. chABC has been successfully
administered in vivo by intracerebroventricular infusion, and it would be
interesting to examine the effect of this enzyme on sprouting and recovery after
UEC.
Thus while chABC clearly shows promise as a potential therapeutic
approach to promote plasticity and recovery after CNS injury, its nonspecific
mechanism of action may also present some drawbacks. Although degradation
of CS may reduce inhibitory effects of many CSPGs, it could also increase
inhibition of axonal outgrowth and plasticity by other CSPGs like phosphacan.
Gaining a better understanding of the contributions of specific ECM components
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in the CNS injury response is an essential first step for developing the next
generation of more specific and effective ECM-manipulating therapies.

Concluding Remarks
In conclusion, the present studies have characterized the expression of
phosphacan/RPTPβ splice variants over the course of reactive plasticity following
brain injury. Protein expression of sRPTPβ, the primary receptor isoform in
mature brain, is persistently increased during the first two weeks after
hippocampal denervation. By contrast, post-injury increases in phosphacan, the
primary extracellular isoform, were limited to the early degenerative phase (2d,
whole hippocampal homogenates) and the later phase of synaptic reorganization
(7d in molecular layer enriched fractions). Using a rigorously validated approach
to our qRT-PCR analysis (as detailed in chapter 3), we show that mRNA for
sRPTPβ is also persistently elevated, while mRNA for phosphacan is increased
during the phase of active tissue reorganization and synaptogenesis (7d). The
protein profile of the sRPTPβ substrate β-catenin, an important regulator of spine
morphogenesis, shows a shift after injury which temporally correlates with the
changes seen in sRPTPβ. We propose that sRPTPβ could promote postsynaptic
structural plasticity after brain injury by controlling the phosphorylation of βcatenin and possibly other intracellular substrates.
In sum, our findings support the hypothesis that phosphacan and sRPTPβ
play a role in the adaptive reactive plasticity and synaptogenesis that occur
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following TBI. It is our hope that the results and discussion presented herein will
contribute to a better understanding of the complexity of ECM responses to brain
injury. It has been scarcely two decades since the concept of a substantial,
functionally significant ECM in the nervous system truly gained widespread
acceptance (Celio 1999). In that time, great progress has been made in defining
which matrix molecules serve adaptive roles and which serve maladaptive roles
after brain and spinal cord injury. Moreover it has been demonstrated that these
roles are not at all static, but are likely to vary with injury type, severity, location,
and post-injury time interval. Since pioneering experiments have recently begun
to show the promise of therapeutic interventions which manipulate ECM, gaining
a better understanding of how different matrix molecules contribute to the
success—or the failure—of recovery from brain injury is now all the more
important. This information will improve our understanding of how such
interventions work, and it will be critical for developing the next generation of
more effective, targeted therapies to improve outcomes for brain injured patients.
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Appendix A

A Representative lanes (3F8)
i

c

i

B Representative lanes (anti-RPTPβ)

c

i

c

i

c
250 kD

450 kD

|-----saline-----| |---detergent---|

|-----saline-----| |---detergent---|

Serial extraction of soluble and membrane-associated proteins from brain
tissue homogenates. Because the 3F8 antibody may recognize both
phosphacan and full-length RPTPβ, we followed serial extraction protocol to
separate soluble protein-enriched and transmembrane protein-enriched fractions,
as previously described by Dobbertin et al. (2003). Phosphacan should be
enriched in the 'saline' fraction, while both transmembrane forms should be found
in the 'detergent' fraction. The representative samples shown here were
extracted from hippocampus 7d after UEC and treated with chondroitinase ABC
(see also Appendix B and detailed methods in Chapter 2). (A) shows that
phosphacan protein is enriched in the saline (detergent-free) tissue fraction,
while (B) shows that sRPTPβ protein is enriched in the detergent tissue fraction.
Consistent with the report by Dobbertin, we did not detect any bands in the
detergent fraction representing the developmentally prominent full-length RPTPβ.
Therefore we believe that the 3F8 signal in our samples represents phosphacan
immunobinding alone. i = ipsilateral; c = contralateral.
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Appendix B

Chondroitinase treatment of protein samples for Western blotting. In order
to expose antigenic sites and maximize antibody detection of phosphacan and
sRPTPβ, all protein samples were treated with chondroitinase ABC (chABC) prior
to Western blotting, to remove chondroitin sulfate side chains. 540μl aliquots of
either saline-extracted or detergent-extracted protein samples were buffered to
pH 8 by addition of 400 mM Tris, and mixed with protease inhibitors (Roche
complete cocktail plus 2μg/ml Pepstatin). The resulting preparations (600μl
volume) were incubated with 0.3 U chABC for 3 h, shaking at 37°C. Reaction
was stopped by returning samples to -80°C. Representative lanes from
hippocampus 7d after UEC were probed with 3F8, and show that chABC
treatment enhances the strength of 3F8 signal and causes the high molecular
weight smear to resolve to a band at around 450 kD. Representative sample
from hippocampus 2d post lesion show that without chABC treatment there is no
detectable signal with anti-RPTPβ. With chABC, a band appears at 250 kD,
representing sRPTPβ. i = ipsilateral; c = contralateral.
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Appendix C

Cortical dissection for qRT-PCR analysis after cFPI. For qRT-PCR analysis
of candidate reference genes after central fluid percussion injury (cFPI), RNA
was extracted from bilateral hippocampi and from parietotemporal cortex. The
cortical regions, diagrammed above, were selected based on the location of
cellular damage previously observed after cFPI and visualized by cellular uptake
of horseradish peroxidase. In our studies, rats were deeply anesthetized with 4%
isoflurane and sacrificed by decapitation. The brain was rapidly removed from the
skull, and both cerebral hemispheres were gently rolled outward from the midline
to expose the subcortical structures. After hippocampi were collected, the
cortical laminae were laid flat and tissue blocks corresponding to the boxed
regions were collected for RNA extraction and analysis.
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Appendix D

Quality assurance of RNA samples. Each RNA sample extracted from rodent
brain after UEC or cFPI was evaluated by microcapillary electrophoresis using
the Experion LabChip (Bio-Rad Laboratories, Inc.) as shown above, or using the
Agilent bioanalyzer system (Agilent Technologies, Inc.) according to the
manufacturer's protocol. The sample shown is RNA isolated from hippocampus
ipsilateral to UEC at 7d post lesion, and the electropherogram trace is
representative of all samples used for our qRT-PCR studies. Clear peaks can be
seen for 18s and 28s, and background signal is very low, indicating good quality
RNA with little breakdown or contamination. RNA concentrations reported in the
Experion analysis were verified with spectrophotometry.
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Appendix E

Intracellular substrates of sRPTPβ
PSD-95

AMPA-R trafficking, synapse stabilization

Kawachi et al. 1999

β-catenin

cytoskeletal regulator, links actin to surface cadherins

Meng et al. 2000

GIT1/Cat-1

growth cone extension, neuronal migration

Kawachi et al. 2001

β-adducin

cytoskeletal regulator, stabilizes actin-spectrin junctions

Pariser et al. 2005

Src family kinase, regulates cytoskeletal plasticity

Pariser et al. 2005

scaffolding protein, also binds β-catenin

Fukuda et al. 2005

Fyn
Magi1

P190Rho/GAP neuronal morphogenesis, synaptic plasticity
ErbB4
TrkA

Tamura et al. 2006

neuregulin receptor, maturation and plasticity of excitatory
synapses

Fujikawa et al. 2007

growth factor signaling, modulates neurite outgrowth

Shintani et al. 2008
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